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Summary
This thesis describes the initial synthetic studies undertaken in three distinct 
research areas, two of which will hopefully involve antibody generation in the 
near future.
Chapter 1.
Monoclonal antibodies have been shown to catalyse a wide variety of chemical 
transformations, including hydrolytic, pericyclic, redox and acyl-transfer 
reactions, with good rate accelerations, high substrate specificity and precise 
stereochemical control. There are many different methods of screening for 
antibody catalysis (see chapter 1). The need to generate a very sensitive 
method for the direct screening of a particular type of antibody catalysis is 
therefore of great importance. It is hoped that suitable catalysts can be 
identified at much lower concentrations of antibody or that have lower catalytic 
activities. We have now almost finished the synthesis part of the ‘firefly’ luciferin 
coupled assay project for the direct screening for hydrolytic activities.
Chapter 2.
To this end the s-luciferin ester (19a) and amide (19b) substrates have been 
successfully synthesised as well as two possible antibody phosphonamidate 
haptens (37) and (38). The synthesis of a similar hapten (64) more closely 
based on the ‘firefly’ substrate structure is also very near completion. Progress 
towards the chiral hapten of (37), with the asymmetric synthesis of the 
intermediate a-amino phosphonic acid (20), is close to being finished. It is 
hoped that these compounds can be used for future antibody generation, as 
well as for improving the techniques used for screening in future monoclonal 
antibody generation.
Chapter 3.
The second of the projects has involved a prodrug activation system for 
cytotoxic agents. To this end initial studies have centred around the synthesis 
of 1,3-dimethyl cyclohexane derivatives (see figures 3.9 and scheme 3.2). We 
hope to utilise antibody catalysis to facilitate the conversion of its conformation 
from an inactive ‘twist-boat’ form to a chair conformation which should allow 
neighbouring carboxylate group participation and drug release (figure 3.9). In
in
the case of (scheme 3.2) we hope to use antibody catalysis to facilitate a 
Claisen rearrangement to produce a carboxylate in the required conformation to 
allow drug release. Initial studies have centred around the generation of model 
compounds that may be used as precursors to both the prodrugs required in 
this project and so far have been based on the synthesis of dialkylated 
intermediates (2). The isolation of the dialkylated product (scheme 3.3) and the 
dimethyl derivative has proven elusive although the trialkylated compound (6) 
and its c/s, trans isomer has been identified as a major reaction product. Other 
work has indicated that when dialkylated products have been isolated, 
extensive epimerization also appears to have occurred. An alternative method 
of dialkylation must be generated before future work can proceed. The 
synthesis of a number of haptens has been achieved based initially on the 
‘twist-boat’ to chair requirement. To this end the haptens were chosen so as to 
orientate all carbonyl bearing moieties axial in order to facilitate antibodies that, 
when generated, would force the conformational change required for internal 
carboxylate attack and subsequent drug release. A number of Kemp’s acid 
anhydride amide and ester derivatives (20) and (23) have been successfully 
synthesised along with an alternative diamide (21). A simpler model prodrug, 
the diamide (28) has successfully been synthesised. A precursor Kemp’s 
anhydride derivative (35) of hapten (36), with the highly UV active 
quinazolinone side chain (30) has also been prepared in order that the level of 
background internal nucleophilic attack can be investigated on a diester 
analogue, which has yet to be synthesised.
Chapter 4.
The last section in this thesis has been directed towards the synthesis of the 
possible model receptors (20) and (21) for the enzyme carbonic anhydrase and 
a polyhydroxy receptor (22) for particular saccharide molecules. The precursors; 
trimesylate (27) or tribromide (28) have been synthesised successfully, although 
initial synthetic studies have resulted in only partial substitution to the 
diimidazole (30) or have shown extensive elimination to the monoimidazole 
dialkene (33). We have successfully synthesised all of the required precursors 
that will hopefully allow completion of model receptors for both the enzyme 
carbonic anhydrase and for various polyhydroxy molecules in the near future. 
There does, however, appear to be some limitation to the degree of substitution
IV
that can be tolerated on the basic cyclohexane molecule before elimination or 
only disubstitution reactions predominate.
V
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Chapter 1 
Catalytic Antibodies
1.1 Differences Between Antibodies And Enzymes
From the early part of this century chemists have been fascinated by ihe 
most intimate secrets of how enzymes function as Nature’s catalysts. 
They demonstrate intricate stereospecificities and astonishing turnover 
numbers. The origin of the enzyme’s power, as elucidated by 
experiments, is achieved by molecular recognition. Enzyme active sites 
are structured so as to selectively bind a specific substrate or substrates 
(E.S). Catalysis is achieved by using the binding energy non-covalently to 
stabilise the transition state of the reaction. The resulting reduction in the 
activation energy for the reaction produces a rate acceleration, (figure 
1.1).1-2
S + E E.S ----- ► E.P E + P
G
E UNCAT




(E.S) (E + P)
(E.P)
Rxn co-ordinate
Figure 1.1 Free energy diagram for enzyme catalysis.
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Just over a century ago Emil Fischer introduced the concept of enzyme- 
substrate complementarity in his “lock and key” analogy.3 Later Haldane 
suggested that the binding energy between the enzyme and the substrate 
was used to distort the structure of the substrate towards that of the 
product.4 Linus Pauling went further in suggesting that the ability of an 
enzyme to catalyse a chemical reaction stemmed from the 
complementarity of the enzyme’s active site structure to the activated 
complex or strained configuration (transition state) of the substrate rather 
than the substrate itself.1,2 Pauling’s idea has since been supported by 
much experimental evidence.
Since the transition state for a particular reaction, by definition, has a 
negligible lifetime (10'13 - 10*14 sec), evidence was sought for transition 
state stabilisation by observing the tighter binding of inhibitors whose 
structures resembled those of the presumed transition state relative to 
the weaker binding of the substrate.5,6 Indeed many examples of high 
affinity transition state inhibitors have been reported.7'9
With at least partial understanding of the features of enzymatic catalysis 
has come the desire to improve existing enzymes by genetic modification 
or chemical manipulation, producing enzymes of increased substrate 
specificity without loss of catalytic efficiency (the field of protein 
engineering).10,11 Having gained a greater understanding of molecular 
recognition and enzymatic power chemists began to search for enzyme 
mimics. In order for this to happen the generation of enzyme mimics 
requires the generation of receptors which are selective and contain 
catalytically active functional groups. To this end researchers have drawn 
on the remarkable capacity of the immune system to generate large 
numbers of antibodies that possess unsurpassed structural specificity 
towards virtually any molecule.12'15 The antibody response is therefore 
capable of fulfilling both of these requirements in providing the chemist 
with “designer catalysts” which utilise molecular recognition.
2
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It is important to appreciate that the natural immune response within the 
body is to generate antibodies that will bind to a particular antigen in its 
ground state, whilst an enzyme exhibits transition state complementarity. 
However, the fundamental processes that govern binding in both 
enzymes and antibodies is the same.1,2 In 1969 W. P. Jencks was the first 
to suggest that if antibodies were generated against a transition state for 
a particular reaction, they should catalyse that reaction, and the concept 
of catalytic antibodies or abzymes was born.16
1.2 The Antibody And Its Structure
Antibodies are molecules of the immune response that can bind to 
regions (epitopes) of any foreign materials such as viruses and bacteria 
thus triggering their elimination.17'23 The mammalian immune system 
produces immunoglobulin molecules in response to chemical groups 
(haptens) on the surface of foreign bodies. The driving force for evolution 
of the antibody specificity is the production of receptors with optimum 
binding affinity to molecules that are viewed as foreign. With no 
foreknowledge of the shapes to be encountered during a lifetime and the 
propensity of pathogens to rapidly mutate, Nature has developed a 
“catch-all” strategy utilising a positive feedback mechanism.
This mechanism is believed to operate as follows:- 
Antibodies are produced by a type of white blood cell known as a B- 
lymphocyte, and a human has of the order of 101° such cells. Each 
individual set of cells (or clones) will produce multiple copies of one 
antibody and in general a human will produce in the order of 108 different 
antibody molecules without contact with any foreign material. Within this 
naive set of antibodies there is expected to be enough diversity of 
molecular shapes in the antibody combining site to recognise virtually 
any foreign molecule, although only with modest affinity. When the naive 
repertoire expressed on the surface of the B cells (each cell expresses
3
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many molecules of an individual antibody) encounters an antigen, a small 
number of cells which express an antibody with affinity for the antigen will 
bind to it. These cells are stimulated and divide to produce more antigen- 
specific cells. In this process a greatly accelerated mutation of the 
antibody genes occurs leading to the generation of many new varieties of 
the first selected clones. This is a process known as ‘somatic mutation’ 
and a particular antigen now binds to and stimulates much more 
effectively those clones having the highest affinity for the antigen. The 
following rounds of mutation and selection thus act to improve on the 
germline antibodies. At the end of this process some cells become 
directed to secreting large amounts of high affinity antibodies, while 
others act as memory cells. For an individual to become immune to a 
given antigen the memory cells are immediately stimulated to produce 
high affinity antibodies on renewed contact.
The initial naive antibody repertoire of 108 molecules would require 107 
genes. This would require an enormous genetic load for each cell and 
therefore a much smaller set of gene fragments encoding for specific 
hypervariable regions is carried, and these are randomly recombined in 
antibody-producing cells to generate the larger set. This results in 
antibodies generated with combinations of different hypervariable 
regions, decorated with different side chains which create a wealth of 
binding sites ranging from flat surfaces to pockets. Presumably the 
variable gene segments and their expressed antibody repertoire reflects 
the efforts of the immune system, over evolution, to encode a diverse 
structural repertoire with the limited genetic code and number of B cells.
Antibodies are macromolecules made up of glycoproteins. There are 
many different classes of antibody, with the most common type of serum 
antibody being the immunoglobulin G (IgG), which contains a disulfide 
cross linked four chain structure, (figure 1.2). The structure contains two 
identical heavy chains of molecular weight approximately 50,000 (450-
4
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575 amino acids) and two identical light chains of molecular weight 
25,000 (220 amino acids).24 A comparison of monoclonal IgG proteins 
indicates that the carboxy terminal half of the light chain and about three 
quarters of the heavy chain from the carboxy end show little sequence 













Figure 1.2 Antibody IgG's consist of four chains, 
two heavy and two light, which in turn are built up of 
domains of similar architecture.
Variable regions are only seen to occur in the first 110 amino acids of the 
heavy (H) and light (L) chains. A fragment containing the entire L chain 
and all the variable, V and the first constant, C domains of the H chain is 
called the antigen binding fragment (F ab). Fragments of only VL and VH 
domains are designated the variable fragment (Fv). Although the range of 
an antibody’s binding specificity is vast, there is a large degree of 
structural and sequence homology between all antibodies. The variable 
regions of the L and H chains contain six hypervariable loops, or 
complementarity determining regions (CDRs), which form the antigen
5
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binding sites (3 CDRs on VH and 3 CDRs on VL). The variable region is 
made up of a twisted eight stranded (3-barrel onto which the six CDRs are 
grafted.27,28 It is important to note that the amino acid diversity within the 
CDRs leads to the vast variety of specificities shown by antigen binding 
sites. Since both H chains and both L chains are identical for any given 
immunoglobulin G molecule, the two antigen binding sites are also 
identical.
1.3 Production Of Monoclonal Antibodies
Following immunisation with an antigen, Nature is able to supply an 
unquantified mixture of antibodies with varying affinities to the antigen 
(polyclonal response).
In order that antibodies can be of use to the chemist, a pure strain of only 
one specificity is needed. A method was developed by Kohler and 
Milstein in 1975 to generate monoclonal antibodies.29 This has resulted in 
the production of cell lines that secrete a single species of antibody 
indefinitely. This process is now considered general and much literature 
is available on the subject.30 This process, known as the ‘hybridoma 
technique’, is shown schematically in figure 1.3 and involves selecting a 
single antibody-secreting cell (B lymphocyte), by serial dilution, to 
produce a single clone in large quantities. The B-lymphocytes have a 
limited life-span in culture medium, so the cells are immortalised by 
fusion with a B lymphocyte tumour. This produces fused cells called 
hybridomas which can now be grown on a particular medium known as 
HAT. The HAT medium contains hypoxanthane, aminopterin and 
thymidine, which is an inhibitor of natural nucleoside synthesis.31
Although normal cells can bypass this via an alternative pathway, the 
mutant tumour cells cannot, thus any non-hybridised myeloma or B- 
lymphocytes die.
6
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Figure 1.3 Schematic representation of hybridoma technology.
In this medium only fused hybridomas grow successfully and are 
propagated as individual clones by a process of dilution and plating 
(separation of single cells into microtitre wells), with each of the clones 
forming a stable and permanent source of a single specific antibody
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(figure 1.3).32 The clones can now be selected for their ability to bind to 
the hapten used for immunisation via immunological assays. In order that 
the catalytic activity of monoclonal antibodies can be detected, there is a 
requirement for large quantities of such antibodies (10 -50 mg). Of the 
many millions produced, only a few (0.1-5%), if any, will exhibit catalytic 
activity. Due to this inefficiency and the need to cut costs, rapid and direct 
screening methods have been designed, (see section 1.5).
1.4 Monoclonal Antibody Production Using Molecular Biology.
1.4.1 Combinatorial library systems created by phage display.
In 1988 it was shown that single chain antigen binding fragments (or 
scFv) of antibodies, in which the VL and VH regions are linked together by 
a 12-14 mer peptide, could be expressed in bacteria.33,34 Furthermore it 
became possible, using the polymerase chain reaction (PCR),35-37 to 
obtain larger amounts of heavy and light chain DNA for cloning from a 
mixture of antibody producing cells. Therefore in order to establish 
antibody repertoires; i.e. allow expression of Vh and VL genes in bacteria 
a cloning vehicle (vector) was required to get the antibody genes into the 
bacteria and expressed. To this end a bacterial infecting virus 
(bacteriophage) was favoured because the high level of infection allows 
the cloning of large numbers of antibody genes. The whole ensemble of 
phage, each containing one heavy and one light chain gene sequence, is 
collectively called a combinatorial antibody library. As a result of the 
heavy and light chain DNA being cloned into the phage vector separately, 
and because no knowledge of the in vivo combinations remains, a 
random combinatorial library is generated.
The first combinatorial antibody library was constructed from an 
immunized mouse using a novel lambda bacteriophage system as the 
cloning vector. An array of antibody Fab fragments binding the immunising
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antigen was identified and isolated from the library by probing with the 
antigen.38
From this early work the methodology was advanced to allow the 
expression of antibody fragment libraries on the surface of the phage 
particles39-42 buiiding on pioneering work of Smith on the expression of 
peptides at the phage surface.43 As a result the antibody-displaying 
phage have antibody genes contained inside the phage particle and the 
corresponding antibody on the outside. The distinct advantage of this 
system is that the specific antibody-phage can now be selected from the 
library by binding to the particular antigen which has been immobilised, 
by a technique called ‘panning’. Once a particular antibody phage has 
been selected it can be used to infect bacteria and grown up to produce a 
large amount of the particular antibody encoded for by the gene 
sequence found inside the original bacteriophage. Therefore the 
recognition and replication process become linked in a similar way as is 
found in B-cells in vivo.
A typical procedure for the generation and identification of binders from a 
combinatorial phage display library is described in figure 1.4. Before the 
phage vector can be constructed, the RNA from a tissue source 
containing antibody-producing cells, (e.g. from peripheral blood, bone 
marrow, or the spleen of a human) has to be isolated. The mRNA is then 
reverse transcribed to cDNA, and then the Fab part of the heavy chain and 
the light chain are amplified using the polymerase chain reaction (PCR). 
Alternatively, the heavy and light chain DNA can be amplified from semi­
synthetic genes. The PCR primers that are required incorporate 
restriction sites which can now be used to clone the PCR products into a 
phagemid vector. The ensemble of heavy-chain inserts in the vector is 
referred to as a heavy chain library, and a light chain library is similarly 
produced. When both chains are present, the new ensemble is referred 
to as a combinatorial Fab library.
9
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Figure 1.4 Strategy for cloning monoclonal Fab fragments from 
combinatorial libraries on the surface of phage.
The next stage is to ‘rescue’ the phagemid library and convert it to a 
phage display library, (figure 1.5). Within this new display library each 
phage expresses an Fab on its surface with the corresponding DNA 
inside. As mentioned earlier, the library is now ‘panned’ against the 
immobilised antigen, and the particular phage-Fabs are selected by their 
ability to bind to the antigen.
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Figure 1.5 Panning for selection of specific Fabs from the 
combinatorial display library.
Last in this process is to convert these specific phage-FabS into phagemid 
form so that they can be inserted into bacterial cells to produce soluble 
Fabs. The phage display technique can be used to produce and screen 
large numbers of antibodies from a library and it looks as though it may 
eventually replace existing hybridoma technology as the most commonly 
used method for generating monoclonal antibodies for catalytic purposes. 
Combinatorial libraries offer ready access to human monoclonal 
antibodies from immune donors, and so we can expect a thorough 
evaluation of the use of human antibodies in the therapy of infectious 
diseases, in particular viral diseases where current drugs have limited 
efficacy.
In the end a blend of design and randomisation followed by selection may 
also prove useful in the field of catalytic antibody generation.
11
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1.4.2 Antibodies without immunisation.
Lerner at the Scripps Institute, and Winter in Cambridge have developed 
a method for producing antibodies that does not require immunisation 
and the subsequent death of an animal.44 The ultimate goal of this work is 
to produce semi-synthetic antibody libraries that exhibit almost limitless 
binding specificities, mirroring our own immune response.
This library is referred to as semi-synthetic because the antibody 
framework is derived from natural antibodies but some, if not all, of the 
complementarity determining regions (CDRs) are derived from synthetic 
gene segments. Early work in this area utilised a single clone selected 
from a library of an immune donor.45 In this research a random 16 amino 
acid sequence was introduced over the CDR3 region of the heavy chain 
to generate a vast number of antibodies, with selection from the library 
using a number of antigens allowing for cloning with new specificities. 
Although the complete randomisation of all 16 amino acids would 
generate a library of 1020 antibodies, libraries have been constructed that 
match or exceed the diversity of clones generated by an animal at a given 
instant of approximately 107.
In one such example, Lerner generated a library derived from a human 
anti-tetanus clone against a new antigen, fluorescein.45 This resulted in 
the isolation of antibodies which had affinities for fluorescein, and found 
that some of the antibodies generated had comparable binding affinities 
to those obtained from mice immunized with free fluorescein. Thus a 
tetanus taxoid binding antibody has effectively been changed into a 
fluorescein binding antibody.
Although the generation of antibodies without immunisation clearly has 
many advantages over the use of immunized animals, there still appears 
to be a number of disadvantages. First, because a greater diversity of
12
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specific antibodies is typically obtained from an immunized library and 
second is that, in human therapy, the extent to which semi-synthetic 
libraries will be perceived as foreign is unknown.
1.5 Screening Techniques
There have been a number of screening techniques developed which 
include catELISA,46 chromogenic assays for hydrolytic reactions,50 
detection of catalytic activity through irreversible inhibition,47 
complementation with auxotrophic bacteria and yeast,48 and use of the 
polymerase chain reaction (PCR) with DNA tagged substrates.49
1.5.1 CatELISA.
Of the many screening methods available to the chemist, one of the most 
commonly used is an enzyme-linked immunosorbent assay (ELISA). In 
this method colonies from the hybridoma production are screened for 
their ability to generate antibodies that bind selectively to the original 
hapten and not the carrier protein. A variation of this technique that 
allows screening for catalysis of antibody libraries, catELISA,46 is shown 
schematically in figure 1.6. This alternative technique allows direct 
screening of the antibodies by their interaction with a substrate-protein 
conjugate attached to a solid phase on a microtitre plate. After this, the 
antibody catalysed conversion of substrate to product can be detected by 
standard ELISA techniques, by utilising antibodies that bind specifically 
to the product. In this way product-specific antibodies remain bound to 
the solid titre plate and can then be assayed with a second antibody- 
enzyme complex which binds specifically to the constant region of the 
first antibody. The anti-antibodies so generated are linked to an enzyme, 
most commonly alkaline phosphatase, which, upon addition of its 
particular phosphate substrate produces a detectable colour change. In 
general the intensity of the colour change is proportional to the amount of
13
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antigen-specific antibody in the supernatant under test, (in a particular 
microtitre well). As a result, thousands of hybridoma clones or an 
antibody library can be rapidly screened for their ability to catalyse the 
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bind to product in 
microtitre well
Colour detection
Figure 1.6 Schematic representation of catELISA.
In order that this technique can be an efficient method for detecting a new 
catalytic antibody, the anti-product antibody must be able to discriminate 
between the substrate and product structures. To produce a highly 
sensitive system the relative amounts of detection antibody and antigen 
must be balanced with the relative dissociation constants for the binding 
of the detection antibody to the substrates and products. In theory 0.1 
fmol dm'3 of antigen can be detected by ELISA utilising microtitre plates.
14
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In practice, allowing for discrimination between substrate and product and 
expecting a reasonable background rate for the reaction, the particular 
catalytic antibody would have to be present in the 1-10 nmol dm'3 range. 
Generally such catalytic species are present in the range 30-300 nmol 
dm'3, making catELISA a powerful and useful screening method for 
catalytic antibody supernatants.
1.5.2 Chromogenic assays.
Catalytic antibodies have been identified by a number of methods, with 
the most common involving the screening of a small number of different 
hybridomas, typically 25-100, by detecting the release of a chromogenic 
group. Gong50 has described a facile, rapid approach for generating 
chromogenic substrates which can be applied to a wide range of 
antibody-catalysed reactions. In this system the assay was developed 
using a p-nitrophenyl phosphonate (1) specific antibody 48G7 as a 
model, which has been shown to catalyse the hydrolysis of a number of 
nitrophenyl carbonates and esters, (scheme 1.1).
O
(1)
The chromogenic substrate (2) was designed such that antibody- 
catalysed hydrolysis at the carbonate should produce nitrophenol and 
indolylbutyric acid (3). The butyric acid was then shown to rapidly cyclize, 
yielding butyrolactone and 3-hydroxy indole (4) which rapidly undergoes 
spontaneous oxidative dimerization to afford the chromophore indigo (5)
as a precipitate (Xmax (H20 )  = 620nm, e = 29,700 mol'1m2). The indigo
produced is insoluble in water and so accumulates at the site of reaction, 
whilst the nitrophenol rapidly diffuses away from the indigo dye, thus
15
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affording a high detection sensitivity. This strategy should allow rapid 
synthesis of chromogenic substrates for many reactions and should 
ensure that a large number of antibodies generated can be examined by 
a simple qualitative and quantitative assay for their catalytic activity.
H p-nitrophenol





1.5.3 Detection of catalytic activity through irreversible inhibition.
Janda47 has been able to generate a semi-synthetic combinatorial 
antibody library utilising phage display technology (see section 1.4.2), 
and used this to select for a cysteine residue in the complementarity- 
determining regions of the antibodies so generated, (phage library 
generated to BSA conjugate of dithio ether (6)). This system has 
therefore been used to screen the semi-synthetic antibodies which 
contain highly nucleophilic residues at their antigen combining sites.
16
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N - 0
0
S - S '
Rac-( 6)
This could therefore be used as a possible screen for antibodies capable 
of catalysing transesterification or hydrolysis reactions, (figure 1.7).
Wall of 
/  micro- 
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Figure 1.7 Illustration of phage-display of Fab fragments to select for 
antibody-combining sites containing nucleophilic sulfur residues.
Phage-Fab fragments that contain nucleophilic cysteine residues were 
identified by utilising a microtitre plate derivatized with a-phenethyl 
pyridyl disulfide. This would render the phage-Fab fragment covalently 
bound to the plate via a disulfide exchange reaction. After a series of 
washings, to remove any unlinked phage, the phage-Fab disulfide link was 
cleaved from the microtitre plate by addition of dithiothreitol and then 
used to infect E. coli.
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Of 10 antibodies identified one, 32-7, was chosen for further investigation 
by over-expression and found to catalyse hydrolysis of thioester (7) with a 
moderate rate acceleration, and shown to have the following kinetic 
parameters, (kcat = 0.030 min'1, KM = 100 jimol, kcat/kUncat= 30).
Other more recent work by Janda51 has utilised a similar screening 
method and allows for the direct selection for catalysis of antibody 
libraries. In this process hydridoma technology and re-formatting in phage 
is coupled so as to link directly chemistry and replication. In this example 
the antibody catalysis of glycosidic bond cleavage is investigated due to 
it having a well understood mechanism.52 The reaction is believed to 
proceed through a flattened twist boat transition state which exhibits 
substantial sp2 character at the anomeric position. Antibodies were first 
generated against the BSA conjugate of hapten (8) to obtain an ‘enriched 
library’ of 100 binders (ELISA) using hybridoma technology. The RNA 
was then removed and reverse transcribed. A semi-synthetic 
combinatorial antibody library was constructed that expressed FabS on the 
surface of filamentous phage. The substrate (9), which was immobilised 
on the walls of a microtitre plate, (figure 1.8), was used in a mechanism- 
based panning procedure to select phage-FabS from the library that 
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The mechanism-based inhibition is produced as a result of glycosidic 
cleavage of the difluorophenol moiety generating the reactive quinone 
methide species (10) which traps the phage-Fab that catalysed its 
generation by alkylating near its active site. After a washing procedure 
the phage-Fab can be cleaved from the linker via a disulfide exchange 
with dithiothreitol (DTT). The phage-FabS can now be expressed as 
soluble Fabs after conversion to phagemid form and expression by 
bacterial cells.




















Release of ’trapped’ 








Figure 1.8 The mechanism-based panning procedure for the selection of 
antibodies that can catalyse the hydrolysis of the glucopyranoside substrate.
One phage clone Fab-1B was identified by the glycosidic bond cleavage 
of the indolyl-glucoside (11), which after oxidative dimerization, produced 
the indigo analogue (12). Fab-1B was chosen for further investigation by
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over-expression and found to catalyse the hydrolysis of the nitrophenol 
glucopyranoside (13) with the following kinetic parameters; kcat = 0.007 















(12) - Blue precipitation 
A number of other approaches to direct screening of catalytic antibodies 
have involved immobilised biotin streptavidin systems for the detection of 
proteolytic activity at very low levels. This has allowed the detection of 
chymotrypsin53 at 10 nmol dm*3, whilst using a slightly different approach 
trypsin54 at a concentration of 0.5 ng pi'1 has been detected.
1.5.4 Complementation of auxotrophic bacteria and yeast.
The catalytic activity of antibodies has also been investigated utilising 
micro-organisms with blocked biosynthetic pathways as selectors. 
Hilvert48,55 has identified such catalytic antibodies by this method. The 
chorismate mutase antibody IF7 has been expressed in the cytoplasm of 
yeast as a functional Fab allowing it to substitute for chorismate mutase in
20
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vivo. The result is to confer a significant growth advantage to a 
permissive (not containing natural chorismate mutase) yeast strain, and 
in doing so demonstrates the possibility of identifying catalytic antibodies 
by the growth advantage conferred on the micro-organism.
In another such example Benkovic56 has detected an orotate 
decarboxylase antibody, (figure 1.9) using a pyrimidine auxotrophic strain 
of E. coli and recombinant antibody technology. From figure 1.9 the upper 
route involves the naturally occurring enzymes orotate 
phosphoribosyltransferase (ORTase) and OMP decarboxylase 
(ODCase). The mutant strains lacking one or both of these enzymes 
could complete the route to uracil monophosphate (UMP) with an 
antibody for orotate decarboxylase and the naturally occurring enzyme 
uracil phosphoribosyltransferase (Uracil PRTase). Six cultures were 
found to express Fab genes that conferred a significant growth advantage 
to the original auxotrophic strain, of these, one in particular, has been 
expressed as a single chain antigen binding protein and is currently 
being characterized further.





















Figure 1.9 Pathways for UMP biosynthesis.
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1.5.5 PCR amplification of DNA tagged substrates.
A reaction cassette has been designed by Fenniri et a/49,57 for the highly 
sensitive detection of the making and breaking of peptide bonds. In this 
method a construct, in which the substrate (a pentapeptide) is linked to a 
45-mer DNA peptide, contains information about the sequence of the 
peptide and two primer sequences. This construct is tethered to a solid 
matrix so that if the substrate is cleaved by exposure to a library of 
catalysts, the polynucleotide tag can be isolated and detected after 
amplification by the polymerase chain reaction (PCR) to indicate the 
substrate specificity of the protease. The system can similarly detect 








PCR on solution 
[Bond cleavage detection]
Substrate
PCR on solid support 
[Bond formation detection]
Figure 1.10 The encoded reaction cassette: spacers ( ' ^ )  separate reaction 
substrate from matrix support and polynucleotide. An active catalyst either binds or 
frees the polynucleotide. Bond cleavage is detected when the solution is submitted to 
the PCR to detect free polynucleotide, and bond formation is detected by subjecting 
the solid support to PCR. The PCR products are analysed by gel electrophoresis.
Furthermore, the sequence of the polynucleotide may be chosen in such 
a way that it reflects the nature of the substrate, so that a library of
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encoded substrates could be designed. On exposure to a library of 
catalysts, one can identify both the catalysts and substrate, since the 
sequence of the cleaved polynucleotide encodes and thus identifies 
which substrate sequence has been cleaved. The system has been used 
successfully to detect oc-chymotrypsin activity at 1 pmol levels and could 
be applied in future to detect catalytic antibody activity from combinatorial 
antibody mixtures.
In a similar simplified version of the above approach, the catalysis of 
amide bond formation by oc-chymotrypsin58 was investigated. The 
formation of a new amide bond between a matrix supported 
phenylalanine carboxyamidomethyl ester and a HLeu-cystamine-LeuH 
group was observed. The disulfide linkage of this group could then be 
cleaved by DTT and a new disulfide bond formed with an oligonucleotide 
tag. Hybridisation of this tag with the pCantab 5 vector and PCR 
amplification has allowed a-chymotrypsin activity of 10 pmol to be 
detected.
1.6 Catalytic Antibody Review
In 1969 W. P. Jencks was the first to suggest than an antibody generated 
against a transition state for a particular reaction should catalyse that 
particular reaction.16 At this time the technology was not available but the 
concept of producing catalytic antibodies was born. It was not until 
seventeen years later that groups led independently by Lerner59,60 and 
Schultz61 prepared the first monoclonal catalytic antibodies for 
carboxylate ester/ carbonate hydrolysis. The field of catalytic antibodies 
is very young and to date the best rate enhancements achieved in a 
reaction by such an antibody has been 6 x 108 faster than the 
uncatalysed reaction.62 Whether rate enhancements comparable to those 
with enzymes can be achieved still remains to be seen.
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There are a number of mechanisms by which an enzyme can induce 
catalysis. One of the most important method is transition state 
stabilisation.
Catalysis can be also be achieved by any one of a combination of the 
following mechanisms:
1. General acid catalysis.
2. General base catalysis.
3. Reduction of unfavourable entropic terms ( i.e. use of free energy 
traps).
4. Electrostatic catalysis.
5. Use of cofactors at the active site (change of mechanism).
6. Covalent catalysis (change of mechanism).
The generation of catalytically active antibodies has also been 
demonstrated utilising each of these mechanisms and since the initial 
successes of catalytic antibodies in 1986, many reactions have been 
catalysed by monoclonal antibodies. It is generally considered that the 
outcome of the catalysed reaction is dictated by the binding energy 
generated in the antibody binding site and to this end initial investigations 
focused on simple, well understood transformations. These reactions had 
transition states that were both electronically and sterically distinct from 
the substrate. For example, antibodies were used to stabilise negatively 
charged tetrahedral transition states found in the hydrolysis of esters,63 
amides,64 carbonates65 and also those found in acyl transfer66 reactions. In 
these examples the acyl carbonyl was replaced by a tetrahedral 
phosphorus;67 a number of such transition states are shown, (figure 1.11).
Recently, more sophisticated antibodies have been generated by 
immunisation against haptens that produce antibodies with catalytic 
groups at their binding sites.68 Nucleophilic and general base catalysis68"70
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has been achieved by utilising the so-called ‘Bait and Switch’ principle, 
which generate antibodies that have a basic or nucleophilic carboxylate 
group situated in the active site, and to date over sixty different chemical 
reactions have been catalysed by antibodies.
ev  v sv° sv/ P \  / P \  / P \
R OR' R NHR' RO OR' R SR'
Phosphonate Phosphonamidate Phosphate Phosphoathionate
Figure 1.11 Possible transition state analogues.
In recent times the field of catalytic antibodies has focused on reactions 
that are chemically difficult to achieve. This has been undertaken in the 
hope of increasing the practicality of such catalysts in chemistry and to 
allow for a greater variety of practical uses for antibodies. A list of some 
of these such areas is given below:
1. Control of stereoselectivity.
2. Control of group regioselectivity.
3. Group transfer reactions.
4. Consecutive reactions.
5. Chemically disfavoured reactions.
6. Clinically useful antibodies.
7. Antibody mimics of enzyme catalysed C-C bond formation.
8. Antibodies used for cationic cyclizations.
A selection of the reactions studied in the above areas will now be given 
below, although there may be some degree of overlap between the 
methodologies used.
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1.6.1 Stereoselective antibody catalysis.
The ability to design reactions in organic synthesis that exhibit stereo 
control and generate molecules of a single chirality has become a very 
important focus in organic chemistry. Enzymes have been used in a 
number of chemical applications, due to their remarkable specificities, but 
the number of enzymes available is limited. The generation of enzyme 
mimics capable of similar stereo- and regio-selectivity on new substrates 
would be of great value. To this end antibodies with binding sites that will 
bind one particular enantiomer are of great interest. These should 
discriminate between prochiral transition states and enable catalysis of 
reactions with high stereoselectivity.
A number of reactions have been investigated which utilise substrate 
enantioselectivity and one of the first examples to demonstrate 
stereoselectivity was the diastereoselective ester cleavage of various 
phenylacetate esters by Kitazume et al (figure 1.12).71
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In this example, Kitazume generated antibodies, using BSA conjugates, 
to both of the enantiomers of the phosphonate (15). Of the antibodies 
obtained, some were able to catalyse the stereospecific hydrolysis of 
(16). The antibodies generated against the R-hapten (15) were found to 
catalyse the hydrolysis of racemic ester (16) to give solely R-difluoro-2- 
decanol (17) in 99% ee. Similarly, antibodies generated against the s- 
hapten catalysed the hydrolysis of racemic ester (16) to give only the s- 
difluoro-2-decanol (17) in 98% ee. These results also indicate how 
important a role antibodies can have in catalytic resolution methodology.
The control of protonation of a prochiral enol ether substrate is a very 
important process in organic chemistry and Lerner has recently attempted 
to catalyse the protonation of such substates.72,73 In other work by 
Keinan74, the A/-methylpiperidinium cation (18) was used as a transition 
state analogue for the acid catalysed hydrolysis of the epoxide (19). It 
was found that using the antibody generated previously by Lerner, the 


















Using enantiomerically pure (1S,2S)-(19), (2S )-(20) and (2R )-(20) the 
enantioselectivity of Lerner’s antibody 14D9 was probed. It was found
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that the hydrolysis of (1S,2S)-(19) gave the corresponding (ls,2R)-diol (21) 
in 87% ee but failed to produce optical enrichment of (2S)-(20) or (2R)- 
(20 ) to the diol (22). Antibody 14D9 was found to exhibit the following 
kinetic parameters; kcat = 2.5 x 10'5 s'1, Km = 2.5 x 10*4 M, kcat/ kunCat = 440, 
ee = 87%. The reason behind this selectivity seems to be that the two 
methylene groups in the five membered ring of the epoxide (19) are 
responsible for interactions that allow the kinetic resolution, because 
these are not present in epoxide (20). As a result of this observation it 
appears that the choice of substrate as well as hapten is important in 
considering design of antibodies for enantioselective reactions.
In organic synthesis, the control of enantioselective proton transfer 
reactions has proved very problematic. With enzymes, however we are 
able to selectively protonate one side of a prochiral substrate with ease. 
Due to such difficulties attempts have been made to generate catalytic 
antibodies capable of comparable selectivities. Work by Lerner75 has 
resulted in the generation of antibodies capable of enol ester hydrolysis, 
as seen before, and to effect enantiofacial protonation of enolates that 
are produced. Therefore antibodies were generated against the KLH 
conjugate of hapten (23), (figure 1.14).
(25) R = (CH2)2Ph (26) (27)
Figure 1.14
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In order that the antibodies generated would influence chirality through 
enantiofacial protonation, rather than ester hydrolysis, a methyl group in 
the substrate (25) was designed to be adjacent to its original position in 
the hapten (24). Of several antibodies isolated, one was found (27B5) 
which directly protonated the product enolate (26) with modest 
enantiofacial selectivity of 42% ee for the R- form of the ketone (27) with 
a rate acceleration of 300 over the background reaction.
It is therefore clear that catalytic antibodies generated to suitable haptens 
can control, enantioselectively, a wide range of chemical transformations 
and that if the hapten mimics the transition state for more than one 
reaction type, a variety of reactions can be catalysed.
1.6.2 Control of group regioselectivity.
Another extremely important and challenging objective for the synthetic 
chemist are to conduct reactions which involve both regio- and stereo- 
control, for example, the selective reduction of diketone (28) to a single 
diastereoisomer of the hydroxy ketone (29).76 The similar environments of 
the two carbonyl groups render the regioselective reduction of one very 
difficult even using the most modern chemical methods. In order to 
catalyse the regio- and stereo-selective reduction of (28), antibodies were 
raised against the A/-oxide hapten (30), (figure 1.15). The antibodies 
generated should not only be able to stabilise the tetrahedral transition 
state resulting from nucleophilic attack of hydride on the carbonyl group, 
but also direct its regio-selective addition to the nitrobenzyl substituted 
carbonyl group on the substrate (28). A highly stereoselective reduction 
should also occur due to the chiral environment of the antibody binding 
site.
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Antibody 37B 39.3  
kcat = 1.6 x 10-3 s-1 Product(29), (S) = 96.3% ee
Km = 52(iM at 50 mM NaCNBH3
kcat/kuncat= 2 . 0 x 1Q6M pH 5.0 , 22oC
Figure 1.15
Similar work has been undertaken by Schultz77, who has generated 
antibodies against the KLH conjugate of the hapten (31) for a very similar 
reaction for the reduction of the ketone (32), also utilising sodium 
cyanoborohydride. In this example antibodies were generated that 
allowed the regioselective and enantioselective reduction of the a-keto 
amide (32) to the (2S)-a-hydroxy amide in 99% de.
(31) (32)
Chemical manipulations involving saccharides or polysaccharides are 
often found to be extremely problematic due to the similarity in reactivity 
of many of the hydroxyl groups present. To this end Fujii78 has developed 
an antibody system to catalyse the regioselective removal of acyl
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protecting groups from the C-4 hydroxyl, (figure 1.16). In this work Fujii 
generated antibodies to a conjugate of hapten (35) and from the 
antibodies generated, two were found to catalyse the hydrolysis of the 
substrate (33) to the alcohol (34). Of these one, 17E11, was found to 













The ability to manipulate polysaccharides through specifically cleaving 
glycosidic bonds is of great interest to chemists as much of the selectivity 
required still eludes us. Therefore, the generation of antibodies that could 
specifically do such a transformation would be of much importance to the 
saccharide chemist.
Lerner79 has generated antibodies against a KLH conjugate of the hapten 
(37) and used the antibodies to test for glycosidic cleavage using the 
model glycoside acetal (36), (figure 1.17). From this, two catalytic 
antibodies were isolated with one of these, 14D9, found to exhibit the 
required hydrolytic properties.
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Antibody 14D9 ; kcat = 7.8 x 105s-1, Km, = 100 jjJVI, K|(38) = 35 mM, 
(kcat/kuncat = 70 (at pH 5.7, 2 0 °C))
Figure 1.17
Although the reaction of glycosidic bond cleavage has been achieved, 
albeit only modestly, with a rate enhancement of 70 over the uncatalysed 
reaction, this work has taken useful steps towards a more efficient 
catalyst in the near future.
1.6.3 Group transfer reactions.
Catalytic antibodies, like enzymes, have been shown to catalyse group 
transfer reactions which exhibit two mechanistic subtypes, either by direct 
group transfer between the antibody-bound donor and substrate 
acceptor80,81 or by an indirect group transfer through an intervening 
covalently-bound antibody donor species.82
Considering the first of these mechanisms, an example of direct transfer 
between antibody donor and substrate acceptor is the antibody
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generated by Benkovic83 which was used for the enantioselective 
aminolysis of the lactone (39) as shown, (figure 1.18).
o o  OH
H2N— V- NH2 --------► H2N - / —y - N - ^ ^ s- / ^ NHAC
k ^ ^ N H A c  \ = /  \ = /  H
(39) (40) (41)
Antibody 24B11
kcat = 1 . 2 x 1 0 - 3  s-1 kcat/kuncat = 16 M
Km (39) = 4 . 9 x 1 0  -4 M kcat/kuncat = 16 M
Km (40) = 1.2 x 10 -4 M K| (42) = 38 nM
(at pH 7.0, 25 °C)
(42)
Figure 1.18
This highly enantioselective aminolysis of lactone (39) with p- 
phenylenediamine (40) was studied using steady state kinetics by 
measurement of the initial rates of product formation upon variation of the 
concentration of either lactone (39) or phenylenediamine (40) in the 
presence of the antibody.
Of the antibodies generated against the phosphonate hapten (42), one 
24B11, revealed a random equilibrium reaction pattern as indicated, 
(figure 1.19). It was therefore found that the binding of the lactone had no 
effect on the subsequent binding of the p-phenylenediamine (40) or vice 
versa, suggesting that the two substrate binding sites are 
conformationally independent. These results also indicate that the 
reaction shows random sequential kinetics with respect to lactone (39) or 
amine (40) as shown, (figure 1.19).
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Ab + (39) Ab.(39) + (40)
Ab + (40)=?==^ Ab.(40) + (39)
Chapter 1
Ab.(39).(40) Ab.(41) Ab + (41)
Where Ab represents the antibody
Figure 1.19
In another example studied by Schultz81 the kinetic parameters were 
measured for the antibody catalysed aminoacylation reaction shown, 
(figure 1.20). The kinetic data obtained indicated that the reaction 
proceeds via the direct transfer mechanism mentioned earlier. In this 
reaction antibodies were generated against a KLH conjugate of the 
hapten (46) and of the many generated, one antibody, 18R. 136.1 was 







R = CH2CN, R-, = CH3
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Antibody 18R.136.1 kcat = 0.24 s-1 ; Km(43) = 770 ^M; Ky(44) = 260 nM; k^t lkimcejl = 2.1 x 10 8 M
Figure 1.20
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Aminoacylation at the 3’-hydroxyl group of the thymidine (43) with the 
acyl donor ester (44) was found to exhibit random sequential binding 
similar to that indicated for the previous antibody example (24B11). From 
the kinetic data, the kcat/kuncat value of 2.1 x 108 is extremely large and thus 
indicates that the catalytic antibody 18R.136.1 is a very efficient catalyst.
The second of the group transfer reaction types catalysed by antibodies 
are those which show indirect transfer via a discrete acyl-antibody 
intermediate. In the first example of this type of antibody catalysed 
reaction, the hydrolysis of the amide (47) and ester (48) were undertaken 
utilising an antibody generated by a KLH conjugate of the hapten (49) as 
shown, (figure 1.21).67 Of the antibodies generated one, NPN43C9, was 
found to catalyse hydrolysis of the amide (47) with a rate acceleration of
2.4 x 105 compared to the uncatalysed reaction. This is much higher than 
a reaction catalysed by only transition state stabilisation and indicates 
that some other mechanism is operating.
...... ^
°2 n h 0 ^ x t ^ O k^ A(CH2)3C° 2H An"body
o 2n -<  y - x
0  N P N 43C 9
O
(47) X = NH y _ ^ ( C h y  c o  H
(48) X = O
O
o
(49) R = (CH2)3C 0 2H
(50) R = CH3
Antibody N P N 43C 9
kcat ~ 8 .3  X 1 0 -4  s-1
K m  = 370  pM
K|(50) = 1 0 p M
kcat/kuncat = 2 .4  x 1 0 5 M
pH 9.0, 37 C
Figure 1.21
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D20  solvent effects and oxygen-18 labelled water studies with the 
antibody NPN43C9 established that a multi-step mechanism via an acyl- 
antibody intermediate existed, as shown, (figure 1.22).
k1 k2 k3[-OH] l<4 k5
Ab + S - ~ —  Ab.S —  Ab.I.Pi -------► A b .P i.P 2 ^ r—*-A b .P 2-N —-  Ab
k-1 k-2 i  *
Where kj are the rate constants, I is the acyl moiety of the substrate, Pi is 
the alcohol or amine leaving group and ?2 the parent acid of the substrate.
Figure 1.22
82In a separate example of an indirect group transfer reaction, Benkovic' 
has generated an antibody for the transesterification of a variety of esters 
(52-55) derived from the parent acid (51), from the benzyl alcohols (56) 
and (57) as shown, (figure 1.23).
Ach^  /
o'
Rl = CH3 (56) 
H c / W  r 2 = H  (57)
Antibody 21H3
(51) R =  H
(52) R =
<53) R = 4 - ( 3 -
(54) R =





Antibodies were generated against a KLH conjugate of the hapten (59), 
and of several isolated, one 21H3 was found, that from steady-state
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kinetic analysis of the reaction, exhibited indirect acyl group transfer 
esterification of the substrate (52) to the ester (58). The data suggested 
the formation of a discreet acyl-antibody intermediate, which was 
confirmed by extending the reaction to include other substrate pairs.
A further direct demonstration of the formation of an acyl-antibody 
intermediate was achieved by incubation with the p-nitrophenol ester (X) 
at various concentrations of antibody 21H3. p-Nitrophenol was liberated 
in equivalent amounts, followed by a steady-state, thus indicating the 
formation of an acyl-antibody intermediate as shown, (scheme 1.24).84
Where Ab represents the antibody, Ab.l the acyl-antibody intermediate, 
Y the substrate alcohol and P the product ester.
Figure 1.24
1.6.4 Consecutive reactions.
One of the most fascinating areas of catalytic antibody design is the 
ability to design catalytic systems that have no enzymic counterparts. 
Consecutive reactions and all other stepwise processes present the need 
to encounter and stabilise more than one transition state. In an example 
of an antibody catalysed consecutive reaction, the conversion of 
asparginylglycine /V-phenethylamide (61) to the intermediate succinimide 
(62) and the subsequent hydrolysis of the latter to the aspartate 
derivative (63) and isoaspartate derivative (64) is typical (figure 1.25).85
Y
Ab + X Ab.X ^  A b.I.Y Ab + P
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The antibodies were generated to the amino phosphinate hapten (60), 
which has two tetrahedral transition-state mimics (the phosphinate and 
secondary alcohol) in order to create an antibody binding site capable of 
stabilising the two separate transition states in the reactions. Of the 
antibodies generated, two classes were identified; those that catalyse the 
only the succinimide hydrolysis and those that catalyse both the
deamination and succinimide hydrolysis steps. From the many antibodies 
isolated, one 23C7 was found to catalyse the hydrolysis of the
succinimide, and another 2E4 was found to catalyse both the
deamination reaction and the subsequent hydrolysis reaction. The 
reaction kinetics for the hydrolysis of the succinimide (62) by the antibody 
23C7 were found to fit the reaction scheme shown, (figure 1.26).
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Asp (63) 5^










Ab. Isoasp (64) ■„ — Ab + Isoasp (64) 
Isoasp (64) k_3
Figure 1.26
Antibodies 23C7 and 2E4 both catalysed the hydrolysis of D- and L- 
succinimide to aspartic acid derivative (83) and isoaspartic acid 
derivative (64) to the ratios shown, (figure 1.27). It is important to note 
that the antibody 23C7 favours the formation of the aspartic acid 
derivative (63) with the D-succinimide (62) and the isoaspartic acid 
derivative (64) with the L-succinimide (62). The reverse is found for the 
enantioselectivity of antibody 2E4. This indicates that a bi-functional 
transition state analogue can be used to generate antibodies that 





D-succinimide L-succinimide D-succinimide L-succinimide
Isoasp/Asp 
ratio (uncat=3.5)
1.2 16.4 4.7 2.4
Figure 1.27
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1.6.5 Chemically disfavoured reactions.
One of the most promising features of catalytic antibodies is the ability, by 
careful design of hapten, to generate a catalyst for virtually any reaction. 
Using antibody catalysis it has been possible to catalyse reactions that 
have no biological counterparts and to give products that are not most 
favoured chemically. In many such reactions, for example Diels-Alder and 
intramolecular cyclization reactions, the product ratios can be understood 
in terms of the stereoelectronic properties of a favoured and a 
disfavoured transition state. In the case of the Diels-Alder reaction, an 
exo or endo mode of cycloaddition is possible with the endo product 
being that favoured under kinetic control. For intramolecular cyclization 
reactions, a 5-exo-tet or 6-endo-tet nucleophilic substitution can occur but 
kinetically the 5-exo-tet product is favoured. In these reactions, the 
binding interactions between the substrate(s) and antibody block off the 
kinetically favoured pathway, or make its transition state higher in energy 
than that of the disfavoured product, so re-routing the reaction.
In one such example, an antibody catalysed intramolecular cyclization 
reaction, Lerner86 has generated an antibody that overcomes these 
constraints and catalyses the highly disfavoured 6-endo-\eX ring closure 
of the epoxy alcohol (65) to form the tetrahyd ropy ran (68), (figure 1.28). 
This antibody-catalysed reaction is in disagreement of Baldwin’s 
guidelines for ring closure, which state that in the case of an 
intramolecular nucleophilic substitution reaction, the favoured product 
arising from the preferred 180° transition-state geometry is the 5-exo-tet 
product (66).87 Two factors must be overcome before antibody catalysis 
can occur. An antibody must lower the energy barrier for the epoxide (65) 
ring opening and also overcome the entropic barrier and strain necessary 
to bring the hydroxyl into a geometry that favours a six membered versus 
a five membered transition state.
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(66)-Racemic (67) R = NHC0(CH2)3C 02-Iinker (68)
Figure 1.28
Antibodies were generated against the A/-oxide (67) in the hope that the 
N-oxide would generate an antibody binding site that would stabilise both 
the developing charge in the breaking of the C -0  bond and the six- 
membered-ring transition state of the disfavoured 6-endo-XeX reaction.
Of the antibodies isolated, one was found, 26D9, to catalyse the 
regioselective ring opening of the epoxide (65) to form the six-membered- 
ring product (68). In the absence of antibody the uncatalysed reaction 
was in agreement with Baldwin’s guidelines, favouring the 5-exo-tet ring 
closure to give only the tetrahydrofuran (66). The value of kcat/ IWat could 
not be established as k unCat (6-endo-XeX)=0, but only the s,s-epoxide was 
found to be a substrate for this antibody, indicating that the antibody 
controls both the regio- and stereo-chemistry of this reaction.
This antibody catalysed reaction underscores the degree to which the 
relative energies of the transition states can be controlled, and in some 
cases reordered, by using the selective binding of the antibody.
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1.6.6 Medicinal applications of antibodies.
The use of catalytic antibodies in medicine has been proposed as a 
potential method for the activation of prodrugs, but to date no examples 
have been seen in direct medical applications. To demonstrate the 
possibilities that catalytic antibodies may play in medicine in the future, 
two examples are given below. The first of these has involved the 
development of an antibody by Schultz.88 The KLH conjugate of the 
hapten (72) was used to generate antibodies capable of hydrolysis of an 












kcat = 5.0x10-4 s-1
KM (70) = 2.18 x 10-4 M
K,(72) = 0.27 pM
kcat /kuncat = 968




A number of antibodies were isolated and of these one, 49.AG.659.22, 
was found to catalyse the hydrolysis of the prodrug (70). The kinetic
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parameters for this reaction are given, (figure 1.29), and indicate an 
almost 1000 fold increase in the rate of hydrolysis over the background 
reaction. The antibody 49.AG.659.22 was used in a number of in vitro 
and in vivo tests, and was found to inhibit the growth of E. coli after 
prodrug administration, thus indicating the possible use in future anti­
cancer chemotherapy.
The second system studied has involved the possible treatment of 
cocaine addiction by utilising antibodies generated against the hapten 
(75).89 The aim therefore was to generate catalytic antibodies capable of 
hydrolysing cocaine (73), in particular the benzoate ester functionality, 





(75) R = Linker
-OMe
Km(73) = 490 pM
kCat = 1.8 X 10-3 s-1
K,(76) = 2.0 |iM
at pH 7.5, 30°C
Antibody SB9
(76) R = CH3 
Figure 1.30
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Of the antibodies isolated, two were found to hydrolyse cocaine. One 
antibody, SB9, was studied further. This was found to catalyse the 
hydrolysis of cocaine to the ecogonine methyl ester (74) and benzoic 
acid, neither of which possess any marked stimulant activity, with a rate 
acceleration over the background reaction of 540. Although this is not a 
therapeutically useful level of deactivation, better antibody catalysts 
generated in the future may be particularly useful because at present 
there are no drugs available to prevent cocaine reaching receptors in the 
brain. As a result, cocaine addiction is one of the most difficult addictions 
to treat.
Further research into this area has been undertaken,90,91 but has yet to 
advance the results seen here.
1.7 Conclusions
A wide range of chemical transformations have been achieved 
successfully utilising the power of antibody catalysis, generating specific 
products with precise control of the stereo- and regioselectivity. The 
immune system has shown the ability to catalyse an ever increasing 
number of reactions with activities approaching that of enzymes. The 
ability to generate antibodies with variable binding specificities by 
conducting mutagenesis on combinatorial systems has led towards the 
generation of catalytic antibodies without immunisation, and new 
screening methods have allowed easier identification of potential 
catalysts. Antibody catalysis has moved from simple transformations to 
reactions which require a high degree of control over transition-state 
energies in order to achieve chemical selectivity. The ability of antibodies 
to catalyse such reactions stems from their high affinity and selectivity, 
and the ability of the experimenter to utilise haptens that more closely 
resemble the reactions transition-state structure(s).
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There have been a number of techniques developed to screen for 
catalytic antibodies (see section 1.5). These include catELISA,1 detection 
through irreversible inhibition,2 complementation with auxotrophic 
bacteria and yeast,3 polymerase chain reaction with DNA-tagged 
substrates4 and more commonly the use of a chromogenic assay.5 The 
aim of this project is to utilise the ‘firefly’, (Photomus pyralis), 
bioluminescent reaction (see section 2.3) to screen directly for catalytic 
activity of ester/ amide hydrolysing antibodies.
W e have designed and are in the process of synthesising transition-state 
analogues for the generation of antibodies capable of releasing substrate 
molecules for the luciferase enzyme from fireflies. W e hope that by 
measuring the light emitted by a specific bacterial colony that co­
expresses the firefly luciferase and phage displaying antibody fragments, 
a rapid assay system can be established.
W e have developed a coupled assay which should be capable of 
measuring the catalytic activity of antibodies which exhibit such 
hydrolytic activity. In this assay antibodies that can catalyse the release 
of the luciferin (2) from an inactive precursor (1) will allow the luciferase 
enzyme to act, with the appropriate co-factors, on (2), thus emitting a 
quantum of visible light, (figure 2.1). This we hope will be detected by a 
sensitive luminescence spectrophotometer.
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2.2 Mechanism Of Action Of The Chemiluminescent Luciferin/ 
Luciferase Reaction
For many years chemiluminescent reactions have been known, in 
particular, the biochemiluminescent reactions involving luciferins and 
luciferases.6 The firefly luciferase catalyses the conversion of S-luciferin 
(2) to the dialkoxide luciferin derivative (7), (scheme 2.1).
ATP PPi










Firefly luciferase ^  s
(3)
o AMP









Scheme 2.1 Mechanism of action of the firefly luciferase enzyme.
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The luciferase reaction mechanism is believed to involve the formation of 
luciferyl AMP (3), catalyzed by the luciferase and requiring ATP and 
magnesium as co-factors. The luciferyl AMP then undergoes oc- 
deprotonation by an active cysteine residue at the luciferase active site. 
Addition of molecular oxygen to the luciferyl AMP anion (4) affords the 
strained dioxetanone (5). This rapidly undergoes a retro 2k  + 2n  cyclo- 
addition reaction. Applying the Woodward-Hofmann rules, one would 
expect this to occur with the generation of the excited product molecule 
(6). Relaxation of this excited state to the ground state causes emission 
of a quantum of light and the generation of molecule (7).
2.3 Chemiluminescence - The Light Emitter
The chemically produced excited states are proposed to arise from the 
dioxetanone (5) collapsing affording, briefly, the excited cyclic ketone 
product (6), which on relaxation produces the oxidized dialkoxide (7) and 
a yellow-green light (ca. 560 nm). Under certain conditions, for example 
higher temperatures, a red light is emitted instead (ca. 630 nm). The in 
vitro luciferase-catalyzed oxidation also yields a.yellow-green light, but 
only produces the red light emission lower pH or in the presence of heavy 
metals.
The consequence of these conditions is that yellow-green or red light is 
produced as a result of relaxation of the excited species (6) or (7), 
although relaxation through (7) predominates in vitro, as shown in the 
Jablonski diagram, (figure 2.2).
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A +B Production of light by a chemical reaction
A = Firefly luciferin substrate
B = Firefly luciferase enzyme
N
v C* = Excited product molecule
HO'
(Product)
Figure 2.2 Jablonski diagram for the firefly chemiluminescent reaction.
The quantum yield of the bio- or chemiluminescent firefly luciferin 
reaction has been dissected into three main components:6
(a) The fraction of reaction that produces the potential light emitter, <J>R.
(b) The fraction of the potential light emitter that is formed in its excited 
state, 0 Ex •
(c) The fraction of excited states that emit light, (quantum yield of 
fluorescence),
The overall probability that luminescence will occur, Opl is given by the 
equation:
O p L =  O r .O e x .O fl
In the luciferase-catalyzed bioluminescence of the native firefly luciferin in 
vitro, the efficiency of the light production has been reported to be 88 +/-
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12%. In order for the quantum yield to be this high the value of each of 
the components (Or.Oex- ^ fl) must be nearly 100% efficient and therefore 
the yield of the chemically produced excited states in this system must 
also be nearly 100%. The firefly chemiluminescent reaction is currently 
the most efficient system known.
2.4 Luciferin Biochemical Assays
As a result of the light given out when one molecule of s-luciferin is 
degraded, a very sensitive chemiluminescent assay could be developed. 
For example, Toya et a l7 have produced various 6-O-alkanoyl luciferins 
(8) and 6-O-phosphoro luciferin (9) based on the firefly luciferin 
substrate, and used them as substrates in the bioluminescent assay of 
hydrolytic enzymes, such as carboxylic esterase and alkaline 
phosphatase, (figure 2.3).
R = H, luciferin substrate (2)
R = acyl, 6-O-alkanoylluciferin (8)












Mg2+ / ATP / 0 2
Figure 2.3 A bioluminescent assay for the detection of hydrolytic 
enzymes.
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The esterase/ phosphatase will hydrolyze the luciferin ester and the 
luciferase enzyme will catalyze the chemilumescent reaction on the ‘free’ 
S-luciferin substrate. In another example a bioluminescent assay for the 
p-galactosidase enzyme8 has been produced and was able to detect the 
enzyme down to 10'21 mol using a luminescence spectrometer (this is 109 
times more sensitive than conventional fluorescence/ absorbance 
assays).
In a more recent report an 6-(A/-acetyl-s-phenylalanyl)-aminoIuciferin (10) 
has been synthesized and used as an example for a new class of highly 
sensitive biolumogenic substrates.9 It was hoped that the 6-(A/-acetyl-S- 
phenylalanyl)-aminoluciferin derivative (10) could be used as a novel 




In this system the test principle of this new substrate (10) is the release of 
aminoluciferin (11) by prior enzymatic cleavage of the 6-(/V-acetyl-S- 
phenylalanyl)-aminoluciferin (10) by a-chymotrypsin, (scheme 2.2). The 
assay is made more sensitive because 6-O-aminoluciferin is an excellent 
substrate for the luciferase enzyme, used in the second part of the assay 
couple. The concentration of aminoluciferin (11) can be quantified easily 
in a luminometric assay as for the original substrate (2), and therefore the 
a-chymotrypsin activity can be established. The kinetic parameters 
determined for the 6-(A/-acetyl-s-phenylalanyl)-aminoluciferin are given 
as kcat = 6.5 s'1, Km = 0.38 mM and kcat /  k unCat = 17,100. Levels of a-
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i Jf^ VVV^0H fYNHN/ 0Hs a-Chymotrypsin  ^ h2nx^ ^ s
NHAcH
(10) (11)
N^j^o luciferase /  Mg2+ I
j O O ~ £ rS S'" a t p  / Os
LIGHT + AMP / PPi
Scheme 2.2
Results:
2.5 Hapten and Substrate
In our luciferin coupled assay (section 2.1) we wish to generate 
antibodies with estereolytic/ proteolytic activities. To generate such 
antibodies we require a hapten that mimics the tetrahedral transition state 
expected in the ester/ amide hydrolysis.
Phosphates, phosphonates, phosphonamidates are generally useful 
transition state analogues for these types of hydrolysis reactions. 
Therefore we hope to utilize the s-luciferin phosphonamidate (12), which 
should act as hapten and thus mimic the tetrahedral intermediate 
expected in the hydrolysis of an ester or amide of the s-luciferin 
substrates (13) and (14). The 4-geminal dimethyl group in the hapten (12) 
is used to prevent in situ oxidation of the luciferin, and the R-valine side 
chain to reduce background chemiluminescent reactions, (few /?-valine 
esterases/ proteases are present in bacterial cells).
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The principal aim of this project is therefore to undertake a formal 
synthesis of the phosphonamidate hapten (12) and substrates (13) and
(14), such that a coupled luciferin assay can be established for the direct 
screening of catalytic antibodies for their hydrolytic activities.
2.6 Synthesis Of s-Luciferin Substrate
In order that a range of s-luciferin derivatives could be produced our 
initial studies were directed towards the synthesis of s-luciferin (2).
The starting material of choice was 2-amino-6-methoxybenzothiazole
(15). This was converted to the 2-chloro compound (16) using 
Sandmeyer methodology10,11 and then on to the 2-cyano derivative (17) 
using potassium cyanide in dimethyl sulfoxide. This was de-methylated 
using pyridine hydrochloride to afford 2-cyano-6-hydroxybenzothiazole 
(18) in 85% yield. The 2-cyano-6-hydroxybenzothiazole (18) was then 
condensed with s-cysteine hydrochloride in a basic solution of water/ 
methanol and afforded the required s-luciferin (2) in 76% yield, (scheme
(2)
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2.3). An initial attempt at the preparation of the ethyl ester (19a), by 
treating the s-luciferin (2) with a saturated solution of hydrogen chloride 
in ethyl acetate proved unsuccessful yielding only starting material and 
some decomposed product. A second esterification attempt was 
undertaken using the milder benzyl chloroformate/ base combination12 
and was also unsuccessful. In an alternative reaction, the s-luciferin was 
heated under reflux conditions in absolute ethanol with a catalytic amount 
of sulfuric acid. This gave mainly one product, the ethyl ester (19a), which 
was isolated by preparative t.I.c. Some decomposition had occurred on 
the preparative t.I.c. plate, but purification by recrystallization from 
acetone-cyclohexane afforded the luciferin ethyl ester (19a) in 58% yield. 
The synthesis of the amide derivative (19b) was achieved utilising DCC 






NHo i) N a N 0 2 /  HC I




P y.H C I /  2 0 0  °C
S-Cysteine /  K 2C 0 3 
+ M e O H  / H20







( 1 6 )  6 5 %
K C N / D M S O / ^
C N
M eO '
(17) 7 5 %
N ...C 0 2Et
5 8 %
D C C / D M F / H O B t
B n N H 2 / 0  oC C O N H B n
72%
Scheme 2.3 Synthesis of s-Luciferin substrates.
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2.7 Synthesis Of A Chiral S-Luciferin Hapten (12)
2.7.1 The chiral phosphorus building block (20).
The synthesis of a phosphonamidate luciferin derivative (12) is near 
completion. This has involved the synthesis of the chiral phosphorus S- 
penicillamine13 derivative (20) and subsequent coupling with 2-cyano-6- 
hydroxybenzothiazole, as described earlier.
S-Tartaric acid (21) is the chiral building block of choice; this was 
converted to the ketal (22) by treatment first with dimethoxypropane 
(DMP), methanol and camphorsulfonic acid, followed by cyclohexane and 
DMP at 105 °C, (scheme 2.4).
(20)
H02C 5fco2H ii) DMP /105 oC / O  
(21)




E t , 0 / A
(24) 85%
MeOH / dil. H,S04
(23) 42%




(27) 53%(25) 83% (26)
Scheme 2.4
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Conversion to the tetramethyl ketal diol (23) was achieved by action of 
methyl magnesium bromide in diethyl ether. Treatment of the diol (23) 
with sodium hydride/ methyl iodide afforded the tetramethyl ketal dimethyl 
ether (24), and hydrolysis with aqueous acidic methanol, the tetramethyl 
dimethyl-ether diol (25). The synthesis of the hydro-phosphite (27) was 
undertaken by the in situ preparation of the chloro-phosphite (26), using 
phosphorous trichloride followed by addition of aqueous triethylamine, 
(scheme 2.4). Mass spectral (C.l.) and 1H NMR analysis of (27) identified 
this as the required product.
The next stage of the chiral synthesis involved the addition of the chiral 
cyclic phosphite (27) to the cyclic imine 2,5-tetramethyl thiazoline (28), 
and was catalyzed by boron trifluoride etherate, (scheme 2.5). The 
addition products, a pair of diastereoisomers (29) and (30) could be 
separated by column chromatography. The hydrolysis of (29) with mild 
acid should have yielded the required chiral phosphorous s-cysteine 
derivative (20), (scheme 2.5), but some difficulties were encountered. The 
purification of the chiral amino phosphonic acid (20) proved unsuccessful 
due to a large degree of phosphorus by-product contamination.
(29) 23% (30) 46%
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An initial attempt at the preparation of the cyclic imine 2,5-tetramethyl 
thiazoline (28) using elemental sulfur, acetone, isobutyraldehyde (31) and 
ammonia gas failed and gave a complex seven component mixture. The 
required product (28) could not be identified by 1H NMR analysis. An 
alternative procedure14 was found and investigated, (scheme 2.6). This 
involved the preparation of 2,2’-dithioisobutyraidehyde (32) from 
isobutyraldehyde (31) followed by a condensation reaction with acetone, 
ammonia gas, hydrogen gas and ammonium chloride to afford the 
required thiazoline (28).
S 2 C I2 /C C I4  ^  ^  Acetone / H 2S (g)
u 4 0 °c H / \  S H NH4CI / NH3 (g) N
O
(31) (32) 73% (28) 56%
Scheme 2.6 Synthesis of 2,2,5,5-tetramethyl thiazoline.
The preparation of the dithioisobutyraldehyde (32) was undertaken by 
treatment of a solution of isobutryaldehyde (31) in carbon tetrachloride 
with sulfur monochloride at 40 °C. Distillation under reduced pressure 
afforded the dithioisobutyraldehyde in 73% yield. Initial attempts at the 
synthesis of the thiazoline (28) proved unsuccessful, although following a 
modified procedure described by Asinger,15 which used thioacetamide as 
the initial source of hydrogen sulfide and 1 equivalent of water to 
hydrolyze its breakdown into ‘h^S’, the thiazoline (28) was produced in 
56% yield. Initial difficulties experienced in purifying the thiazoline (28) 
resulted from the fact that it sublimated upon concentration under high 
vacuum. Indeed the first purification technique attempted was to use a 
sublimation finger. This however was not useful because the excess 
thioacetamide present was also found to sublime readily under high 
vacuum. Therefore the only way to purify this compound without loss or 
serious decomposition was to use silica-gel chromatography.
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The chiral hydrophosphite (27) was successfully added to the thiazoline
(28) under boron trifluoride catalysis, although yields of (29) remained 
low at around 55% in repeat reactions, (scheme 2.5). Initial attempts at 
the hydrolysis of the addition product (29) in concentrated hydrochloric 
acid16 have proved difficult, although the 1H NMR spectra of the crude 
material did contain the required product as well as unhydrolysed starting 
material (27).
Due to the problems encountered in the purification of the phosphorus 
penicillamine derivative (20), a simpler non-chiral method was sought. 
This was so that a quantity of rac-phosphorus penicillamine could be 
isolated for initial investigations into the synthesis of the phosphono- 
luciferin (34), (see later). In order to produce a large batch of the rac- 
phosphorus penicillamine derivative (20), the reaction of diethylphosphite 
with the previously synthesised tetramethyl thiazoline (28) was 
undertaken with the aid of boron trifluoride etherate catalysis. The 
addition product (33) was successfully hydrolysed by heating under reflux 
conditions in concentrated hydrogen chloride. The required rac- 
phosphorus penicillamine of (20) was afforded by acidification to pH 5 
and trituration with ethanol.
H N
(33)
2.7.2 Synthesis of a phosphono-luciferin transition-state analogue.
The required luciferin phosphonic acid (34) was obtained by reaction of 
the previously synthesised 2-cyano-6-hydroxybenzothiazole with the rac- 
phosphonic acid of (20) and potassium carbonate at pH 8 in a solvent
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mixture of methanol/ water (1:1) at 0 °C. An initial attempt to synthesise a 
mono-alkylated phosphonate (35) was also undertaken using para- 
nitrophenol, and proceeded in 28% yield utilising standard DCC/ DMAP 
chemistry.
Synthetic studies towards the luciferin phosphonamidate hapten (12) 
have required the synthesis of an ester of R-valine. W e initially attempted 
the synthesis of R-valine methyl ester. R-Valine was heated under reflux 
conditions in distilled methanol with a catalytic amount of sulfuric acid, 
but only starting material was recovered. In an alternative procedure for 
the preparation of the ethyl ester, a suspension of the amino acid in 
absolute ethanol was saturated by the passage of hydrogen chloride gas 
through the solution followed by warming to 75 °C. This route proved 
successful yielding the required ethyl ester (36) in 80% yield.
Attempts at the coupling of the penicillamine luciferin phosphonic acid
(34) with the ethyl ester of R-valine hydrochloride (36) under a wide range 
of conditions have yielded crude mixtures that, by 1H NMR spectrum, 
appear to contain signals consistent with two diastereoisomeric products 
with some remaining starting material. A summary of the reaction 
conditions utilised is given in figure 2.4. Purification of these mixtures has 
so far proven extremely difficult, with 1H NMR spectra indicating possible 
conversions of about 20%.
(34) (35)
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Conditions:
A) i D C C / D M F ii r -V a l.E t ester.HCI /  K2CO 3 /  0 °C - RT
HO'
(34) B) i E D C .H C I/ DM F ii R-Val.Et ester.HCI /  K 2O3 /  0 °C - RT
C) i D C C / D M F/ DM AP ii R-Val.Et ester.HCI /  K 2O3 /  0 °C - RT
Conditions D) i E D C .H C I/ D M F/ D M A P ii R-Val.Et ester.HCI /  K 2O3 /  0 °C - RT
E) i SO C I2/  reflux/ 3h. ii R-Val.Et ester.HCI /  0 °C - RT
F)# i D C C / D M F / H O B tii R-Val.Et ester.HCI /  K 20 3 /  0 °C - RT
[# 1H NM R encouraging, although purification by prep. t.I.c. 
or recrystallization proved unsuccessful]
(12)
Figure 2.4 The attempted synthesis of phosphonamidate (12).
In order to test the viability of these types of reactions, the less sterically 
hindered and more nucleophilic amines, methylamine and benzylamine 
were utilised. Both gave significant improvements in the overall 
conversion to the methyl and benzyl phosphonamidates (37) and (38) of 
65% and 40% respectively compared to the R-valine phosphonamidate 
(12) generation. Preparative t.I.c. of the A/-methyl phosphonamidate (37) 
yielded a (1:1) mixture of diastereoisomers. In the case of A/-benzyl 
phosphonamidate (38), a single diastereoisomer was isolated as the main 
kinetic product. A reason for these selectivities cannot be given at this 
time.
2.7.3 An alternative route - utilising para-nitrophenol phosphonates.
In an attempt to improve the yield of these phosphonamidates and to 
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Tawfik et al.,17 (scheme 2.7). In this system the phosphonic acid (39) is 
first converted to the dichlorophosphine oxide (40) by treatment with 
phosphorus pentachloride in carbon tetrachloride. Addition of the sodium 
para-nitrophenoxide (PNP) salt results in the formation of bis-para- 
nitrophenyl phosphonate (41). DBU-mediated transesterification/ 
amidification of the b/s-nitrophenyl phosphonates with various alcohols/ 
amines, produced rapidly the mono- alkyl/ aryl, mono-PNP phosphonates 
in excellent yield. The mono-PNP phosphonate could then be selectively 
hydrolysed by treatment with lithium hydroxide in a solution of 
acetonitrile/ water to afford the mono- alkyl/ aryl phosphonic acid (43).
0 . 0  O
^  PCI5 (10 equiv.) / CCI4 ||^  PNPO'Na+ (2 equiv.) N
r "'P\~~OH , , , 0„  *■  *■ r -'^ -'O P N P
R QH M 5 ° C  R / DCM/ RT/ 3  h R 'Q pN p
(39) (40) (41)
RiOH or R1NH2 (1-10  equiv.)
I DBU (1 equiv.) / DCM /1 h
0  n11 LiOH (2 equiv.) / (H20 / MeCN) U
r - ' ^ " x r 1 -*----------------------------------------------------  X ¥B
K n ’l i+ / RT /1 -2 h R \ XRi
OPNP
(43) (42) - (X = 0,NH)
Scheme 2.7 Utilising PNP-phosphonates for the synthesis of mono alkyl/ 
aryl phosphonamidates and phosphonates.
Applying this methodology to the luciferin phosphonic acid (34), the 
dichlorophosphine oxide (44) was produced successfully, although 
numerous attempts to produce the bis-PNP phosphonate (45) gave only 
complex intractable mixtures.
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Due to the significant problems encountered in the synthesis and 
isolation of hapten (34), possibly due to the steric hindrance of the 
geminal-6\methyl group, it was decided to investigate the preparation of 
the analogous hapten based on the condensation product of 2-cyano-6- 
hydroxybenzothiazole (18) with a cysteine-phosphonic acid (62), (see 
later).
2.8 An Alternative Hapten (64)
2.8.1 Review of the synthetic routes for the generation of a-amino 
phosphonic acids.
There have been a number of successful attempts at the synthesis of a - 
amino-phosphonic acids reported in the literature. These have included 
an asymmetric synthesis using (+)-camphor as a chiral auxiliary,18 
(scheme 2.8).
Here the lithium derivative (49) of the Schiff base (48), obtained from (+)- 
camphor (46) and diethyl (aminomethyl)-phosphonate (47), reacts 
diastereoselectively with alkyl halides to give products (50) with 
asymmetric inductions of between 11-95% d.e. The aminoalkyl 
phosphonic acids (50) followed after mild acid hydrolysis.
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O






I  OH 
R
(51)










Scheme 2.8 Enantioselective synthesis of a-amino phosphonic acids 
utilising (+)-camphor for chiral induction.
In another approach, a simple general procedure for the synthesis of 
chiral a-amino phosphonic acids (55) is achieved. The chiral 
phosphonate (53) is formed by addition of R-(-)-phenylglycinol (52) to 
formaldehyde and dimethyl phosphite in refluxing methanol,19 (scheme
2.9).
°  Ph  ^ Ph^
HPfOM efe f t  'B u -L i °  | o
M e O -P .  ► M e O -P . ^ N - ^ y
NH2 H=C = 0  MeO ^  RX MeO Y
R
(52) (53) (54)
Scheme 2.9 Enantioselective synthesis of a-amino phosphonic acids 
utilising R-(-)-phenylglycinol for chiral induction.
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The phosphonate (53) could then be alkylated by a number of 
electrophiles after treatment with tert-butyl lithium, yielding the alkylated 
product diester (54). Following acid hydrolysis, hydrogenation over 
palladium hydroxide catalyst and further acid hydrolysis, the chiral a- 
amino phosphonic acid was revealed (55), (scheme 2.10).
o
OH
Ph* - P\ ^ J  o
V ^ " \  O  p  1. H2 / Pd(OH)2 / C II
0  HCI / H20  (pH 2-3) N I / MeOH / RT /1 5  h H O — P \ ^ ^ N H 2n O 2 I M eO  P . .N H  iwicv-»n / r\ i / i «j u
M e O — P .  ► /  V    HO  i
M eO  Y  RT/24h Me° I  2 . cone. HCI H°  |
p R / reflux
(5 4 )  (5 5 )
Scheme 2.10
In a more recent approach, a-amino phosphonic acids have been 
produced by the enantioselective synthesis of 1-hydroxyalkyl- 
phosphonates (57) via oxazoborolidine catalysed borane reduction of 
diethyl a-ketophosphonates (56).20 The a-aminophosphonic acids (58) 
have been generated after Mitsunobu reactions utilising hydrogen azide, 
(scheme 2.11).
r A Pb
o V - N V  (5  rnol%) HOv  H _  0 PPh3 /d e a d  / h n 3 / h  v  >  H 2oh
Ji OEt 'bu 0Et / dcm X  , OH
p / X o E t  --------------------     R ^ P '-O E t   R ^ P - O H
|| 0.9 eq. BH3 / THF / 2h II ii) PPh3 / benzene / RT / 2h ^
0  0  iii) H30 + / reflux /5 h
(56) (57) (58)
[ R = Et, Bu
[ R = Et, Bu, i-Bu, Ph ] [ Ri = OH; R2 = H] i-Bu, Ph ]
Scheme 2.11 Enantioselective synthesis of a-amino phosphonic acids 
utilising oxazoborolidine catalysed borane reduction.
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Various a-aminophosphonic acids (58) were obtained with enantiomeric 
excesses of 53-83%.
In later work by Demir et aP  a-aminophosphonic acids have been 
generated by a procedure in which diethyl-phosphonates were first 
converted to hydroxyimino-phosphonates (59) via treatment with 
hydroxylamine hydrochloride. Treatment of (59) with sodium borohydride 
in methanol in the presence of molybdenum trioxide or nickel dichloride 
afforded the amino phosphonate (60), (scheme 2.12). Literature19,22 
hydrolysis of these afforded the corresponding a-aminophosphonic acids
(61).
HO>
N NaBH4 NH2 H30+  /  5 h. VH2A '°B ---- ► A /OEt —   A  '°HR r oEt /Mo°3 R r oEt /^ fiux R r ° H
°  °  ONiCl2
(59) (60) (61)
[R = alkyl, Bn, furyl, 
thiophenyl.cyclo- 
propyl, phenyl etc.]
Scheme 2.12 Molybdenum trioxide/ nickel dichloride-catalysed sodium 
borohydride reduction of hydroxyimino-phosphonates (59).
Although this is a racemic method, a larger number of substrates has 
been tolerated than has been seen previously. Of the many methods 
open to us for the synthesis of a-amino phosphonic acids, we decided to 
use an earlier reported procedure which detailed a method for the 
synthesis of a cysteine a-amino phosphonic acid.23"25 This was 
undertaken because the chiral methods reviewed were not used when a 
sulfur containing residue was present in the molecule.
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2.8.2 Towards the synthesis of an alternative phosphono-cysteine 
luciferin hapten, (64).
During synthetic studies towards the phosphono-cysteine luciferin 
derivative (63), our initial approach was to produce a racemic sample of 
cysteine phosphonic acid (62).
The approach investigated involved the initial synthesis of ferf-butyl thio- 
(diethylacetal) (67). A series of reactions were attempted before a 
satisfactory method could be found. These involved reaction of a pre­
formed fe/f-butyl sulfide with bromoacetal (6 6 ) in absolute ethanol and 
the use of sodium ethoxide in ethanol followed again by addition of the 
bromoacetal but both failed producing, at most, trace amounts of the 
required product (67). Eventually a method was optimised which involved 
the addition of solid sodium methoxide to a solution of tert-butane thiol 
(65) in absolute ethanol followed by the addition of the bromoacetal (6 6 ) 
three hours later, (scheme 2.13). The fe/f-butylthioacetal (67) was 
eventually hydrolysed by the addition of an aqueous solution of 2M 
sulfuric acid in methanol at room temperature and rapid stirring for one 
hour. An earlier attempt utilising PTSA and acetone yielded only trace 
amounts of the fe/t-butylacetaldehyde (68 ), with polymerisation occurring 
generally under these conditions. The next step in the synthesis of the 
phosphorus cysteine analogue (62) was to produce the fully protected 
intermediate (69), (scheme 2.13). This was achieved by an elegant single 
pot reaction and involved the addition of triphenylphosphite to a solution 
of the aldehyde (6 8 ), in glacial acetic acid. A/-Phenylthioacetamide was 
then added and the suspension stirred vigorously. After one hour stirring
(62) (63) (64)
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the suspension was heated to 80 °C, when dissolution occurred. After a 
further hour the solution was treated with water and then allowed to stir 
overnight at room temperature. The thiophosphonate (69) was isolated in 
78% yield and was then hydrolysed in a solution containing concentrated 
hydrogen bromide (50 wt%) and glacial acetic acid. 1H NMR spectra of 
the crude reaction mixture and comparison with the known NMR data 
have indicated that the required product cysteine phosphonic acid (62) 
was indeed present although isolation of a pure sample has not been 
achieved. The attempted purification of the crude cysteine phosphonic 
acid (62) was undertaken using the same procedure as for the 
phosphorus penicillamine derivative (20 ), and involved dissolving the 
crude reaction mixture in a minimum amount of water, adjusting the pH to 
five, followed by trituration with ethanol. Unfortunately only between 5- 
10% of the cysteine analogue (62) was present in the triturated solid.
(65)
-SH















A  , ph
HN NH
i) P(OPh)3 / H2N J L NH"Ph
/ AcOH / 80 qC_________







HBr (50 wt%) / AcOH (glacial)
/ reflux 16 h
NH2
H0"  'o h  
(62)
Scheme 2.13 Synthetic route towards the cysteine phosphonic acid (62).
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Various other procedures were then undertaken in an attempt to isolate 
and crystallise an authentic sample of the required phosphonic acid (62). 
These have included acid/ base washes at different pHs (2, 5, 8 and 12) 
with the organic and freeze dried aqueous layers being analysed by 
proton NMR. Although some degree of separation was achieved the 
problem still seems one of unwanted by-products being extracted into or 
crystallising out with the bulk phosphonic acid. To date, unreacted N- 
phenyl thioacetamide (70) from the previous reaction, and A/-phenyl 
thiocarboxylic acid (71), a by-product of the hydrolysis reaction, have 
been most difficult to remove.
The thiophosphonate (69) was further purified prior to the hydrolysis 
reaction and a number of less forcing conditions were investigated in 
order to minimise the formation of other impurities which, by proton NMR 
spectra, also appear present. This has so far had limited success, with a 
sample of phosphonic acid (62) being isolated in only 75% purity.
One alternative procedure26 has been investigated in an attempt to 
isolate a pure sample of the required phosphonic acid (62). This has 
involved the preparation of a mercury salt by treatment of the crude 
reaction mixture (from the hydrolysis) with mercury (II) chloride. However, 
rapid addition of hydrogen sulfide gas and passage of the product mixture 
through a column of (H+) Dowex 50 W(x 2) resin failed to separate out 
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2.9 Future Work And Conclusions
Although we have successfully synthesised the A/-methyl and A/-benzyl 
luciferin phosphonamidates (37) and (38), more work needs to be 
undertaken towards the isolation and purification of the cysteine 
phosphonic acid (62). This should allow completion of three possible 
transition state analogues for ester/ amide hydrolysis so that we may 
progress to the biochemical part of this project (i.e the in vitro 
immunisation with the haptens and testing of our direct screen for 
antibody catalysis (see section 2 .1)).
2.10 Experimental
Melting points are uncorrected and 1H/ 13C NMR spectra were recorded 
on either Jeol JX270, Bruker AM250 or AM400 FT-NMR spectrometers 
and referenced to tetramethylsilane unless otherwise stated. Coupling 
constants (J) are given in Hz. I.R. spectra were obtained using a 1600 
series FT I.R. and mass spectra with a VG analytical 7070E 
spectrometer. All solvents were purified by distillation as detailed in 
“Purification of Laboratory Chemicals” by Perrin and Armarego.27 T.I.c. 
analyses were performed on Merck silica-gel 60 (F254) plates and 
visualized with cerium ammonium molybdate unless otherwise stated. 
Preparative t.I.c. analyses were performed on Merck silica-gel 60 plates 
(F254, 500pm thickness). Merck silica-gel (240-400) was used for flash 
chromatography. Optical rotations were measured in 10 cm cells on a 
Perkin-Elmer 141 polarimeter, with the values given in 10‘1 deg cm2 g'1.
2-Chloro-6-methoxybenzothiazole (16).
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To a solution of 2-amino-6-methoxybenzothiazole (15), (18.0 g, 0.10 mol) 
in formic acid (50 ml), glacial acetic acid (20 ml) and concentrated 
hydrochloric acid (20 ml) at -5 °C was added a solution of sodium nitrite 
(7.0 g, 0.10 mol) in water (10 ml), dropwise with stirring. After addition 
was complete, stirring was continued for a further 15 minutes at 0 °C and 
the mixture added slowly to an ice cold, vigorously stirred, solution of 
cuprous chloride (8.9 g, 0.13 mol) in concentrated hydrochloric acid (5 
ml). After 0.5 h the mixture was heated to 60 °C over a steam bath until all 
evolution of nitrogen had ceased. The solution was then diluted with 
water (200 ml) and extracted with diethyl ether (3 x 250 ml). The organic 
extracts were combined, dried (anhyd. Na2S 0 4) and concentrated in 
vacuo to afford a brown solid which was chromatographed on silica, 
eluting initially with petrol (60-80 °C) and gradient eluting to petrol/ diethyl 
ether (1:1). The title compound was isolated as a beige solid (13.0 g, 
65%), mp 52.5-53 °C (from petrol-diethyl ether) (lit.,29 52.5-53 °C); 8H(270 
MHz; CDCI3) 7.77 (1H, d, J 8.9, 4-H), 7.17 (1H, d, J 2.8, 7-H), 7.03 (1H, 
dd, J 8.9 and 2.8, 5-H), 3.82 (3H, s, 4-OCH3); m/z (C.I., isobutane) 199/ 
201 (100%, M+), 167(58, M+-C/).
2-Cyano-6-methoxybenzothiazole (17).
Potassium cyanide (0.65 g, 10 mmol) was dissolved in distilled DMSO 
(150 ml) by heating to 140 °C for 20 minutes. The temperature of the 
solution was lowered to 70 °C and 2-chloro-6-methoxybenzothiazole 
(2.00 g, 10 mmol) in DMSO (25 ml) was added dropwise with stirring 
under nitrogen. The solution was heated to 140 °C for a further 1 h and 
the red solution was cooled and diluted with diethyl ether (200 ml). The 
resulting solution was partitioned between water (300 ml) and diethyl 
ether (3 x 400 ml) and the organic extracts washed with water (200 ml),
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dried (anhyd. Na2S 0 4) and concentrated in vacuo to afford a brown solid. 
This was chromatographed on silica eluting first with petrol (60-80 °C) 
and gradient eluting to petrol/ diethyl ether (1:1). The title compound (17) 
was isolated as a pale yellow solid (1.41 g, 75%), mp 128-130 °C (from 
petrol-diethyl ether) (lit.,29 129-131°C); 5H(270 MHz; CDCI3) 8.00 (1H, d, J 
9.2, 4-H), 7.34 (1H, s, 7-H), 7.22 (1H, dd, J 9.2 and 2.6, 5-H), 3.92 (3H, s, 
6 -0 CH3); m/z (E.l.) 190 (100%, M+), 175 (45, M-CH3), 147 (40).
2-Cyano-6-hydroxybenzothiazole (18).
2-Cyano-6-methoxybenzothiazole (17), 0.50 g, 2.63 mmol) was treated 
with pyridine hydrochloride (3.3 eq., 1.04 g, 9.0 mmol) and placed in a 
test tube then stoppered under nitrogen. The mixture was heated to 200 
°C via an oil bath for 45 minutes. During this time it was necessary to 
push sublimed pyridine hydrochloride back into the solution. The solution 
was cooled, partitioned between water (30 ml) and ethyl acetate (2 x 40 
ml), the organic extracts combined, dried (anhyd. Na2S 0 4) and 
concentrated in vacuo. The residue was chromatographed on silica 
eluting initially with petrol (60-80 °C) and gradient eluting up to diethyl 
ether/ petrol (1:1) and afforded the title compound (18) as an off white 
solid (0.39 g, 85 %), mp 210-212 °C (from petrol-diethyl ether) (lit.,30 212- 
215 °C); 5h(270 MHz; CDCI3) 10.53 (1H, br. s, OH), 8.05 (1H, d, J 9.0, 4- 
H), 7.36 (1H, d, J 2.4, 7-H), 7.17 (1H, dd, J 9.0 and 2.4, 5-H); m/z (C.I., 
isobutane) 177 (100%, (M+1)+), 151 (46, (M-C/V+1)).
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2-(6’-Hydroxy-2,-benzothiazoyl)-A2-thiazoline-4-carboxylic acid (s- 
Luciferin (2)).
o
s-Cysteine hydrochloride (0.20 g, 1.14 mmol) and potassium carbonate 
(1.5 eq., 0.24 g, 1.71 mmol) were dissolved in water (5 ml) and the 
solution pH adjusted to 7.5-8. The solution was left to equilibrate for 1 h 
under nitrogen at 0 °C. Concurrently a solution 2-cyano-6-
hydroxybenzothiazole (18), (0.24 g, 1.14 mmol) in methanol (5 ml) was 
equilibrated for 1 h, whilst light was excluded from the vessel. The 
solution containing s-cysteine was then added dropwise to the 
benzothiazole solution at room temperature under nitrogen and left to stir 
for 1.5 h. The methanol was removed in vacuo and the aqueous phase 
adjusted to pH 8.5 by addition of aqueous sodium hydroxide (0.1 M), then 
water (30 ml) was added and the solution extracted with ethyl acetate (25 
ml). The aqueous layer was acidified with dilute hydrochloric acid to pH
1.0 and the solution extracted into ethyl acetate (3 x 20 ml), dried (anhyd. 
Na2S 0 4) and the organic extracts combined and concentrated in vacuo to 
afford the title compound (2) as an off white solid (0.24 g, 76 %), mp 212- 
215 °C (from ethyl acetate) (lit.,31 206-209 °C (decomp.));[a]D25 -29.5 (c
1.0 in DMF) (lit.,32 -36 (c 1.2 in DMF)); vmax (nujol mull)/ cm'1 3345 (OH), 
1702 (C =0), 1614, 1573, 1559; 8H(270 MHz; DMSO-cfe) 10.3 (1H, br. s, 
OH), 7.98 (1H, d, J 9.0, 4 ’-H) 7.45 (1H, d, J 2.4, 7-H), 7.05 (1H, dd, J 9.0 
and 2.4, 5'-H), 5.40 (1H, t, J 10, 4-H), 3.71 (2H, m, 5-H), (acid OH not 
observed); m/z (C.I., isobutane) 281 (10%, (M+1)+), 236 (55, (M- 
C 0 2H+1)+), 89(100).
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Ethyl 2-(6’-Hydroxy-2*-benzothiazoyl)-A2-thiazoline-4-carboxylate (s-
Luciferin ethyl ester) (19a).
o
A suspension of S-luciferin (2), (50 mg, 0.18 mmol) in absolute ethanol (5 
ml) was treated with one drop of concentrated sulfuric acid and left to 
reflux for 12 h under argon. T.I.c. (silica /  petrol (60-80 °C)/ ethyl acetate 
(1:1)) indicated that one main high Rf product and some starting material 
remained. The solution was concentrated in vacuo, partitioned between 
ethyl acetate (2 x 20 ml) and water (10 ml) and the organic extracts 
combined, dried (anhyd. Na2S 0 4) and concentrated in vacuo. The crude 
mixture was purified by preparative silica t.I.c. (petrol (60-80 °C)/ ethyl 
acetate (1:1)) and the one main component isolated. Some 
decomposition had occurred on the silica plate, but recrystallization from 
acetone-cyclohexane afforded the high Rf product ester (19a), which was 
most fluorescent on t.I.c. and stained bright yellow under cerium 
ammonium molybdate treatment, (35 mg, 58%), mp 115-117 °C (lit.,33 
117-119 °C); vmax (nujol mull)/ cm'1 3125 (C-H), 1721 (0 = 0 ), 1602, 1594; 
6h(270 MHz; DMSO-ofe) 10.86 (1H, br. s, OH), 7.95 (1H, d, J 9, 4'-H), 7.42 
(1H, d, J 2.4, T-H ), 7.06 (1H, dd, J 9.0 and 2.4, 5 ’-H), 5.49 (1H, t, J 8.4,
4-H), 4.21 (2H, dd, J 7.0, O C H £ H 3), 3.76 (2H, m, 5-H), 1.23 (3H, t, J 7.0, 
CH3); 5c (68 MHz; DMSO-d6) 169.9 (q), 157.8 (q), 157.5 (q), 157.2 (q),
146.3 (q), 137.3 (q), 125.0 (CH), 117.3 (CH), 106.9 (CH), 77.8 (CH2), 61.4 
(CH2), 34.7 (5-C), 14.1 (CH3)\ m/z (C.I., isobutane) 309 (14.5%, (M+1)+), 
235 (15, (M -C 02£f+1)+), 281 (53), 177 (100).
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s-Luciferin benzamide (19b).
o
To a cooled, stirred solution of s-luciferin (50 mg, 0.18 mmol) in DMF (2 
ml) was added distilled benzylamine (1.2 eg., 24 pi, 0.21 mmol) under 
nitrogen. The mixture was then treated rapidly, in one portion, with a 
solution of DCC (1.2 eg., 45 mg, 0.21 mmol) and HOBt (24 mg, 0.18 
mmol) in DMF (1 ml). T.I.c. (ethyl acetate) indicated that one main 
product was present, with the loss of all starting material. The solution 
was filtered to remove DCU and concentrated in vacuo to afford an 
orange solid, (48 mg, 72%), mp 185-189 °C (decomp., from ethyl 
acetate); vmax (nujol mull)/ cm'1 3122 (C-H), 1683 (C =0), 1615, 1573; 
8h(250 MHz; CDCI3) 7.86 (1H, d, J 9.3, 4'-H), 7.52 (1H, d, J 2.0, 7'-H), 
7.35-7.10 (5H, m, Ph), 7.05 (1H, dd, J 9.3 and 2.0, 5'-H), 6.05 (1H, m, 
A/H), 5.23 (1H, t, J 7.8, 4-H), 4.04 (2H, d, J 7.2, NCH^Ph), 3.38 (2H, m, 5- 
H), (nb OH  not observed); m/z (C. I., isobutane) 370 (30%, (M+1)+), 200 
(80, (M-NHBu + '\)+).




To a solution of S-tartaric acid (21), (16.59 ml, 47 mmol) in 
dimethoxypropane (200 ml) and methanol, was added camphorsulfonic 
acid (cat., 1.50 g), and the solution left to stir for 3 h at 95 °C under 
nitrogen. After this, additional dimethoxypropane (100 ml) was added and 
the solution was treated with cyclohexane (200 ml) and left to stir for 12 h 
at 105 °C, under nitrogen. T.I.c. (silica/ diethyl ether) indicated that one 
main component was present. The solution was concentrated in vacuo
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then partitioned between sodium carbonate (sat, 250 ml) and DCM (3 x 
250 ml) and dried (anhyd. Na2S 0 4). The organic extracts were combined 
and concentrated in vacuo to afford an orange oil. This was 
chromatographed on silica eluting with petrol (60-80 °C)/ diethyl ether 
(1:1) and afforded the title compound (22) as a yellow oil (8.13 g, 70%), 
bp 86  °C at 0.1 mm Hg (lit.,34 80 °C at 0.05 mm Hg); ([ocJd20 +51.6 (neat), 
(lit.35 +51.2 (neat)); 6H(270 MHz; CDCI3) 4.81 (2 H, s, 2x CH), 3.85 (6 H, s, 
2x O CH3), 1.49 (6 H, s, 2x CH3); m/z (C.I., isobutane) 219 (100, (M +1)+), 
160 (45), 100 (60).
(3S,4S)-2 ,5-D ihydroxy-2 ,5-dimethyl-3 ,4-hexanediol acetone ketal. (23).
To a solution of the ketal (22), (1.00 g, 4.1 mmol) in diethyl ether (25 ml) 
was added, at 0 °C under nitrogen, methyl magnesium bromide (5 eg., 
6.70 ml, 20 mmol) and the reaction heated under reflux conditions for 2 h 
The solution was cooled, quenched by addition of water (1 ml) and 
concentrated in vacuo and the residue partitioned between water (25 ml) 
and diethyl ether (3 x 30 ml). The ether extracts were combined, dried 
(anhyd. Na2S 0 4) and concentrated to afford a beige solid, which was dry 
loaded on silica and chromatographed eluting with petrol (60-80 °C)/ 
diethyl ether (1:1). The title compound (23) was isolated as white solid 
(0.36 g, 42%); [ajo20 +8.0  (c 1.5 in CHCh); [Found C, 60.51; H, 10.20. 
C11H22O4 requires C, 60.33; H, 10.16%]; 8h (270 MHz; CDCU) 3.73 (2H, s, 
2x CH), 3.70 (2 H, s, 2x OH), 1.36 (6H, s, C(CH3k ), 1-30 (6 H, s, 2x CH3), 
1.26 (6H, s, 2x CH3); 8c (100 MHz; CDCI3) 107.7 (q), 82.7 (CH), 70.5 (q),
29.1 (CH3), 27.3 (CH3), 23.7 (CH3)\ m/z (C.I., isobutane) 219 (10%, 
(M+1)*), 161 (18), 143 (100), 100 (28).
c X o
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(3S,4S)-2,5-Dimethoxy-2,5-dimethyl-3,4-hexanediol acetone ketal(24).
To a solution of the dihydroxy ketal (23), (1.04 g, 4.77 mmol) in THF (25 
ml) was added sodium hydride (2.5 eg., 80% disp., 0.36 g, 12 mmol) 
portion-wise over 2 minutes with stirring under nitrogen at room 
temperature. After 0.5 h the solution was treated with methyl iodide (2.1 
eg., 0.62 ml, 10 mmol) and left to stir at reflux for 12 h. The reaction 
mixture was concentrated in vacuo, partitioned between water (40 ml) and 
diethyl ether (2 x 50 ml) and the organic extracts combined and dried 
(anhyd. Na2S 0 4) to afford a yellow oil. The oil was chromatographed on 
silica eluting initially with 10% petrol (60-80 °C)/ diethyl ether and 
gradient eluting to 30% and the title compound (24) was isolated as a 
colourless oil (0.94 g, 85% );'3 6h (270 MHz; CDCfe) 4.00 (2H, s, 2x CH),
3.21 (6H, s, 2x O CHS), 1.44 (6H, s, C(CH3)2), 1.20 (6H, s, 2x CH3), 1.16 




To a solution of the dimethoxy ketal (24), (0.94 g, 3.82 mmol) in methanol 
(15 ml) was added 4M sulfuric acid (10 ml) and the solution stirred for 12 
h under nitrogen at room temperature. The solution was concentrated in 
vacuo, treated with water (25 ml) and the residue extracted into DCM (25 
ml), dried (anhyd. Na2S 0 4) and concentrated to afford the title compound 
(25) as a colourless oil, (0.65 g, 83%), bp 91.5 °C at 0.01 mm Hg (lit.,13 90 
°C at 0.01 mm Hg). Further purification was not required, [ajo20 +6.85 (c
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1.00 in CHCI3) (lit.,13 ([alo20 +8.5 (c 1.55 in CHCI3)); 8h (270 MHz; CDCb)
78.8 (q), 73.8 (CH), 49.5 (OCH3), 21.6  (CH3), 20.5 (CH3); m /z (C.I., 
isobutane) 207 (20%, (M+1)+), 73 (100).
(3S,4S)-2}5-Dimethoxy-2,5-dimethyl-3,4-hexanediol hydrophosphite 
(27).
To a stirred solution of phosphorous trichloride (0.55 ml, 6.31 mmol) in 
DCM (20 ml) was added triethylamine (1.76 ml, 12.6 mmol), and a 
solution of the diol (25), (1.30 g, 6.31 mmol) in DCM (10 ml) at 0  °C under 
argon. After 1 h at room temperature the solution was concentrated in 
vacuo, redissolved in THF (20 ml) and treated dropwise with a solution of 
water (0.11 ml, 6.31 mmol) and triethylamine (0.88 ml, 6.31 mmol) in THF  
(10 ml) at 0 °C under argon. After a further 1 h at room temperature the 
solution was concentrated in vacuo, treated with DCM (25 ml) and 
successively washed with sat sodium hydrogen carbonate (25 ml) and 
water (25 ml). The combined aqueous extracts were treated with 2M 
hydrochloric acid (50 ml), partitioned with DCM (3 x 25 ml) and the 
combined organic extracts concentrated in vacuo. The pale yellow 
residue crystallized on standing affording an off-white solid (0.90 g, 53%), 
mp 51-53 °C (lit.,13 51-52 °C); (alo20 +50 (c 1.48 in CHCI3) (lit.,13 +54.4 (c 
1.48 in CHCU); Vmax (nujol mull)/ cm'1 2444.5 (P-H), 1290 (P = 0 ), 1082; 
8h(270 MHz; CDCI3) 4.34 and 4.24 (2H, each dd, J 16 and 2.5, 2x CH), 
3.25 and 3.22 (6 H, s, 2x O CH3), 1.28, 1.26, 1.11, and 1.10 (12H, s, 4x 
CH3); 8o(100  MHz; CDCI3) 77.2 (CH), 76.5 (q), 76.3 (1C, CH), 75.9 (q),
3.65 (2H, d, J 6 , 2x CWOH), 3.52 (2 H, d, J 6 , 2x CH OH), 3.30 (6 H, s, 2x 
OCH3), 1.30 (6H, s, 2x CH3), 1.28 (6H, s, 2x CH3)\ 8c(68 MHz; CDCI3)
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49.3 and 49.4 (2x O CH3), 21.6, 20.7, 20.5 and 19.8 (4x CH3)\ 6P (CDCI3; 
H3PO3) +22.73; m/z (C.I., isobutane) 253 (60%, (M+1)+), 221 (20), 139 
(100).
Dithioisobutyraldehyde (32).
A solution of the isobutyraldehyde (31), (10 g, 0.11 mol) in carbon 
tetrachloride (10 ml) was treated with sulfur monochloride (0.5 eq., 4.32 
ml, 54 mmol) and heated at 45 °C for 3 h under argon. The solution was 
then heated to 35 °C for a further 12 h while a current of argon was 
passed into the reaction mixture to remove excess hydrogen chloride 
generated. The resulting solution was concentrated in vacuo to remove 
solvent and excess sulfur monochloride. The residue was distilled under 
reduced pressure, (88 °C, 0.5 mm Hg) yielding a pale yellow oil (8.08 g, 
73%);14,15 Vmax (liquid film)/ cm'1 2969-2927, (C-H, aid.), 1711 (C =0); 
8h (270 MHz; CDCI3) 9.41 (2H, s, CHO), 1.56 (12H, s, CH3)\ m/z (C.I., 
isobutane) 208 (69%, (M+2)+), 179 (20, (M-CHO+2 )*), 104 (100).
2,2,5,5-Tetramethyl-thiazoline (28).
To a solution of the dithiol (32), (1.20 g, 5.86 mmol), pyridine (1.87ml, 23 
mmol) and thioacetamide (3 eq., 1.34g, 17.6 mmol) was added acetone (6 
eq., 2.57 ml, 35 mmol) and water (0.35 ml, 5.86 mmol), and the solution 
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and acetone added (6 eq., 2.57 ml, 35 mmol). After addition of ammonium 
acetate (3 eq., 1.34g, 17.6 mmol) the solution was simultaneously treated 
with hydrogen sulfide and ammonia gas at a rate of 10 ml per minute 
each. After a period of 3 h the solution was left to warm to room 
temperature over 12 h. The reaction mixture was treated with water (30 
ml), extracted into diethyl ether (3 x 50 ml) and the organic extracts 
combined, dried (anhyd. Na2S 0 4) and concentrated in vacuo. The yellow 
oil residue was chromatographed on silica eluting with DCM/ acetone 
(30:1) and afforded the required product as a colourless oil which 
solidified on standing, (0.9g, 56%), mp 48-50 °C, (lit.,15 50-52 °C); vmax 
(liquid film)/ cm'11649 (N=C); 8h (270 MHz; CDCl3) 6.91 (1H, s, 4-H), 1.68
To a solution of the chiral phosphite (27), (0.20 g, 0.79 mmol) and 
thiazoline (28), (0.125 g, 0.87 mmol) in DCM (5 ml) was added boron 
trifluoride etherate (1 pi, 0.16 mmol) and the solution left to stir for 12 h 
under argon. T.I.c. (silica/ diethyl ether) indicated the presence of two 
high Rf components and loss of starting material. The solution was 
washed with water (25 ml) and concentrated in vacuo. The resulting 
orange solid was chromatographed on silica eluting with diethyl ether and 
afforded the diastereomeric thioamino phosphonates (29) and (30) in 
r 0.33 g (23%) and 0.65 g (46%) yields respectively. The phosphonate (29)
(6H, s, 2x CH3), 1.56 (6H, s, 2x CH3)\ 8c(100 MHz; CDCI3); 165.6 (CH, 4- 
C), 89.3 (q, 2-C), 65.62 (q, 5-C), 33.7 (CH3), 29.9 (CH3)\ m/z (C.I., 
isobutane) 144 (100%, (M+1)+), 99 (50), 69 (51).
Thioam ino phosphonates (29) and (30).
(29) (30)
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crystallized on standing, mp 118 °C (from diethyl ether) (lit.,13 118 °C); 
[oOd20 8.25 (c 1.0 in CHCI3) (lit.,13 -12.20 (c 1.7 in CHCU)); 8h (270 MHz; 
CDCI3) 4.46 (1H, dd, J 13.5 and 3.3, CH), 4.30 (1H, dd, J 19.6 and 3.5, 
CH), 3.61 (1H, d, Jrh 18 Hz, 5-H ), 3.23 (6H, s, 2x OCH3), 3.18 (1H, br. s, 
NH), 1 .68,1 .58, 1.54, 1.31 and 1.10 (24H, s, 8x CH3); 5c(68 MHz; CDCI3); 
86.7 (CH), 82.8 (CH), 75.9 (q), 75.6 (cj), 66.8 (1C, d, JCp 140, CH), 62.0  
(q), 61.9 (q), 49.4 (OCH3), 49.0 (OCH3), 32.8, 31.7, 29.9, 29.5 22.4, 20.7,
20.6 and 17.9 (8C, 8x CH3); 6p(CDCI3; H3PO3) +45.0 ppm; m/z (C.I., 
isobutane) 396 (100%, (M+1)*), 253 (85), 144 (100).
The phosphonate (30) was isolated as a white solid, mp 126 °C (from 
diethyl ether) (lit.,13 126 °C); [a]D“  +64.6 (c 1.0 in CHCI3) (lit.,13 +67.4 (c
1.2 in CHCU)); 5h (270 MHz; CDCU) 4.43 and 4.29 (2H, s, 2x CH), 3.92  
(1H, d, JPH 20, 5-H), 3.26 and 3.24 (6H, s, 2x O CH3), 3.23 (1H, br. s, NH), 
1.69, 1.55, 1.31 and 1.10 (24H, s, 8x CH3); 5c(68 MHz; CDCU) 85.6 (CH),
83.3 (CH), 76.3 (q), 75.4 (q), 66.6 (1C, d, JCP 140, CH), 48.4 (O CH3), 
32.8, 31.6, 29.5, 28.8, 22.1, 21.1, 19.8 and 17.8 (8C, 8x CH3); 8p(CDCI3; 
H3PO3) +44.7 ppm; m/z (C.I., isobutane) 396 (50%, (M+1)+), 253 (80), 144 
(100).
Diethyl rao(2,2,5,5-tetram ethyl-4-thiazolidinyl) phosphate (33).
HN‘
The previously prepared thiazoline (28), (560 mg, 3.99 mmol) was treated 
with diethyl phosphite (1.1 eq., 0.56 ml, 4.04 mmol) and 2 drops of boron 
trifluoride etherate were added and the mixture stirred for 12 h under 
nitrogen. The solution was then heated under reflux conditions for a 
period of 5 h under nitrogen. The solution was concentrated in vacuo 
then recrystallized from 10% diethyl ether/ petrol (60-80 °C), affording the 
thiazole (33), (1.0 g, 90%) as an off-white solid, mp 52-53 °C (from petrol-
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diethyl ether) (lit.,16 30-70 °C); 8h (270 MHz; CDCI3); 4.35-4.18 (4H, m, 
O C H £ H3), 3.48 (1H, d, JPH 18.8, 5-H), 2.78 (1H, br. s, NH), 1.76, 1.74, 
1.61, 1.57 (12H, s, 4x CH3), 1.48-1.41 (6 H, m, 2x OCH2CH3).; m/z (C.I., 
isobutane) 281 (23%, (M+1)+), 266 (29), 207 (70), 144 (100, (M- 
PO (O Et)^))).
Penicillamine phosphonic acid (20).
O
H OI?H
A solution of the thiazole (33), (1.0g, 3.56 mmol) in hydrochloric acid (15  
wt% in water; 20 ml) was heated under reflux conditions for 3 h. The 
solution was then concentrated in vacuo for 4 h then water (2 ml) and 
ethanol (10 ml) were added and the pH of the solution adjusted to 5 via 
addition of triethylamine. On standing for 12 h the required product 
precipitated out as a white crystalline solid (0.63 g, 95%), mp 241-243 °C, 
(from ethanol-water) (lit.,23 242-244 °C); 5h(270 MHz; D20 )  3.33 (1H, d, 
JPH 15.40, CH), 1.59 (3H, s, CH3), 1.53 (3H, s, CH3)\ 8c(70 MHz; D20 )
60.6 (1C, d, JCf> 136.4, CH), 45.8 (q), 32.31 (Me), 28.31 (Me); 8p (CDCIV 




A solution of 2-cyano-6-hydroxybenzothiazole (18) (37 mg, 0.20 mmol) 
was dissolved in methanol (2 ml) and equilibrated for 1 h under argon 
with the light excluded. A solution of the raophosphorous penicillamine of 
(20), (39 mg, 0.20 mmol) in water (2.5 ml) was adjusted to pH 8.0 by 
addition of solid sodium carbonate (anhyd.). The aqueous solution was
86
Antibody Screening Chapter 2
cannulated into the methanol solution rapidly at 0 °C under argon. Light 
was excluded during this process and the solution stirred at room 
temperature for a further 2 h. The solution was concentrated in vacuo to 
remove the methanol, and the water removed by freeze drying. The solid 
was re-dissolved in water (5 ml) and the pH adjusted to 2 by addition of 
dilute hydrochloric acid. A yellow precipitate was filtered, washed with 
water and freeze dried and was found to be the required phosphonic acid 
(34) (57 mg, 83%), mp 197-202 °C (from water); 5H(270 MHz; D20 )  10.22 
(1H, br. s, 6 -O H ) , 7.66 (1H, d, J 9.0, 4 -H ) , 7.15 (1H, d, J 2.4, 7 -H ) , 6.93 
(1H, dd, J 9.0 and 2.40, 5 -H ) , 4.25 (1H, d, JPH 19.0, 4-H ) , 1.69 (3H, s, 5-  
C H 3), 1.64 (3H, s, 5-CH3y, 8C(70 MHz; DMSO-cfe) 163.5 (q), 159.6 (q),
159.1 (q), 146.2 (g), 127.0 (g), 124.7 (C H ) , 117.0 (C H ) , 106.76 (C H ) , 81.9 
(1C, d, Jcp 152, 4-C), 61.1 (g), 28.3 (C H 3) 27.4 (C H 3); 5P(CD3OD; 
P(OMe)3) 1{H} = +10.70 ppm; m/z (E.l). 341 (50%, (M-3)); FAB(-) 343 
(100%, (M-1)+), 249 (22), 149 (32); (HRMS: found M+, 344.0040. 
Ci2H13N204PS2 requires M, 344.0052).
2-(6’-Hydroxy-2’-benzothiazoyl)-A2-thiazoline-4-para-nitrophenyl 
phosphonate (35).
To a suspension of the phosphorus penicillamine luciferin (34), (30 mg, 
87 pmol) in THF (2 ml) was added DCC (1.1 eg., 19.8 mg, 95.9 pmol) and 
DMAP (0.2 eg., 2 mg, 14.5 pmol) and the solution allowed to stir at room 
temperature for 2 h under argon. The solution was then treated with p- 
nitrophenol (13 mg, 90 pmol) and allowed to stir for 2 h. T.I.c. (silica / 
(DCM/ MeOH / 2M NH4OH(ag.))[60:35:5]) indicated appearance of one 
main product and a large percentage of starting material. The reaction 
was stirred for a further 14 h and a further 0.5 equivalents of DCC (10 
mg, 48 pmol) were added and the solution allowed to reflux for 12 h. T.I.c.
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(as above) indicated that all p-nitrophenol had reacted and the reaction 
was cooled, then partitioned between water (5 ml) and chloroform (5 ml). 
The aqueous layer was washed with chloroform (5 ml) and freeze dried, 
affording the title compound as a yellow solid (10 mg, 28%), mp 172-175 
°C; 5h (270 MHz; D20 )  8.10 (2H, d, J 9.2, o-H), 7.73 (1H, d, J 8.8, 4'-H), 
7.29 (1H, s, 7-H ), 7.03 (1H, d, J 8.8, 5 -H ), 6.91 (2H, d, J 9.2, m-H), 4.43 
(1H, d, Jph 19.8, 4-H), 1.71 (3H, s, CH3), 1.70 (3H, s, CH3)\ m/z (C.I., 
isobutane) 466 (37%, (M+1)+), 329 (65, (M -OPhN02+2)+), 262 (100).
/7-Valine ethyl ester.hydrochloride (36).
\ y
HaNrT^ COfcEt
Through a solution of the /7-valine hydrochloride (1.20 g, 6.51 mmol) in 
absolute ethanol (50 ml) was passed a steady stream of dry hydrogen 
chloride gas, (generated by the treatment of concentrated hydrochloric 
acid with anhyd. sulfuric acid). After the solution was saturated it was 
warmed to 75 °C for a period of 18 h, then concentrated in vacuo to afford 
an off white solid residue. The residue was triturated with DCM and 
filtered to afford the required ethyl ester hydrochloride, (0.94g, 80%), mp 
108-110 °C (from DCM) (lit.,37 107-109 °C); [ab20 -16.4 (c 3 in ethanol) 
(lit.,37 -17.1 (c 3.3 in ethanol)); 8h (270 MHz; CDCI3) 8.66 (3H, s , NH3*),
4.21 (2H, m, OCHJCH*), 3.88 (1H, m, CH), 2.38 (1H, m, CH), 1.25 (3H, t, 
J 6.9, OCH2CH3), 1.05 (6H, d, j 10.2, 2x CH3); m/z (C.I., isobutane) 181 
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To a stirred solution of the luciferin phosphonic acid (34), (100 mg, 0.29 
mmol) in DMF (2 ml) were added DCC (60 mg, 0.29 mmol) and 
methylamine hydrochloride (20 mg, 0.29 mmol), and the solution left to 
stir for 1 h with all light excluded by wrapping with aluminium foil. T.I.c. 
(silica /  (DCM/ MeOH /  2M NH4OH(ag.))[60:35:5]) indicated loss of all 
starting material and the appearance of two higher Rf products, (the two 
NHMe diastereoisomers). The solution was filtered to remove DCU and 
concentrated in vacuo to remove DMF. The oily residue was purified by 
preparative t.I.c., although separation of the two NHMe diastereoisomers 
was not possible. A 1:1 mixture of the NHMe phosphonamidates (37) was 
isolated as fluorescent yellow gum, (41 mg, 40%); 6H(250 MHz; DMSO -d6) 
(mix of diastereoisomers) 8.08 + 7.92 (1H, d, J 9, 4 -H ), 7.62 + 7.44 (1H, 
d, J 1.2, 7'-H), 7.25 + 7.08 (1H, dd, J 9.2, and 1.2, 5'-H), 5.72 (1H, br. s, 
NH), 4.30 (1H, d, JpH 21.3, 4-H), 1.74 (3H, s, CH3), 1.63 (3H, s, CH3); m/z 
(C.I., isobutane) 357 (70%, (M+1)+) 329 (100, (M-A/HCH3)+1)+).
2-(6’-Hydroxy-2’-benzothiazoyl)-A2-thiazoline-4-/V-benzyl luciferin 
phosphonamidate (38).
To a stirred solution of the luciferin phosphonic acid (34), (200 mg, 0.57 
mmol) in DMF (4 ml) was added benzylamine (63 jil, 0.57 mmol). To this 
mixture was added a solution of DCC (118 mg, 0.57 mmol) in DMF (1 ml) 
and the solution left to stir for 1 h with all light excluded by wrapping with 
aluminium foil. T.I.c. (silica /  (DCM/ MeOH /  2M NH4OH(aqr.))[60:35:5]) 
indicated presence of some starting material and the appearance of two 
higher Rf products, (the two NHBn diastereoisomers). The solution was 
filtered to remove DCU and concentrated in vacuo to remove DMF. The 
oily residue was purified by preparative t.I.c., although separation of the 
two NHBn diastereoisomers led to only one being isolated. One of the N- 
Bn phosphonamidates, the higher Rf diastereoisomer, was isolated as a
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fluorescent yellow oil that solidified on standing, (160 mg, 65%) mp 212- 
215 °C (decomp.); 6H(250 MHz; CD3OD) 7.83 (1H, d, J 10.2, 4'-H), 7.40-
7.00 (5H, m, Ph), 7.25 (1H, d, J 1.2, 7'-H), 7.05 (1H, dd, J 10.2 and 1.2,
5-H ), 4.39 (1H, d, JPH 19.12, 4-H), 4.35 and 4.26 (2H, 2x dd, J 20.3 and
6.6, 2x Bn), 1.83 (3H, s, CH3), 1.80 (3H, s, CH3); 6c(70 MHz, CD3OD)
165.2 (q), 164.8 (q), 158.7 (q), 147.9 (q), 143.6 (q), 138.7 (q), 130.0 (q),
129.1 (CH), 128.6 (CH), 125.4 (CH), 117.9 (CH), 107.4 (CH), 86.6 (CH, d, 
J cp 133, 4-C), 63.15 (q, C(CH3)2), 47.42 (CH2), 35.80 (CH3), 25.95 (CH3); 
5p(CD3OD, P(OMe)3 ext.) +9.91; m/z (C.I., isobutane) 436 (2%, (M+3)+), 
328 (60, (M -NH Bn+l)+), 262 (100); m /z((+) FAB) (HRMS) (found (M+1)+, 
434.0751. C i9H2iN 30 3PS2 requires (M+1)+, 434.0761).
2-(6*-Hydroxy-2’-benzothiazoyl)-A2-thiazoline-4-dichlorophosphine 
oxide (44).
A stirred suspension of the luciferin phosphonic acid (34), (100 mg, 0.29 
mmol) in carbon tetrachloride (10 ml) was treated with phosphorus 
pentachloride (10 eq., 610 mg, 2.86 mmol) under nitrogen, and heated to 
45 °C for 12 h. The resulting solution was cooled and concentrated in 
vacuo to remove excess phosphorus pentachloride. The required 
dichlorophosphine oxide was obtained as an orange moisture-sensitive 
solid; (110 mg, 98%); 6h (250 MHz; DMSO-cfe) 8.08 (1H, d, J 8.9, 4'-H), 
7.98 (1H, d, J 1, T-H), 7.38 (1H, dd, J 8.9 and 1, 5'-H), 4.38 (1H, d, JPH
21.6, 4-H), 1.73 (3H, s, CH3), 1.62 (3H, s, CH3). Further characterisation 
of this compound was not possible at this time due to its rapid 
decomposition and time constraints of this project; m/z (C.I., isobutane) 
382 (20%, (M+1)+), 262 (100).
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To a stirred solution of tert-butane thiol (65) (16.0g, 20 ml, 0.21 mol) in 
absolute ethanol (100 ml) was added, in two portions, sodium methoxide 
(1.1 eq., 13.0 g, 0.24 mol) at 0 °C under nitrogen. After 3 h the solution 
was treated with distilled a-bromo diethylacetal (66), (1.1 eq., 33.2 ml,
0.24 mol) and left to warm to room temperature. The solution was then 
left to stir for a further 12 h under nitrogen. The reaction mixture was 
concentrated in vacuo and then partitioned between brine {sat, 200 ml) 
and diethyl ether (3 x 250 ml). The combined organic extracts were dried 
(anhyd. Na2S 0 4), then concentrated in vacuo and chromatographed on 
silica, eluting initially with 2% diethyl ether/ petrol (40-60 °C) and gradient 
eluting to 4% diethyl ether/ petrol (40-60 °C).The title compound was 
isolated as a colourless oil (24.6 g, 70%), bp 90-93 °C at 10 mm Hg (lit.,36 
85-89 °C at 54 mm Hg); Vmax (liquid film)/ cm'1 2980-2750 {CH), 1459, 
1364; 5h (270 MHz; CDCI3) 4.60 (1H, t, J 5.5, 2-H), 3.73-3.62 (2H, m, 
OCH2CH3), 3.61-3.55 (2H, m, OCH^CHs), 2.75 (2H, d, J 5.9,7-H2)1.32 
(9H, s, Bif), 1.17 (6H, t, J 7.2, 2x OCH2CH3)', m/z (C.I., isobutane) 207 
(100%, (M+1)+), 161 (72, (M-OEf+1)+).
tert-Butyl thioacetaldehyde (68)
To an ice cold solution of the te/t-butylthio diethylacetal (67), (1.0g, 4.87 
mmol) in water/ methanol (2.5 ml/ 5 ml) was added, cautiously, 
concentrated sulfuric acid (1.0 ml) and the solution left to stir for 1.5 h at 
0 °C. The solution was partitioned between water (25 ml) and diethyl 
ether (3 x 30 ml) and the organic extracts combined and dried {anhyd. 
Na2S 0 4), then concentrated in vacuo. The title compound was afforded as 
a pale yellow oil (630 mg, quant.); vmax (liquid film)/ cm'1 2980-2750, 1723
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(C=0), 1460, 1364, 1169; 8H(270 MHz; CDCI3) 9.56 (1H, t, J 3.5, 2-H)
2.59 (2H, d, J 3.5, 1-H), 1.32 (9H, s, St/); m/z (C.I., isobutane) 133 
(100%, (M+1)+), 76 (82, (M-Bu‘+1 )*).
Thioureidoalkane phosphonate (69).
s
To a solution of freshly distilled thioaldehyde (68 ) (4.50 g, 34 mmol) in 
glacial acetic acid (5 ml) was added triphenylphosphite (1.2 eq., 11.08 ml, 
41 mmol) at room temperature. Powdered /V-phenylthiourea (1.2 eq., 6.34 
g, 41 mmol) was added in one portion and the reaction flask fitted with a 
CaCI2 drying tube. The solution was stirred for 0.5 h at room temperature. 
During this time almost all solid residues dissolved. The solution was 
then heated to 80 °C (oil bath temperature) for a further 1 h and the 
solution cooled to room temperature when water (0.72 ml, 34 mmol) was 
added. The milky suspension, which then formed, was allowed to stir for a 
further 12 h after which the precipitated solid was filtered off, washed with 
ice cold acetic acid/ water (1:1) and dried in vacuo to afford the title 
compound as a fine white solid, (13.3 g, 78%), mp 170-172 °C (from 
acetic acid/ water) (lit.,25 170-171 °C); [Found: C, 59.25; H, 5.84; N, 
5.52%. Calc, for C25H29N2O3PS2: C, 59.57; H, 5.84; N, 5.60%]; vmax (nujol 
mull)/ cm’1 3400-2800, 2370, 1595, 1540, 1490, 1350, 1320, 1240, 1200, 
1180, 1170, 1070; 5H(270 MHz; DMSO-cfe) 9.94 (1H, s, A/H-Ph), 8.37 (1H, 
d, J 9.6, NH), 7.54-7.15 (15H, m, 3x Ph), 5.93-5.61 (1H, m, 2-H), 3.19- 
3.12 (2H, m, 2x 1-H), 1.33 (9H, s, Bu).
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A solution of the purified thioureidoalkanephosphonate (69), (2.00g, 3.99 
mmol) in a mixture of acetic acid (5 ml) and 50% hydrobromic acid (10 ml) 
was heated under reflux conditions for 16 h. The solution was 
concentrated in vacuo to dryness and water was added (2ml). The pH 
was then adjusted to 5 by addition of solid potassium carbonate and 
ethanol was added (~10 ml). The solution was triturated to afford, after 
standing for 12 h, a semi-pure sample of the a-amino phosphonic acid
(62) which was isolated as an off-white solid, (0.40g, 64%), mp 220-232  
°C (from ethanol-water), (lit.,26 251.5-252.5 °C); vmax (nujol mull)/ cm*1 
3600-2000 (br. s), 1730, 1650, 1560, 1430, 1230, 1155, 1050, 915; 
5h(270 MHz; D20 )  7.60-7.10 (2H, m, /VH2), 4.22 (1H, m, 2-H), 3.61 (1H, m, 
1-H), 3.38 (1H, m, 1-H), 2.0-1.18 (1H, m, SH); 5P(DMSO-cf6; H3P 0 4 ext) 
+15.2 ppm (lit ,26 +14.3 ppm).
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Chapter 3
Progress Towards A Universal Prodrug Activation 
System For Cytotoxic Agents
Introduction:
3.1 Project Aim
The aim of this project was to develop a novel drug delivery system 
utilizing a prodrug based on “Kemp’s triacid” (1) (c/'s,c/s-1,3,5-trimethyl 
cyclohexane-1,3,5-tricarboxylic acid), (figure 3.1 ).1 There are a number of 
methods that can be used for prodrug targeting and activation. The use of 
either a monoclonal antibody-enzyme conjugate or a bispecific antibody2 
are two common methods. The use of a chimeric antibody allows for one 
tumour binding pocket and a pocket capable of catalyzing the prodrug 
activation step. The aim of our research was the synthesis of prodrugs to 





Figure 3.1 Kemp’s Triacid.
The major limitation of most anti-cancer drugs used in the 
chemotherapeutic treatment of cancer is that there is little discrimination
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between the destruction of normal rapidly dividing cells and neoplastic 
cells. This severely limits the amount of drug that can be administered.
3.2 mAb-Drug Conjugates
Since the idea of the ‘magic bullet’ was born from Paul Ehrlich’s Nobel 
lecture of 1S083 many drug delivery systems which would recognize and 
selectively bind to specific tissues or proteins has been examined, but the 
ideal system still eludes us.
The discovery of the hybridoma technique4 (see chapter 1, section 3) has 
given us easy access to monoclonal antibodies (mAbs). These have been 
shown experimentally to recognize and selectively bind specific epitopes 
on the surface of neoplastic cells.5 As a result of this, much attention has 
been directed towards using antibodies as drug targeting agents.6 Initial 
studies have involved the use of mAb-drug conjugates (figure 3.2), which 




There are typically 5-1 




Figure 3.2 A mAb-drug conjugate.
Poor tumour penetration and the ‘HAMA’ response have restricted this 
approach. The HAMA response or Human Anti-Mouse Antibody response 
can be a significant problem when mouse monoclonals are used for
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therapeutic purposes. This is because they are very immunogenic in 
humans and are therefore rapidly cleared from the body when 
administered on the second or subsequent occasions. This
hypersensitivity reaction can result in very few drug conjugates reaching 
tumour cells. Some of these problems have been overcome by Celltech, 
who have a mAb-calicheamicin conjugate currently undergoing clinical 
trials.
3.3 mAb-Enzyme Conjugates
More recently selective activation of prodrugs has been achieved by the 
use of mAb-enzyme conjugates (figure 3.3). In this system the prodrug is 
administered separately after an appropriate period of time (~ 48 hrs). 
This allows any unbound antibody conjugate to be excreted. Most of the 
recent work in this area has been undertaken in the laboratories of 
Bagshawe7 and Senter,8 and has resulted in the development of several 
antibody-enzyme systems.9'21 Some of these systems have been utilized 
in clinical trials with positive results and have the advantage that far fewer 
antibody conjugates are required due to the ability of a single conjugate 






Figure 3.3 A mAb-enzyme conjugate.
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Although this approach has yielded some encouraging results, 
researchers have outlined several disadvantages.8,22 Both the antibody 
and enzyme have to come from foreign species and thus are extremely 
immunogenic, resulting in an immune response that causes the serum 
levels of the conjugate to be actively reduced so depleting the amount 
available at the tumour site (a ‘one shot’ therapy). Possible 
humanization23 of antibodies, or modified enzymes of human origin could 
be used. Although research into humanization has yielded promising 
results the science is still in its infancy. Strategies using modified 
enzymes obtained by site directed mutagenesis24 or bioimprinting25 to 
change their substrate specificity to that required for prodrug activation 
has resulted in considerable loss of catalytic activity. The obvious 
drawback of these approaches is therefore that an increased dosage of 
the prodrug would have to be used, resulting in increased destruction of 
healthy tissue.
3.4 Bispecific Antibodies
The latest developments in antibody technology26 is in the creation of 
bispecific antibodies2 (figure 3.4) capable of targeting and activating a 
prodrug molecule. In this system a genetically modified antibody is 
generated with a dual binding capability. One of the antibody’s pair of 
binding pockets selectively binds to a tumour cell, with the other pair 
being able to catalyze the prodrug activation step.
TUMOUR CELL----
BINDING POCKET BINDING POCKET
Figure 3.4 A bispecific antibody.
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There are a number of advantages and disadvantages to using either 
bispecific antibodies or mAb-enzyme conjugates, (figure 3.5).
Target + 
activation
mAb-drug conjugate mAb-enzyme conjugate Bispecific
antibody
Use Selectively targets 
certain cell types.
Selectively activates 








Advantages Neoplastic tissue 
selectively targeted 
and destroyed.
Much less antibody- 
enzyme conjugates 




Better solid tumour 
penetration by small 
drug molecules























Immune response is 
main problem. Enzyme 
specificity is not good.
Catalytic activity 
is normally 104- 




Figure 3.5 A comparison of the possible drug delivery media.
3.5 Drug Delivery Criteria
W e have designed a drug delivery system using the following criteria:
1. Non-activation under physiological conditions.
2. Prodrug resistance to metabolism (proteases, lipases etc.).
3. Activation mechanism suitable for a wide range of drugs.
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4. Good pharmokinetic profile.
5. Fast release of drug at site required.
6. Ease of synthesis.
From these guidelines on general prodrug structure, the potential 
prodrugs were based on Kemp’s triacid (1). The general prodrug structure 
is shown later, (figure 3.7).
3.6 Potential Prodrugs
The choice of potential prodrug was based on Kemp’s acid (1) due to the 
rigid conformation obtained with three equatorially orientated methyl 
groups positioning their corresponding carboxylates axially.27 Work 
carried out by Menger28 showed that an amide derivatized with pyrrolidine 
exhibited amide bond cleavage with a half life of 7.7 min. at pH 7.0, 
(scheme 3.1). This was found to be the most efficient non-enzymatic 
amide bond cleavage under physiological conditions (pH 7.0), as 
opposed to a normal amide bond, which Still et a l29 determined had an 
average half-life of around 77 years.
Scheme 3.1 Demonstration that intramolecular nucleophilic attack is a 
suitable method for our prodrug activation step.
H
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W e can use this observation to our advantage in that prodrugs can be 
linked to the cyclohexane carrier as un-activated amides. Due to the 
steric hindrance, such amide bonds are unlikely to be attacked by 
proteases present in the cell. The drugs would then only be released 
when a free carboxylate was generated and positioned axially with 
respect to the neighbouring drug-carrying amide bonds.
The requirement that drugs are only released when a free carboxylate is 
generated and positioned correctly has been demonstrated in later work 
by Dubowchik.37 He used the Kemp’s acid amide of the anti-cancer drug 
‘Doxorubicin’ shown below, (figure 3.6) and found that it was stable to 
hydrolysis and subsequent drug release at physiological pHs. Release of 
the drug from the Kemp’s acid carrier was found only to occur at a pH 
below 5.
Figure 3.6 Acid cleavable linker based on Kemp's acid suitable for 
delivering the anti-cancer drug DOXORUBUCIN via endocytosis to 
lysosomes.
This is important and should result in a potential prodrug candidate only 
releasing the active drug at physiological pHs when a particular antibody 
forces the free carboxylate into the required position for internal 
nucleophilic attack. A number of modifications should be possible with a
o  OH o
niuie o  o h  H O
t i /2 (pH 1 )1 37 °C  = > 100  days  
t i /2 (pH 5 )/ 37 °C  = 40  Hours
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simple carrier molecule, (figure 3.7). From this a potential prodrug 
structure has been suggested:
O
Me' 'Me
A B For mAb-enzyme con j. (D —H) and C —J






*  ^ h - y co*h
c o 2h
Or a radio label for 
tumor imaging
# ^ 0P03»
# 123,125,131 | *  V - Mono-saccharide
Or a solvating group i.e.
# Polyglutamate
# Phosphate
For bispecific antibody i.e. 




(when D=C) — ^
Figure 3.7 The use of the triacid carrier molecule should allow a wide 
range of prodrug modification.
The use of this versatile carrier molecule should allow triacid modification 
to carry:
a) Two identical drug molecules.
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b) Two synergistic drugs, e.g. two different types of anti-cancer drugs.
c) One released drug and a radioactive element, e.g. iodine for tumour 
imaging or radiation treatment.
d) One drug and one solvating molecule, i.e. polyglutamate, an 
oligosaccharide or phosphate group. This would be useful for very 
insoluble cytotoxic agents such as Taxol, which on activation could be 
released from the soluble carrier and marooned on the tumour, resulting 
in increased uptake into the tumour cell.
3.7 The Activating Mechanism
3.7.1 Monoclonal antibody enzyme conjugates.
There are a whole range of enzyme-conjugates that have been reported 
which will catalyze the hydrolysis of the required amide, phosphate or 
ester bond. For example, using a conjugate of alkaline phosphatase (from 
bacteria) the drug doxorubicin can be catalytically released from the 
prodrug doxorubicin phosphate and correspondingly the conjugate 
carboxypeptidase A will release the drug methotrexate from the prodrug 









Figure 3.8 Activation of the prodrug methotrexate A/-alanine by 
carboxypeptidase A will release the drug methotrexate.
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Although these studies still exhibit problems with an immune response in 
mammalian systems, due to the bacterial enzyme, recent work involving 
‘humanization’ of antibodies23 has yielded some very promising results.
3.7.2 Bispecific antibodies.
The use of bispecific antibodies offers much greater control over reaction 
and substrate specificity, and although their catalytic efficiency is several 
orders of magnitude lower than comparable enzymes, it is possible to 
choose an activation reaction that is not catalyzed in vivo. The substrate 
and reaction specificity is determined by the antigen structure used to 
generate the antibody. W e therefore require that the antigen resembles 
the transition state for the reaction to be catalysed. This has the effect of 
forcing the substrates (reactants) into a favourable conformation for the 
reaction and therefore stabilizes the transition state (see chapter 1, 
section 1).
Catalysis is achieved by using the binding energy produced by the forces 
which occur during the formation of the antibody-substrate complex (see 
chapter 1) to reduce the free energy of activation and hence accelerate 
the reaction. The antigen is based on a transition state mimic (hapten) of 
the reaction to be catalysed , and is conjugated to a carrier protein such 
as keyhole limpet hemocyanin (KLH) to elicit an immune response. In a 
particular reaction it is important that the transition state does not too 
closely resemble the product. If this is the case there may be a problem 
of product inhibition with subsequent loss of catalytic activity. The 
bispecific nature of these antibodies also allows them to be directed 
towards a particular cell type such as a neoplastic cell. They can then be 
further utilized, for example in our case, for prodrug activation.
Within the course of this project it was hoped to examine two types of 
antibody catalysed triggering, with a ring inversion or a Claisen 
rearrangement to facilitate the drug release.
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3.8 The Triggering’ Mechanism 
3.8.1 A ring inversion.
From molecular modelling experiments using Macromodel,30 predictions 
were made regarding potential prodrug conformations. Modelling has 
indicated that a possible prodrug which would exist in a ‘twist-boat’ 
conformation, which would prevent internal nucleophilic attack from a free 
carboxylate. In this case a catalytic antibody would be generated against 
a molecule that created a pocket capable of forcing the prodrug into a 
chair conformation so initiating drug release by allowing internal 
nucleophilic attack of the drug-carrying amide, (figure 3.9).
A
Figure 3.9 Prodrug activation by a ring inversion.
Schultz and coworkers have produced an antibody capable of catalyzing 
a c/s/ trans isomerization,31 which has slightly higher energy 
requirements, was found to catalyze that reaction with kcat = 4 .8  min'1 and 
Km = 220 pM.
3.8.2 A Claisen rearrangement.
The second prodrug activation mechanism involves an antibody 
catalysed Claisen rearrangement. Two separate groups have produced 
antibodies that catalyze the Claisen rearrangement of chorismic acid to 
prephenic acid,32 (figure 3.10). The most efficient of these antibodies had 
kcat = 4.3 min'1 and Km = 21 pM. Currently there are no enzymes found in 




An antibody-catalysed r n Q v ^ — NH
















Figure 3.10 An antibody catalysed Claisen rearrangement of chorismic 
acid to prephenic acid.
This methodology can be applied to Kemp’s acid (1) derivatives such that 
the antibody-catalysed reaction will produce an axially orientated 
carboxylate that will undergo spontaneous drug release, (scheme 3.2).
DRUG B
DRUG A










DRUG B- hn' C o
Esterase in 
tumour cell
Drug release DRUG A 
HN ^ O
r COoH ■ 2
Scheme 3.2 After a tumour cell esterase has revealed the acid 
functionality, an antibody catalysed Claisen rearrangement could proceed 
releasing the active drug.
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3.9 Advantages Of Prodrug Carrier
The use of this versatile carrier molecule based on Kemp’s acid (1) 
should allow future modification of the prodrug structure:
• Allows a wide range of prodrugs to be used for a single activating and 
targeting system.
• With only slight structural modification of prodrug structure many 
different activation mechanisms could be utilized.
• By adding polar groups to change the solubility/ hydrophobicity, the 
pharmokinetic profile of the prodrug can be changed.
•  This work should also answer the question of whether the use of 
bispecific antibodies (or fragments scFvs) offer a better alternative and 
less immunogenic delivery system to that of mAb-enzyme conjugates.
Results: 
3.10 Prodrug Alkylation Studies
To date our investigations have centered around the synthesis of 
dialkylated cyclohexane analogues (2), which we hope should exist in our 
preferred ‘twist-boat’ conformation. Therefore in this part of the project 
synthesis has been directed towards molecules of the form (2), which we 
later hope to use in an antibody-catalysed ring inversion for amide 
derivatives carrying potential cytotoxic agents. This work was undertaken 
in order to investigate the feasibility of the dialkylation reactions required.
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The starting material of choice was 1,3,5-cyclohexane tricarboxylic acid 
(3). This was converted to the trimethyl ester (4) using oxalyl chloride in 
methanol/THF mixture, (scheme 3.3).
H02C ^  > C 0 2H Me02C< ^ \ > C 0 2Me
i) (COCI2)2 / THF / DMF | ]
ii) THF / Methanol / 0 °C T
C 0 2H C 0 2Me
(3) (4)
Scheme 3.3
An initial dialkylation attempt was undertaken using lithium 
diisopropylamide as a base and benzylchloromethyl ether as alkylating 
agent,33 (scheme 3.4). The alkylating agent was chosen due to the ease 
of de-benzylation to the corresponding alcohol, which would be required 
for preparation of compound (2). The reaction, unfortunately, resulted in 
production of a multi-component mixture which proved inseparable using 
silica-gel flash chromatography.
Me02C ^ ^ ^ \ ^ C 0 2Me
v
C 0 2Me
i) THF / LDA/-78°C  
* —
«) f s -Cl
= /  o
M e C ^ C ^ ^ ^ ^ C C ^ M e




As a result, the reaction was repeated using freshly prepared lithium 
diisopropylamide and also repeated using diethyl ether instead of 
tetrahydrofuran. Both reactions proved unsuccessful yielding only 
inseparable multi-component mixtures.
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Further investigation indicated that our alkylation component may have 
been at fault (4 components by silica-gel t.I.c.). An attempted distillation 
allowed isolation of a more pure alkylating mixture but repeated alkylation 
attempts using this failed. With the quality of the alkylating agent still 
suspect we invested in a new sample from a Japanese firm (T.I.C via 
Fluorochem), this proved to be far superior. However repeated alkylation 
attempts using this source again proved unsuccessful. Before going any 
further it was decided to undertake an alkylation study using methyl 
iodide as electrophile and lithium diisopropylamide as base. The initial 
reaction gave a multi-component mixture that proved inseparable but a 
second attempt using distilled methyl iodide afforded two main 
components, after chromatographic separation. NMR spectral data 
(1H/13C) and mass spectral (C.l.) evidence indicated that the higher Rf 
component was the c/s/ trans trialkylated product (5) and a slightly lower 
Rf component, the cis/cis trialkylated ester (6). The isomers were formed 
in the ratio (2:3).
The reason for the stereo-inversion at one of the carbon centres during 
this reaction is not clear but Rebek34 found that alkylation of triester (4) 
with LDA/ dimethyl sulfate yielded an isomer ratio of c/s, c/s : c/s, trans 
(85:15). Reasons for this product ratio were not given.
M e C ^ C ^ ^ ^ ^ C C ^ M e  M e02C^^^v^^C02M e
At this point we had doubts regarding the solubility of the di- or possible 
trianions produced and a repeat reaction using hexamethyl 
phosphoramide (HMPA) and the initial alkylating agent (benzyl
Me C02Me
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chloromethyl ether) in our reaction mixture was attempted. This reaction 
had been successful for Rebek41, who was able to produce the 
trialkylated cyclohexane derivatives (7) and (8). Therefore we reasoned 
that by using two equivalents of LDA, we might be able to isolate the 
required dialkylated products. On this occasion, however, a multi- 
component mixture again resulted and purification proved unsuccessful. 
No dialkylated products were isolated on this occasion either or on other 
repeat alkylation attempts using less base and/ or alkylating agent. At this 
point an alternative route was sought.
M e02C ^^^\^^C 02M e  
BnO— i'""T P'""!—  OBn
Me02C -— OBn 
(7)
M e 0 2 C ^ ^ ^ \^ C 0 2 M e
BnO—  ....   OBn
BnO— *  C02Me  
(8)
An alternative route suggested is shown, (scheme 3.5) and started from
1,3,5- cyclohexane tricarboxylic acid (3). It was envisaged that we could 
convert 1,3,5-cyclohexane tricarboxylic acid (3) into the imide acid (9) in 
much the same manner that the Kemp’s acid (1) was by Rebek.35 The 
resulting acid could be reduced and protected and so would hopefully 
allow deprotonation and alkylation at the two positions alpha to the 
carbonyl groups (most acidic). This would lead to the imide alkylated acid 
(10) which we had hoped could be converted to the two required prodrug 
types (11), (12), (see earlier).
i l l





c o 2h .0i) S O C I2 /  7 0  o C /4 h  P h N ^  Q C q 2|_,
ii) P h N H 2 /  D M A P / 4  h
170 ° c /1 2 h
PhN^'0 ^ 0 -okou
f  / i ) 2 e q .  L D A /H M P A
\
O -S i-tB u
(9)
i) U A IH 4
ii) T B D M S C I /  
IM ID A Z O L E /D M F




i) T F A
ii) P D C
O -S i-tB u
\
H
.0PhN^/ Q Cq2h 
BnO ~^^1--^7L-H
(10)
(D R U G  A ) N F L ^ °  
(D R U G  B ) N H - X ^ °
O B n
(11)
(D R U G  A ) N H ^ °  
(D R U G  B) N HJ .O 
BnO
Antibody -catalysed  
O M  ^ a rra n g e m e n t






Scheme 3.5 A suggested alternative route for prodrug synthesis.
A range of reactions were undertaken in order to try and prepare the 
imide acid intermediate (9), and some of these reactions are summarized, 
(figure 3.11). Unfortunately all reactions gave intractable mixtures of 6 
components or more and purification proved impossible, although 1H 
NMR spectral patterns would seem to indicate some consistency in 
reaction product mixtures. The use of more nucleophilic amines, in the 
initial condensation reaction, also proved equally unproductive.
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A i) SOCI2 / 4 h ii) DMAP / Pyr./ PhNH2 / reflux 12 h
B i) SOCI2 / 4 h ii) DCM / Pyr./ PhNH2 / reflux 12 h
C i) CICOCOCI / DCM / DMF ii) Pyr./ PhNH2l 70 °C 
/1 2  h
D i) CICOCOCI / DCM / DMF ii) DMAP / PhNH2 / 
D C M /70 °C / 12 h
E i) SOCI2 / 4 h ii) DMAP / p-OMe-PhNH2 / THF 
/ 60 °C /1 2 h
F i) SOCI2 / 4 h ii) DMAP / Pyr. / p-MeO-PhNH2 
/ D C M / 50 °C / 12 h
Figure 3.11 Attempted synthesises of the A/-phenyl imide (9).
It should be noted that this route (scheme 3.4) was suggested during the 
earlier part of this project. On reflection, this route would have posed a 
number of problems. Firstly, the formation of the imide acid (9) would 
have been energetically disfavoured compared to Rebeks Kemp’s acid 
derivative (see later (15)) due to the unfavorable conformational change 
required to convert the carboxylic acid moieties in (9) from all cis- 
equatorial to c/s-axial to allow imide formation. In the Kemp’s acid (1) all 
carboxylates are already locked in the cis, cis-axial conformation by the
1,3,5-methyl groups, which are not present in triacid (3). Secondly, it was 
realized that had we been able to produce the imide acid and protect it, 
there would be little chance of alkylation at the required positions. This 
would be as a result of a possible anion being unable to adopt a planar 
resonance stabilized intermediate in the reaction due to the extreme
113
Prodrug Activation Chapter 3
geometrically strained structure that must be involved in producing an sp‘ 
carbon at a bridgehead, (figure 3.12).
O
Figure 3.12
Due to the problems associated with the synthesis of the imide acid (9), it 
was decided to adopt a different approach for model prodrug systems.
3.11 Rationalized Prodrug And Hapten Synthesis
A simpler rationalized approach for the prodrug and hapten synthesis has 
involved the attempted preparation of structurally simpler diamide acids 
(13) based on 1,3,5-cyclohexane tricarboxylic acid (3) and the 
preparation of triamides (14) based on the Kemp’s acid (1).
CChH CO?H
The basis of this strategy was to use the triamides (14) as haptens, 
where all amides would exist axially (due to 1,3 diaxial interactions of 
bulky methyl groups) to evoke an immune response and hence produce 
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the diamide acid (13) from equatorial orientations to tri-axial 
conformations. This would allow the proximity of the neighboring free 
carboxylate to cleave one of the amide moieties. The synthesis of these 
structurally simpler molecules would hopefully allow development of more 
effective and structurally diverse molecules in the future.
3.11.1 Hapten synthesis based on Kemp’s acid (1)
A precursor of the triamide (14), the imide acid (15), based on Kemp’s 
acid (1), was successfully synthesized and followed from work by Rebek 
et a l35 The preparation of the imide acid was achieved by heating the 
Kemp’s acid (1) under reflux conditions for 4 hours in thionyl chloride. 
This produced the anhydride acid chloride (16) which was isolated as a 
crystalline white solid in quantitative yield.
COCI
(16)
This was then converted to the imide acid (15) by treatment of the acid 
chloride in dichloromethane with pyridine and phenylamine, (scheme 
3.6).
O
COCI p hN ==c^x.° C 0 2H
Pyr. /  DCM /  70 °C
(15)
P h N H 2 /1 2 h
(16)
Scheme 3.6
A modification of this reaction was reported by Kunitake et a /36 and 
produced the isomeric anhydride amide (17), (scheme 3.7). This was
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achieved by treatment of the acid chloride anhydride (16) with 
phenylamine in tetrahydrofuran and heating to 40 °C for 12 hours.
0 = ^  / P  CONHPh
THF / 2  h. /4 0 °C 3 0 %
(17)
0 = c /  / P  COCI
(16)
Scheme 3.7
The conversion from an anhydride amide similar to (17) to a diamide acid 
(18) was also reported using different amines, (scheme 3 .8 )36,39 Initial 
studies into these reactions has indicated that we have been able to 
produce small quantities of impure diamide acid (18) by heating the 





Reflux / 12 h.
CONHPh C 0 2H 
(18)
Scheme 3.8
Greater success has come from repeat reactions using the anhydride 
para-methoxyphenyl amide (20), and has allowed the synthesis of the 
diamide (21). It should be possible to convert the diamide acid (21) easily 
into the triamide derivative, although this reaction has not been attempted 
at this time, (scheme 3.19).
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CONHRi(OMe) C Q 2H
I cow^ omL
CONHFh(OMe) CONHFh(OMe) 
CONHFh(OMe)i) ED C  /  HO Bt /  DM AP
ii) PhNH 2 /  RT
(21)
Scheme 3.9
Although we were able to synthesize the p-methoxy anhydride (20) and 
the diamide (21) using Rebek’s35 and Kunitake’s36 method (seen earlier), 
the synthesis of the p-nitro derivative (22), has proven unsuccessful, 
yielding only starting amine and anhydride acid from unreacted anhydride 
acid chloride (16). This was probably due to the reduced nucleophilicity 




To avoid the difficulties encountered in the preparation of the nitrophenyl 
anhydride amide (22) we turned our attention to the corresponding ester 
derivative (23), (scheme 3.10). The synthesis of this compound was 
straightforward and involved treatment of the sodium salt of p-nitro aniline 
with the anhydride acid chloride (16). Although this compound was found 
to decompose on silica-gel, purification by crystallization proved 
adequate.
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c o 2h c o 2h CO-




3.11.2 Prodrug synthesis based on cis,cis- 1,3,5-cyclohexane tricarboxylic 
acid (3).
Initial attempts at the formation of the diamide (13) have been 
unsuccessful. They have utilized DCC or EDC chemistry, and N- 
hydroxybenzotriazole to form the activate ester component or an excess 
of triethylamine, (scheme 3.11). 1H NMR spectral data appeared to 
indicate that our complex reaction mixtures contain, among other things, 
mono- di- and triamides as well as possible dimerized products.
i) CICOCOCI / THF/ DMF
ii) (p -N 0 2)PhNH2 /  E^N / 
THF/ DMAP
i) D C C /H O B t /T H F /D M A P
i) EDC.HCI /  EtgN HOBt / 
DCM / DMAP
(p -N 0 2) P hH N O C  
(p- N 0 2)P h H N 0 C
PhH N O C  




(M u lticom ponent 
in tractable  m ixtures)
Scheme 3.11 The attempted synthesis of diamides of the form (13).
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Due to the importance of preparing the diamide compounds, a slightly 
modified procedure was attempted. This procedure has involved the 
preparation of a mono protected diacid (24), which should reduce 
possible dimerization or other intramolecular reactions occurring 
(compared to Kemp’s anhydride formation).
W e had initially hoped to produce a monobenzyl ester diacid (25) and 
then attempt diamide formation using standard amide bond forming 
chemistry. This reaction was undertaken with the triacid (3) using 
EDC.HCI/ triethylamine/ DMAP/ A/-hydroxybenzotriazole and 
dichloromethane as solvent. The reaction mixture was purified and 
afforded the required diacid ester (25) in 20% overall yield.
Conversion of the diacid ester (25) to the diamide (26), was attempted 
using EDC/ HOBt chemistry and reactions utilizing triethylamine as 
nucleophilic amine catalyst. Both these methods gave crude samples 
which, by 1H NMR spectra, appeared to contain the required product as 






Prodrug Activation Chapter 3
P h H N O C ^ ^
PhHNOC
(26)
Purification of these reaction mixtures proved problematic although 
similar reactions using para-methoxyaniline allowed isolation of a main 
component in both cases. This was found to be the required diamide 






i) EDC.HCI / Et3N / THF / RT





Hydrogenation of the diamide ester (27) over palladium hydroxide in 
ethanol/ acetic acid failed to reveal the required diamide acid (28). As did 
an attempted hydrolysis utilizing pig liver esterase (PLE) in phosphate 
buffer.
In an attempt to overcome these difficulties the EDC reaction was 
examined in absence of base, using only the p-methoxyaniline 
nucleophile and starting from 1,3,5-cyclohexane tricarboxylic acid (3). 
This reaction proved more successful yielding one major product, the 
required cis diamide acid (28) as a white solid. A repeat reaction for the 
preparation of the p-nitro diamide (29), using p-nitroaniline again proved 
unsuccessful, probably as a result of the reduced nucleophilicity when 
the para-nitro group was present.
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Ac o 2h
c o 2h
(p-MeO)PhHNOC' 'CONHPh(p-OMe) (p-N02)PhHN0C! 'C0NHPh(-N02)
(28) (29)
3.12 Novel Hapten And Prodrug Synthesis Based On The 
Quinazolinone Moiety (30)
In order to measure the level of internal nucleophilic attack within 
possible prodrugs the highly UV active quinazolinone (30) side chain has 
been synthesized. The quinazolinone (30) was successfully prepared in 
four steps.
3.12.1 Synthesis of 2-(2’-hydroxyphenyl)-4-(3H)-quinazolinone (30).40
The synthesis of the dihydroquinazolinone (34) was achieved by heating 
equimolar amounts of anthranilamide (31) and salicyaldehyde (32) in 
methanol for 0.5 h under reflux conditions, followed by suspending the 
solid imino product (33) in ethanol and heating under reflux conditions for 
1 h in the presence of p-toluenesulfonic acid (PTSA). The 
dihydroquinazolinone (34) product was then oxidized to the 
quinazolinone (30) by action of DDQ in methanol and heating under 
reflux conditions, (scheme 3.13).
The dihydroquinazolinone was not isolated at this stage due to problems 
associated with its extensive decomposition during purification by flash 
chromatography, and so was taken on to the required quinazolinone 
product (30) prior to successful isolation.
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MeOH
Reflux
(31) (32) (33) 65%
EtOH / PTSA / 
Reflux
D D Q / MeOH
Reflux
(30) 66% over 2 steps
Scheme 3.13 Synthesis of 2-(2’-Hydroxyphenyl)-4-(3H)-quinazolinone
(30).
3.12.2 Towards the synthesis of a quinazolinone hapten and prodrug.
Initial investigations into the reactions of this compound have allowed the 
synthesis of the anhydride ester (35), (scheme 3.15) by the addition of 
the anhydride acid chloride to a solution of the sodium salt of the alcohol, 
prepared by action of sodium hydride on the quinazolinone (30).
O
C 0 2H c o 2h
(1)
NH
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As before, in order to measure the level of internal nucleophilic attack of 
the free carboxylate (uncatalysed/ catalysed by antibodies) it was 
necessary to synthesize the diester acid (36), which will act as hapten. 
Although this reaction has not been completed, it was believed that 
treatment of the sodium salt of (30) to a solution of the anhydride ester
(35) should prove adequate.
An initial attempt at the synthesis of the quinazolinone diester (36) has 
been undertaken via treatment of the anhydride (35) with an equivalent of 
the sodium salt of the alcohol (30). A complex mixture of products, 
including >25% unreacted starting material, resulted. The substrate (37), 
which will be used to measure the level of internal nucleophilic attack has 





3.13 Future Work And Conclusions
Future work should include the synthesis of the diquinazolinone ester
(36) and the various amide derivatives. The synthesis of various potential 
prodrug models needs to be investigated further to reduce the number of 
side products produced. To achieve this we need to develop a more 
reproducible method for alkylating alpha to ester functionalities, without 
the usual problem of subsequent epimerization.
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3.14 Experimental
cis, c/s-Trimethyl-1,3,5-cyclohexane tricarboxylate (4).
CQ2Me
Me02C CQ2Me
To a solution of 1,3,5-cyclohexane-tricarboxylic acid (3), (10.0g, 47 mmol) 
in THF (50 ml) was added oxalyl chloride (3 eg., 16.2 ml, 0.153 mol) and 
DMF (2 drops) and the reaction stirred at room temperature for 3 h under 
nitrogen. The solution was concentrated in vacuo and redissolved in THF  
(50 ml) and a solution of 10% methanol/ THF (50 ml) was added dropwise 
at 0 °C under nitrogen. The solution was left to stir for 12 h at room 
temperature. The solution was then concentrated in vacuo then 
recrystallized from 60-80 °C petrol/ diethyl ether (1:1) to afford the title 
compound (4), (7.80 g, 65%), mp 45-47 °C (from petrol-diethyl ether) 
(lit.,39 48-49 °C) as a pale yellow crystalline solid; vmax (nujol mull)/ cm'1 
1736, 1255, 1174; 6h (400 MHz; CDCI3) 3.64 (9H, s, 3x OCH3), 2.35 (3H, 
m, 3x CH), 2.22 (3H, d, J 12.5, 3x CH**), 1.48 (3H, q, J 12.5, 3x CHax)\ 
6c(100 MHz; CDCI3) 174.3 (q, C 0 2CH3), 51.7 (O CH3), 41.6 (CH, C-7), 
30.3 (CH2, C-2)’, m/z (C.l, isobutane) 259 (100%, (M+1)+), 227 (100), 139 
10).
cis, trans and cis, cis Trimethyl 1,3,5-trimethylcyclohexane-1,3,5- 
tricarboxylates (5) and (6).
MeOfcC Me£Q>Me
MeQ>C' CQ>Me MeQ>C' 'CQ?Me
(5) (6)
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A solution of diisopropylamine (3.3 eq., 0.54 ml, 3.83 mmol) in THF (25 
ml) was treated dropwise at 0 °C under nitrogen with n-butyllithium (3.3 
eq., 1.53 ml, 3.83 mmol) and left to stir for 15 minutes. To the resulting 
solution was added a solution of the triester (4), (300 mg, 1.16 mmol) in 
THF (5 ml). The solution was left to stir for 2 h at 0 °C then treated with 
methyl iodide (2.2 eq., 0.16 ml, 2.55 mmol) and allowed to warm to room 
temperature for 12 h under nitrogen. The solution was concentrated, 
acidified with dilute hydrochloric acid (25 ml) and partitioned into DCM (3 
x 25 ml) then dried (anhyd. Na2S 0 4) and concentrated to give an orange 
oil. This was chromatographed on silica eluting initially with petrol (60-80 
°C) and gradient eluting to 30% diethyl ether/ petrol and afforded two 
main products. The first component could not be purified completely but 
1H NMR spectra identified this as the cis, cis- trimethyl ester of Kemp’s 
triacid (G)34, (23 mg); 5H(250 MHz; CDCI3) 3.68 (9H, s, 3x C H 3), 2.73 (3H, 
d, J 13.9, 3x CHeg), 1.23 (9H s, 3x C H 3), 0.99 (3H, d, J 13.9, 3x C H a*). The 
second was obtained in pure form as the cis, trans- trimethyl ester of 
Kemp’s triacid (5J34, (30 mg); 6h (400 MHz; CDCI3) 3.61 (3 H, s, O C H 3), 
3.58 (6H, s, 2x O C H 3), 2.66 (1H, d, J 14.2, CHeq), 2.13 (2H, d, J 14.6, 2x 
CHeq), 1.72 (2H, d, J 14.6, 2x CHax), 1.14 (6H, s, 2x C H 3), 1.10 (3H, s, 
CH3), 1.08 (1H, d, J 14.2, CHeq); 5c(100 MHz; CDCI3) 178.7 (q), 177.83 
(q), 51.88 (O CH 3), 51.76 (O C H 3), 42.00 (C H 2), 41.94 (q), 41.37 (q), 40.38 
(C H 2), 29.71 (CH3), 26.0 (CH3); m/z (C.l, isobutane) 301 (10%, (M+1)+), 
269 (100), 242 (60%, (M -C 0 2M e)+).
1,5,7-Trimethyl-2-4-dioxo-3-phenyl-3-azabicyclo [3:3:1] nonane-7- 
carboxylic acid (15).
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A solution of Kemp’s acid (1), (0.38g, 1.47 mmol) in thionyl chloride (4 ml) 
was heated under reflux conditions for 4 h under nitrogen. The solution 
was concentrated in vacuo to afford the anhydride acid chloride (16), 
(100%) as a white crystalline solid. This was dissolved in DCM (10 ml), 
treated with pyridine (1.1 eq., 0.13 ml, 1.62 mmol) and aniline (1 eq.,
0.137 ml, 1.47 mmol) and then stirred at room temperature for 2 h. The
mixture was treated with pyridine (5 ml) and then heated under reflux 
condtions for a further 12 h under nitrogen. The solution was
concentrated in vacuo and the residue partitioned between sat.
ammonium chloride (25 ml) and ethyl acetate (3 x 20 ml), then dried 
(anhyd. Na2S 0 4) and concentrated to afford the title compound (15) as a 
single product (0.38 g, 82%), mp 251-253 °C (from ethyl acetate) (lit.,35 
251-252 °C); vmax (nujol mull)/ cm' 1 3206 (OH), 1729, 1708 (C =0, acid), 
1677 (C=0, amide)] 5H(270 MHz; CDCI3); 7.36-7.29 (4H, m, Ar), 7.05 (1H, 
m, Ar), 2.81 (2H, d, J 13.2, 2x CHeq), 2.13 (1H, d, J 14.6, CHeq), 1.48 (1H, 
d, J 14.6, CHax), 1.33 (6 H, s, 2x CH3), 1.32 (3H, s, CH3), 1.28 (2H, d, J
13.2, 2x CHax); m/z (E.l.) 315 (100%, M+), 266 (10), 167 (51).
1,5,7 Trimethyl-2-4-dioxo-3-oxabicyclo [3:3:1] nonane-7-(/V-phenyl) 
carboxamide (17).
CONHPh
A solution of Kemp’s acid (1), (0.20g, 0.78 mmol) was treated with 
distilled thionyl chloride (2.1 ml) and heated under reflux conditions for 4 
h, then concentrated in vacuo to afford the acid chloride anhydride (16) 
as a white solid. This was treated with a solution of aniline (72.54 pi, 0.78 
mmol) in THF (25 ml) and left to stir for 12 h under nitrogen. T.I.c. (silica/ 
diethyl ether) indicated that two main components had been produced
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and starting material had gone. The solution was concentrated in vacuo 
and partitioned between dilute hydrochloric acid (10 ml) and ethyl acetate 
( 3 x 1 0  ml). The organic extracts were combined, dried (anhyd. Na2S 0 4) 
and concentrated to afford a yellow solid. The solid was dry loaded on 
silica and chromatographed eluting with diethyl ether. The higher Rf 
component was unidentified due to hydrolysis during purification. The 
lower Rf component, however, was found to be the required anhydride 
amide (17) and was isolated as a white crystalline solid, (70 mg, 30 %), 
mp 121-123 °C (from diethyl ether-hexane); [Found: C, 68.37; H, 6.85; N, 
4.30. Ci8H2iN 0 4 requires C, 68.54; H, 6.72; N, 4.44%]; vmax (nujol mull)/ 
cm'1 3406, 3340 (NH , amide), 1793, 1763 (C =0, anhydride), 1696, 1667, 
1642 (C=0, amide)', 6H(270 MHz; CDCI3) 7.36-7.24 (3H, m, Ar), 7.21 (2 H, 
m, Ar), 2.64 (2H, d, J 14.1, 2x CH.,), 1.96 (1H, d, J 13.6, CHeq), 1.32 (2H, 
d, J 14.1, 2x C H .X), 1.29 (6 H, s, 2x C H 3), 1.23 (1H, d, J 13.6, C H .X), 1.21 
(3H, s, C H 3), (n.b. amide N H  not observed); m/z (E.l.) 315 (100%, M+), 
167(45), 149 (55).
1,5,7 Trimethyl-2, 4-dioxo-3-oxabicyclo [3:3:1] nonane-7-(A/-(para- 
methoxyphenyl)) carboxamide (20 ).
CONI+ OMe
A solution of Kemp’s acid (1), (1.0g, 3.88 mmol) was treated with distilled 
thionyl chloride (5 ml) and heated under reflux conditions for 4 h, then 
concentrated in vacuo to afford the acid chloride anhydride (16) as a 
white solid. The acid chloride (16) was treated with a solution of a para- 
methoxyaniline (0.477 mg, 3.88 mmol) in THF (25 ml) and left to stir for 
12 h under nitrogen. T.I.c.(silica/ ethyl acetate) indicated that one main 
component had been produced and starting material had been 
exhausted. The solution was concentrated in vacuo, treated with ethyl
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acetate (25 ml) and successively washed with sat. sodium 
hydrogencarbonate (25 ml) and water (25 ml). The combined aqueous 
extracts were treated with 2M hydrochloric acid (50 ml), partitioned with 
ethyl acetate (3 x 25 ml) and the combined organic extracts concentrated 
in vacuo. The beige solid produced was recrystallized from ethyl acetate, 
affording the product amide (20) as a white solid (0.77g 60%), mp 176- 
178 °C (from ethyl acetate); vmax (nujol mull)/ cm'1 3300 (NH), 1794, 1765 
(C =0, anhydride), 1645 (C=0, amide)', 5H(270 MHz; CDCI3) 8.11 (br. s, 
NH), 7.25 (2H, d, J 8.9, 2x CH), 6.78 (2H, d, J 8.7, 2x CH), 3.73 (3H, s, 
O CH3), 2.80 (2H, d, J 13.9, 2x (2-Heq)), 2.70 (1H, d, J 13.4, 4-Heq), 2.05 
(2H, d, J 13.9, 2x (2-Hax)), 1.35 (1H, d, J 13.4, 4-Hax), 1.32 (6 H, s, 2x 
CH3), 1.29 (3H, s, CH3); m/z (C.I., isobutane) 346 (100%, (M+1)+), 224 
(30, (M-A/HP/j+1 )+).
c/s-3,5-Di-(para-methoxyphenyl) carboxamide 1,3,5 trimethyl 
cyclohexane 1-carboxylic acid (21).
MeO-
MeO-
To a solution of the anhydride amide (20), (100 mg, 0.29 mmol) in 
chloroform (10 ml) was added p-methoxyaniline (36 mg, 0.29 mmol) and 
the solution stirred at room temperature for 12 h under argon. T.I.c. 
(silica/ ethyl acetate) indicated that one main component and starting 
material remained. A second equivalent of p-methoxyaniline (36 mg, 0.29 
mmol) was added and the solution left to stir for a further 36 h. The 
solution was concentrated in vacuo, treated with ethyl acetate (10  ml) and 
successively washed with sat. sodium hydrogencarbonate (10  ml) and 
water (10 ml). The combined aqueous extracts were treated with 2M 
hydrochloric acid (50 ml), partitioned with ethyl acetate ( 3 x 1 0  ml) and
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the combined organic extracts concentrated in vacuo. The off white solid 
was recrystallized from ethyl acetate/ petrol (60-80 °C) affording the white 
solid diamide (115 mg, 85%), mp 156-158 °C (from ethyl acetate); [Found: 
C, 66.54; H, 6.95; N, 6.12. C26H32N2O6 requires C, 66.63; H, 6.89; N, 
5.98%]; vmax (nujol mull)/ cm'1 1701 (C=0, acid), 1633, 1610 (C =0, 
amide)\ 5H(270 MHz; CDCI3) 8.81 (br. s, NH), 7.20 (4H, d, J 9.0, 4x CH),
6.61 (4H, d, J 8 .8 , 4x CH), 3.72 (6 H, s, 3x 0 CH3), 3.02-2.88 (3H, m, 1 -Heq, 
2x (2 -Heq)), 1.30 (6 H, s, 2x CH3), 1.28 (3H, s, CH3), 1.18-1.12 (3H, m, 1- 
Hax, 2x (2-/-/ax)); m/z (E.l.) 450 (35%, (M-OH)), 279 (15), 149 (100); m/z 
(C.I., isobutane) 451 (14%, (M-OH+1)+), 391 (20), 346 (100%, (M- 
CONHPh-OMe)+).
1,5,7 Trimethyl-2, 4-dioxo-3-oxabicyclo [3:3:1] nonane-7-(A/-(para- 
nitrophenyl)) carboxylate (23).
NO-CO.
The Kemp’s acid (1), (250 mg, 0.97 mmol) was treated with distilled 
thionyl chloride (5 ml) and heated to reflux for 4 h, then concentrated in 
vacuo to afford the acid chloride anhydride (16) as a white solid. The acid 
chloride (16) was dissolved in THF (10 ml) and treated with a solution, in 
THF (25 ml), of p-nitrophenyl alkoxide (173 mg, 0.97 mmol), (sodium salt 
produced by addition of 95% sodium hydride to a solution of the alcohol 
in THF), and left to stir for 12 h under nitrogen. T.I.c. (silica/ diethyl ether) 
indicated one main product. The solution was concentrated in vacuo, 
treated with ethyl acetate (25 ml) and successively washed with sat. 
sodium hydrogencarbonate (25 ml) and water (25 ml). The combined 
aqueous extracts were treated with 2M hydrochloric acid (50 ml), 
partitioned with DCM (3 x 25 ml) and the combined extracts dried (anhyd. 
Na2S 0 4) and concentrated in vacuo. The beige solid produced was
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chromatographed on silica, eluting with diethyl ether and afforded the 
required anhydride as a white solid (85 mg, 25 %), mp 220-222  °C (from 
diethyl ether); vmax (nujol mull)/ cm'1 1791, 1770 (C =0, anhydride), 1750 
(C =0, ester), 1593, 1528 (A/02); 5H(270 MHz; DMSO-cfe) 8.26 (2 H, d, J
9.2, 2x CH), 7.28 (2H, d, J 9.5, 2x CH), 2.60 (2H, d, J 14.1, 2x (2-Heq)), 
2.23 (1H, d, J 13.4, 4 -Heq), 1.55 (2H, d, J 14.1, 2x (2-Hax)), 1.50 (1H, d, J 
13.4, 4-Hax), 1.39 (3H, s, CH3) 1.27 (6 H, s, 2x CH3); 5C(100 MHz; DMSO- 
d6) 172.6 (qr), 171.2 (q), 154.9 (qr), 145.2 (g), 124.9 (CH), 122.6 (CH), 54.2 
(q, 1-C), 43.0 (CH2, 2-C), 42.1 (q, 3-C), 40.1 (CH2, 4-C), 29.5 (CH3), 24.2 
(CH3); m/z (C.I., isobutane) 362 (100%, (M+1)+), 332 (50), 167 (60).
c/s-1 -Benzylcarboxylate cyclohexane c/s-3,5 dicarboxylic acid (25).
A suspension of the triacid (3), (1.00g, 4.63 mmol) in DCM (25 ml) was 
treated with 1-(dimethylaminopropyl)-3-ethylcarbodiimide.HCI (1 eq., 0.88 
g, 4.68 mmol), triethylamine (0.68 ml, 4.68 mmol), dimethylaminopyridine 
and A/-hydroxybenzothiazole (1.25 g, 9.36 mmol) and left to stir at room 
temperature for 2 h. The resulting solution was then treated with benzyl 
alcohol (0.51 ml, 4.68 mmol) and left to stir for 12 h under nitrogen. T.I.c. 
(silica// 4:1 DCM/ MeOH) indicated that, along with starting materials two 
other components were present. The solution was concentrated in vacuo, 
partitioned between dilute hydrochloric acid (50 ml) and ethyl acetate (3 x 
50 ml) and the organic extracts combined, dried (anhyd. Na2S 0 4) and 
concentrated to afford a yellow solid. The solid was dry loaded onto silica 
and chromatographed, eluting initially with DCM and gradient eluting to 
4% (acetic acid/ DCM). Starting material and an unidentifiable component 
were isolated, along with the required monobenzyl diacid product (25) 
which was isolated as a beige solid (0.28g, 20%), mp 151-152 °C (from
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DCM-acetic acid); vmax (nujol mull)/ cm'1 1735 (C=0, ester), 1692 (C=0,
CH2At), 2.42-2.20 (6 H, m), 1.50 (3H, m); 6C(100 MHz; CDCI3) 176.8 (q),
174.0 ((/), 135.8 (q), 128.5 (CH), 128.1 (CH), 127.9 (CH), 66.3 (CH2), 41.9 
(CH), 41.6 (CH), 30.5 (CH2), 30.4 (CH2); m/z (C.I., isobutane) 307 (15%, 
(M+1)+), 261 (25), 169(100).
c/s-3,5-Di-(para-methoxyphenyl) carboxamide cyclohexane-c/s-1 - 
benzyl carboxylate (27).
To a stirred solution of the diacid (25) (400mg, 1.31 mmol) in DCM (15 
ml) was added EDC.HCI (491 mg, 2.61 mmol), triethylamine (0.33 ml,
2.61 mmol) and DMAP (0.1 eg., 16 mg, 0.13 mmol) under nitrogen. After 
2 h para-methoxyaniline (2 eq., 323 mg, 2.61 mmol) was added and the 
solution stirred for a further 12 h. The reaction mixture was concentrated 
in vacuo , treated with ethyl acetate 15 ml) and then successively washed 
with sat sodium hydrogencarbonate (20 ml) and water (25 ml). The 
organic extract was concentrated in vacuo and afforded the diamide 
benzyl ester (27) as a beige solid, which was chromatographed on silica, 
eluting with petrol (60-80 °C)/ ethyl acetate (1:1). The required diamide 
benzyl ester (27) was isolated as white plates, (290 mg, 43%), mp 185- 
187 °C (from petrol-ethyl acetate); [Found: C, 70.03; H, 6.39; N, 5.34. 
C30H32N2O6 requires C, 69.78; H, 6.24; N, 5.34%]; vmax (nujol mull)/ cm'1 
3450 {NH, amide), 1730.8 (C=0, ester), 1650 (C=0, amide)] 8H(270 MHz; 
CDCI3) 8.94 (2H, br. s, 2x NH), 7.34 (5H, m, Ph), 7.45 (4H, d, J 9.0, 4x 
CH), 6.82 (4H, d, J 9.0, 4x CH), 5.12 (2H, s, CH2Ph), 3.77 (6 H, s, 2x 
OCH3), 2.59-2.48 (3H, m, 1,3,5-H), 2.27-2.22 (3H, m, 2,4,6-Heq), 1.88-
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1.76 (3H, m, 2,4,6-Hax)\ m/z (C.I., isobutane) 517 (55%, (M+1)+), 394 
(100), 123 (60).
c/s-3,5-Di-(para-methoxyphenyl) carboxamide cyclohexane-1- 
carboxylic acid (28).
A suspension of the triacid (3), (1.00 g, 4.85 mmol), EDC.HCI (2 eg., 1.82 
g, 9.70 mmol), triethylamine (2 eq., 0.68 ml, 9.70 mmol) and DMAP (0.1 
eq., 60 mg, 0.49 mmol) in THF (20 ml) was left to stir for 4 h under argon. 
The solution was then treated with p-methoxyaniline (2 eq., 1.20 g, 9.70 
mmol) and left to stir for a further 14 h. T.I.c. (silica/ EtOAc (1% H C 0 2H)) 
indicated that a multicomponent mixture had been produced. The solution 
was concentrated in vacuo, treated with ethyl acetate (25 ml) and 
successively washed with sat. sodium hydrogencarbonate (25 ml) and 
water (25 ml). The combined aqueous extracts were treated with 2M 
hydrochloric acid (50 ml), partitioned with ethyl acetate (3 x 25 ml) and 
the combined organic extracts concentrated in vacuo. T.I.c. (silica/ EtOAc 
(1% C 0 2H)) indicated that one main component remained. This was 
chromatographed on silica, eluting with ethyl acetate/ petrol (60-80 °C), 
(1:1). The required diamide (28) was recrystallized from ethyl acetate, 
affording a white solid (0.80 g, 40%), mp 255 °C (decomp.)) (from ethyl 
acetate-acetic acid); [Found: C, 64.90; H, 6 .2 2 ; N, 6.37. C23H26N20 6. 
requires C, 64.76; H, 6.15; N, 6.57%]; vmax (nujol mull)/ cm' 1 3274 (OH, 
acid), 1709 (C=0, acid), 1649 (C=0, amide), 1247; 5H(270 MHz; DMSO- 
d6) 9.74 (2H, br. s, 2x NH), 7.50 (4H, d, J 9.0, 4x CH), 6.86  (4H, d, J 9.0, 
4x CH), 3.71 (6 H, s, 2x OCH3), 2.54-2.30 (3H, m, 1-H, 3-H, 5-H), 2.05




Prodrug Activation Chapter 3
120.9 (CH), 113.8 (CH), 55.2 (OCH3), 43.2 (CH, 3-C, 5-C), 41.4 (CH, 1C, 
1 -C), 31.2 (CH2, 2-C, 6-C), 31.1 (CH2, 4-C); rn/z (E.l.) 427 (30%, (M +1)+), 




To a stirred suspension of anthranilamide (31), (1.30 g, 10 mmol) in 
distilled methanol (15 ml) was added salicyaldehyde (32), (1.20 g, 10 
mmol) and the mixture heated under reflux conditions for 1 h under 
nitrogen. The orange/ brown solid product was filtered and washed with 
cool methanol, then recrystallized from 1,4-dioxane, affording the 
required product (33) as bright orange needles (1.56 g, 65%), mp 178- 
181 °C (from 1,4 dioxane);40 vmax (nujol mull)/ cm'1 3450, 3100 (NH), 1664 
(C =0, amide), 1615 (C=N), 1235 (ArOH)\ 6H(270 MHz; DMSO-cfe) 9.64 
(1H, br. s, OH), 7.65 (1H, d, J 1.5, CH), 7.34 (1H, dd, J 7.6 and 1.5, CH), 
7.15 (1H, dt, J 7.3 and 1.5, CH), 7.07 (1H, dt, J 7.9 and 1.5, CH), 6.82 
(1H, m), 6.73 (2H, m), 6.02 (1H, d, J 2.1, imine CH), 3.41 (2H, br. s, NH2)’, 
6c(100  MHz; CDCI3) 164.2 (q), 154.4 (q), 147.8 (q), 132.9 (CH), 128.9 
(CH), 127.2 (CH), 126.8 (q), 118.6 (CH), 117.0 (CH), 116.3 (CH), 115.2 
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To a suspension of the imine (33), (1.1 g, 4.58 mmol) in distilled ethanol 
(20 ml) was added a catalytic amount of p-toluenesulfonic acid (5 mg), 
and the suspension heated under reflux conditions for 1 h under argon. 
The colourless solid formed was recovered by suction filtration and 
washed with cold ethanol. Attempted recrystallization or chromatographic 
separation proved unsuccessful, therefore the crude reaction mixture was 
brought forward to the next step The crude dihydroquinazolinone (33) 
was suspended in methanol (10  ml) and treated, with rapid stirring, with a 
solution of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ), (1.04 g, 
4.58 mmol) in methanol (10 ml) under nitrogen. The mixture was heated 
under reflux conditions for 1.5 h until the disappearance of the blue 
fluorescent dihydroquinazolinone (33) by t.I.c. (silica// EtOAc/ petrol (60- 
80 °C), (3:2)). The suspension was cooled and the green solid recovered 
by suction filtration. 2D t.I.c. analysis indicated the products instability on 
silica-gel. Therefore the solid was recrystallized from 1,4-dioxane, and 
afforded the required quinazolinone (30) as bright fluorescent yellow/ 
green needles, (720 mg, 66% over 2 steps); mp 300-301 °C (from 1,4 
dioxane) (lit.,40 297-298 °C); vmax (nujol mull)/ cm'1 1671 (C=Ot amide), 
1606 (C=N), 1564, 1512; [Found: C, 70.5; H, 3.99; N, 11.75. C i4H10N2O2 
requires C, 70.59; H, 4.20; N, 11.76%]; 8h (270 MHz; DMSO-Gfe) 14-12 
(1H, br. s, OH), 8.21 (1H, dd, J 8.2 and 1.5, CH), 8.14 (1H, dd, J 7.7 and 
1.1, CH), 7.87-7.81 (1H, m, CH), 7.75-7.72 (1H, m, CH), 7.52 (1H, dt, J
8.7 and 1.1, CH), 7.44 (1H, dt, J 8.4 and 1.5, CH), 7.00-6.92 (2H, m, 2x 
CH), (n.b. N H ’s obscured by H20  in DMSO); 6c(100 MHz; DMSO -d6)
161.6 (q), 160.2 (q), 153.9 (q), 146.1 (q), 135.1 (CH), 133.8 (CH), 127.8 
(CH), 127.0 (CH), 126.1 (CH), 126.0 (CH), 120.8 (q), 118.9 (CH), 118.0 
(CH), 113.8 (q).
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1,5,7 Trim ethyl-2 , 4 -dioxo-3 -oxabicyclo [3:3:1] nonane-7-(2-(phenyl)- 
4-(3H)-quinazolinone-2’-carboxylate (35), (Kemp’s anhydride ester of 
quinazolinone (30)).
A solution of Kemp’s acid (1), (100 mg, 0.39 mmol) was treated with 
distilled thionyl chloride (2.5 ml), and heated under reflux conditions for 4 
h, then concentrated in vacuo to afford the acid chloride anhydride (16) 
as a white solid. A solution of the quinazolinone alcohol (30), (92.2 mg,
0.39 mmol) in THF (5 ml) was cooled to 0 °C and treated portion-wise 
with sodium hydride (95%, anh., 1.1 equiv., 11 mg, 0.43 mmol), then left 
to stir for 0.5 h under argon. The anhydride acid chloride (16) was 
dissolved in THF (5 ml) and cannulated into the alkoxide solution 
prepared above. A violent reaction occurred followed by a colour change 
after 0.5 h. T.I.c. (silica// EtOAc/ petrol (60-80 °C), (1:1) indicated that one 
main product and disappearance of starting material. The was 
concentrated in vacuo, treated with ethyl acetate (10  ml) and 
successively washed with sat sodium hydrogencarbonate (10  ml) and 
water (10 ml). The combined aqueous extracts were treated with 2M 
hydrochloric acid (20 ml), partitioned with ethyl acetate (3 x 25 ml) and 
the combined organic extracts concentrated in vacuo. Resulting beige 
solid was recrystallized from ethyl acetate/ petrol (60-80 °C), (2 :1) and 
afforded the anhydride ester as a white solid, (150 mg, 84%), mp 232-235 
°C (from petrol-ethyl acetate); vmax (nujol mull)/ cm'1 3317 (NH), 1794, 
1784 (C = 0 , anhydride) 1768 (C = 0 , ester), 1685, 1639 (C =0, amide), 
1600 (C=N, imine), 1004; 5H(270 MHz; DMSO-cfe) 12.56 (1H, s, NH), 8.13 
(1H, dd, J 6 .6 , CH), 7.83 (1H, t, J 7.0, CH) 7.71-7.62 (3H, m, 3x CH), 7.52 
(1H, t, J 8.1, CH), 7.44 (1H, t, J 7.7, CH), 7.25 (1H, d, J 8.1, CH), 2.49
O
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(2 H, d, J 11.0, 2x (2-Heq)), 2.58 (1H, d, J 12.9, 4-H*,), 1.49-1.44 (3H, m, 
2x (2-HaxA 4-Hax), 1.21 (6 H, s, 2x CH3), 0.96 (3H, s, CH3); 6c(70 MHz; 
DMSO-de) 172.7 (g), 171.7 (g), 170.8 (q), 161.8 (g), 151.2 (g), 147.8 (g), 
134.5 (g), 131.9 (CH), 130.6 (CH), 127.8 (g), 127.4 (CH), 126.9 (CH), 
126.2 (CH), 125.8 (CH), 122.5 (CH), 121.1 (g), 120.8 (CH), 42.8 (CH2, 2- 
C, 6 -C), 42.0 (q, 1-C), 39.9 (CH2, 3-C, 5-C), 29.3 (1C, CH3), 24.3 (1C, 
CH3); m/z (E.l.) 460 (100%, M), 238 (86 ), 119 (38); (HRMS)(found (M), 
460.1625. C 26H 24N 206 requires (M), 460.1648).
3.15 References
1. Kemp, D.S.; Petrakis, K.S.; J. Org. Chem. 1981, 46, 5140.
2. Shin, S.U.; Morrison, S.L.; Meth. Enzymol. 1989,178, 459.
3. Silverman, R. B.; in “The Organic Chemistry of Drug Design and Drug 
Action” Academic Press, San Diego, 1992, 352.
4. Kohler, G.; Milstein, C.; Nature 1975, 256, 495.
5. Pozanansky, M.J.; Juliano, R.J.; Pharm. Rev. 1984, 36, 277.
6 . Pimm, M.V.; CRC Crit. Rev., Ther. Drug Carrier Syst. 1988, 5, 189.
7. Bagshawe, K.D.; Sharma, S.K.; Springer, C.J.; Antinow, P.; Rogers, 
G.T.; Burke, P.J.; Melton, R.; Sherwood R.; Antibody, Immuno., 
Radiopharm. 1991, 4, 915.
8 . Senter, P. D.; Wallace, P.M.; Svensson H.P.; Vrudhula, V.M.; Kerr, 
D.E.; Hellstrom, I.; Hellstrom, K.E.; Bioconjugate Chem. 1993, 4, 3-9.
9. Senter, P.D.; FASEBJ. 1990, 4, 188.
10. Haisma, H.J.; Boven, E.; van Muijen, M.; De Vries, R.; Pinedo, H.M.; 
Cancer Immunol. Immunother. 1990, 50, 6944.
136
Prodrug Activation Chapter 3
11. Sahin, V.; Hartmann, F.; Senter, P.D.; Pohl, C.; Engert, A.; Diehl, V.; 
Pfreundschuh, M.; Cancer Res. 1990, 50, 6944.
12. Wallace, P.M.; Senter, P.D.; Bioconjugate Chem. 1991, 2, 349.
13. Haenseler, E.; Esswein, A.; Vitols, K.S.; Montejano, Y.; Mueller, B.M.; 
Reisfield, R.A.; Huennekens, F.M.; Biochemistry 1992, 31, 891.
14. Springer, C.J.; Bagshawe, K.D.; Sharma, S.K.; Searle, F.; Boden, 
J.A.; Antoniw, P.; Burke, P.J.; Rogers, G.T.; Sherwood, R.F.; Melton, 
R.G.; Eur. J. Cancer 1991, 27, 1361.
15. Senter, P.D.; Su P.C.D.; Katsuragi, T.; Sakai, T.; Cosand, W.L.; 
Hellstrom, K.E.; Bioconjugate Chem. 1991, 3, 176.
16. Rowlinson-Busza, G.; Bamias, A.; Krausz, T.; Epenetos, A.A.; 
“Monoclonal Antibodies: Applications in Clinical Oncology”, Ed. 
Epenetos, A.A: Capman and Hall, London, 1991.
17. Wang, S.-M.; Yeh, M.-Y.; Ng, J.C.; Tung, E.; Roffler, S.R.; Cancer 
Res. 1992, 52, 4484.
18. Svensson, H.P.; Kadow, J.F.; Vrudhula, V.M.; Wallace, P.M.; Senter, 
P.D.; Bioconjugate Chem. 1991, 3, 176.
19. Alexander, R.P.; Bentley, N.R.A.; O’Driscoll, M.; O’Neil, F.P.; Millican, 
T.A.; Pratt, A.J.; Willenbrok, F.W.; Tetrahedron Lett. 1991, 58, 654.
20. Vrudhula, V.M.; Senter, P.D.; Fischer, K.J.; Wallace, P.M.; J. Med. 
Chem. 1993, 36, 919.
21. Gignami, G.S.; Senter, P.D.; Grothaus, P.G.; Fischer, K.J.; 
Humphreys, Wallace, P.M.; Cancer Res., 1992, 52, 5759.
22. Bagshawe, K.D.; Br. J. Cancer 1989, 60, 275.
23. Riechmann, L.; Clark, M.; Waldmann, H.; Winter, G.; Nature 1988, 
332, 323.
24. Smith, M.; Annu. Rev. Genet. 1985, 19, 423; Carter, P.; 1986, 237, 1.
137
Prodrug Activation Chapter 3
25. Stahl, M.; Jeppsson-Wistrand, U.; Mansson, M.-O.; Mosbach, K.; J. 
Am. Chem. Soc. 1991, 113, 9366.
26. Huse, W.D.; Science, 1989, 246, 1275; 32. Winter, G.; Milstein, C.; 
Nature 1991, 349, 293.
27. Rebek, J.; Marshall, L.; Wolak, R.; Parris, K.; Killoran, M.; Askew, B.; 
Nemeth, D.; Islam, N.; J. Am. Chem. Soc. 1985, 107, 7476.
28. Menger, F.M.; Ladika, M.; J. Am. Chem. Soc. 1988, 110, 6794.
29. Kahne, R.; Still, W.C.; J. Am. Chem. Soc. 1988, 110, 7529.
30. Mohamadi, F.; Richards, N.G.J.; Guida, W.C.; Liskamp, R.; Cranfileld, 
C.; Chang, G.; Hendrickson, T.; Still, W.C.; J. Comput. Chem. 1990, 
11,440.
31. Jackson, D.Y.; Schultz, P.G.; J. Am. Chem. Soc. 1991, 113, 2319.
32. Hilvert, D.; Nared, K.D.; J. Am. Chem. Soc. 1988, 110, 481.
33. Rotello, V.; Viani, E.; Deslongchamps, G.; Murray, B.; Rebek Jr, J.; J. 
Am. Chem. Soc. 1993, 115, 797.
34. Rebek Jr, J.; Askew, B.; Killoran, M.; Nemmeth, D.; Lin, F.T.; J. Am. 
Chem. Soc. 1987, 109, 2426.
35. Rebek Jr, J.; Park, T.K.; Schroeder, J.; Tetrahedron 1991, 47, 2507.
36. Kunitake, K.; Ikeura, Y.; Honda, Y.; Kurihara, K.; Chem. Lett. 1990, 
169.
37. Dubowchick, G.M.; Padilla, L.M.; Firestone, R.A.; Bioorg. Med. Chem. 
Lett. 1993, 3, 2843.
38. Ikeura, Y.; Kurihara, K.; Kunitake, T.; J. Am. Chem. Soc. 1991, 113, 
7342.
39. Newman, M.S.; Lowrie, H.S.; J. Am. Chem. Soc. 1954, 76, 4598.
40. Haugland, R.P.; USP 06957/1992.
138
Chapter 4
Molecular Receptors Chapter 4
Chapter 4
Synthesis Of Molecular Receptors For 




Molecular recognition is of paramount importance in Nature as it is 
essential that enzymes, receptors and antibodies recognise their 
complementary reaction partners so that they may function successfully. 
The specificity of Nature’s macromolecular receptors, as well as reaction 
selectivity in organic synthesis is therefore an extremely important part of 
biological chemistry.
The general principle of the molecular receptor is to provide an active site 
capable of identifying and accepting a specific species or reactant. In 
biological systems the high degree of ‘host’/ ‘guest’ selectivity required to 
distinguish all species present, and to select the correct guest molecule 
can be achieved in a number of ways:
1. By providing co-ordinating groups which will preferentially bind the 
guest species through covalent, electrostatic or hydrogen bonding 
interactions.
2. By presenting a molecular cavity at the receptor site of the correct 
dimensions so as to only allow the guest species near the hosts active 
site.
3. By providing a co-ordination site of the correct geometry so as to 
selectively bind the guest molecule.
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Due to the high degree of recognition achieved by biological macro­
molecules, the study and use of molecular receptors has become an area 
of great interest in recent years.1'3 Since many biological molecules which 
contain receptors are relatively large and complex, it has been desirable 
to focus on smaller, more accessible molecules to use as model systems 
for their biological counterparts.
Extensive work has been undertaken in the study of molecular receptors, 
with early studies being based on the macrocyclic structures such as 
crown ethers,4 cyclophanes,5 and cyclodextrins.6 Their appeal seems to 
be a result of their ability to selectively bind particular types of substrate 






Similar ideas have been utilised in carbohydrate recognition by the 
generation of synthetic glycophane receptors7,8 and others that 
selectively bind particular disaccharide molecules.9 New shapes/ types of 
receptor molecules have also been utilised to complex and transport a 
number of substrates such as amino acids,10 phosphates11 and 
nucleotides12 into solvents that they would otherwise not dissolve, as well 
as acting in model systems for biological molecules.13
Of the new shapes that have been found to exhibit molecular recognition, 
many systems have been based on the structure of Kemp’s triacid (1).
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Rebek2 has taken advantage of the rigid molecular skeleton of Kemp’s 
triacid to develop a new class of host molecules, including (2) and (3), in 
which two hydrogen bonding groups converged to form molecular clefts, 
(figure 4.2). These molecules were found to act as receptors for a range 
of heterocyclic amines of complementary size, shape and functionality 
where ionic as well as covalent interactions were possible with the 
receptor.
. . /  (1) \
2,7-diam ino fluorene 3 ,6-d iam ino acridine
HOOHHOOH
(2)
Figure 4.2 Molecular receptors for the binding of heterocyclic amines of 
complementary size, shape and functionality.
In other work by Rebek, molecular receptors for the selective binding of 
adenine,14 cytosine15 and guanosine16 have been generated. In particular 
one analogue of Kemp’s acid, the azacytosine (4), was synthesised and 
found to bind guanosine (5) with association constants of the correct 
magnitude for a system containing three hydrogen bonds, (figure 4.3). A 
binding enhancement is also observed due to n-n  stacking and the 
favourable positioning of 2-ethylnaphthyl ester substituent. Importantly, 
the selectivity of the new receptor for guanosine is about 10 times that of 
other bases, this being due to the contribution of the third hydrogen bond 
found in the new receptor-substrate complex.
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Figure 4.3 Molecular receptor for the selective binding of guanosine.
A potentially useful variation of the Kemp’s acid structure would be to 
have an amine in place of one of the carboxylic acid moieties. One such 
molecule (6 ) has been synthesised by Curran,17 which he envisages 
could be used to construct molecular clefts like structure (7) that may be 
useful in the binding of ligands possessing acidic functionalities.
(7)
H
Although no receptor binding data is yet available, 1H NMR studies have 
confirmed that c/s-3,5-dimethyl-3,5-piperidinedicarboxylic acid (6 ) exists 
in a similar conformation to that of Kemp’s triacid (1), and so should allow 
construction of suitable receptors such as diimide (7) in due course. In a
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reversal of the host/ guest organisation seen above, Ballester18 has 
developed a new receptor capable selectively binding tricarboxylic acids, 
like Kemp’s acid, in an organic medium. To achieve this the triamide (8) 
was synthesised and found to bind the Kemp’s acid derivative, cis,cis- 
1,3,5-cyclohexane tricarboxylic acid (9), (figure 4.4).
Figure 4.4 A molecular receptor for the selective binding of cis, cis -1,3,5- 
cyclohexane tricarboxylic acid.
The conformation of the receptor allows hydrogen bonding groups to 
converge on the tricarboxylic acid simultaneously ‘grasping’ it into the 
induced cleft of the receptor. An essential feature is the intramolecular 
hydrogen bonding between the amide carbonyls and the phenolic protons 
which allows for the successful receptor pre-organisation.
Most of the ‘host’ molecules described so far are only effective in organic 
solvents due to the denaturing effect of water which competes with the 
guest for H-bonding sites in aqueous solution. However, in biological 
systems the sites of molecular recognition are usually exposed to the 
aqueous phase. It is therefore desirable to develop systems in which the 
guest can recognise the host when in direct contact with water. To this 
end Kunitake19,20 has utilised long chain derivatives of Kemp’s acid to 
form stable monolayers at an air-water interface, (figure 4.5). It was found 
that the carboxylic acid groups produced the cyclic dimer and served as a
O'
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molecular cleft for the specific binding of various nitrogen heteroaromatic 
and amino acid species.
Figure 4.5 Schematic representation of molecular receptor monolayer 
with an acidic cleft for the binding of particular nitrogen aromatic species.
Molecular recognition is widespread in nature and lies at the heart of 
enzyme-substrate specificity, as well as being the source of reagent 
selectivity in synthetic organic chemistry.
One such biological macromolecule that has been undergoing extensive 
modelling studies at present is the enzyme carbonic anhydrase.21,22 Here,
W a t e r
A i r
0 —H...... O
A c i d i c  c l e f t  f o r  
s p e c i f i c  b i n d i n g  o f  
n i t r o g e n  a r o m a t i c s
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the active site of the enzyme is known to contain the zinc (II) ion and it is 
this active site that we wish to model in this project.
4.2 Carbonic Anhydrase
4.2.1 Enzyme function.
One of the first families of zinc containing metalloenzymes to be 
discovered are the carbonic anhydrases.24 They occur throughout nature 
in animals, plants and bacteria and play an essential role in the 
physiological control of pH and respiration. They also play a role in the 
transport of carbon dioxide between metabolising tissues and the lungs, 
the intracellular CO2/ HCCV equilibrium and the calcification of shell 
formation.
To this end carbonic anhydrases function to catalyse the reversible 
hydration of carbon dioxide, or the dehydration of carbonic acid. At 
physiological pH the following equilibrium exists:-
c o 2  + h2o ^— -  h c o 3' + H+
The nucleophilic attack of carbon dioxide by water is kinetically an 
extremely slow process and is therefore of limited biological use. If 
however the water nucleophile is replaced with the hydroxide ion the 
reaction is greatly accelerated and the useful biological equilibrium below 
is established:-
C 0 2 + HO' -  —  HCO3'
The carbonic anhydrase enzyme acts to eliminate the need for an 
intracellular increase in pH to achieve hydroxide formation, allowing 
stabilisation of a hydroxide ion at physiological pH.
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4.2.2 Enzyme active site.
Human carbonic anhydrase has a molecular weight of between 28,000-
30,000 and consists of 259 amino acid residues. Three isozymes (I, II 
and III) are known to exist, and all possess the ability to catalyse the 
reaction. The most efficient of these is isozyme (II).24 The mechanism of 
action of all three is believed to be the same.
The structures of several forms of the enzyme have been determined by 
X-ray diffraction experiments25 and these have indicated that the active 
site of the enzyme is composed of a pseudo-tetrahedral zinc(ll) centre, 
co-ordinated to the nitrogen donors of three histidine residues (via their 
imidazole moieties). The zinc ion is found to exist at the bottom of a 
conical shaped intramolecular cavity, which is approximately 0.15 nm 
wide at its entrance and 0.16 nm deep. Half the cavity is dominated by 
hydrophobic amino acid side chains and the other half contains mostly 
hydrophilic amino acid side chains. The zinc (II) ion, which exists here, is 
co-ordinated to the three histidine residues (His 94, 96 and 119), with the 
fourth co-ordination site being taken up with a water molecule at 
physiological pH, (figure 4.6). The pKa of the zinc bound water is 7.5, 
since this is much less than that of ‘free’ water molecules (pKa 14.0), the 
species can release a proton easily to give the Zn-OH moiety. It is 
therefore believed that either Zn-H20  or Zn-OH may be the catalytic 
species depending on the pH. An important feature of the active site is 
the ring of residues, including His 64, 67, Phe 91, Glu 92 and His 200, 
which act to prevent contact between the inner water environment (8 
waters present) and the active site.26 Of the eight water molecules 
hydrogen bonded in the carbonic anhydrase conical cavity, one is 
believed to be replaced during the catalytic cycle.
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H yd rophob ic  portion
T h r199 
OH
T h r200 x " ?
His 64 te N H  
X N
Proton relay
H. M  O
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-n Q n h
His 119 val 121
H is 96
H is 94
Scheme 4.6 S chem atic  rep resen ta tion  o f hum an ca rb on ic  anhyd rase  (II).
4 .2 .3  C a rbon ic  anhyd rase  reaction  m echanism .
There  are  be lieved  to be th ree  essen tia l m echan is tic  s teps invo lved  in the 
opera tion  o f the  ca rbon ic  anhydrase  enzym e,27 (figu re  4.7).
[ H is = h is tid ine  im idazo le  group ]
BH1
(His)3Z n + - 0 C 0 2H (His)3Zn+ -O H
C 0 2
Figure 4.7 C ata ly tic  cyc le  o f the  z inc  hyd rox ide  ca rb on ic  anhydrase  
m echanism .
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The first step is the deprotonation of the zinc co-ordinated water 
molecule, which produces the activated zinc hydroxide species. This step 
has an associated pKa approximately equal to 7 and therefore hydration 
of carbon dioxide is dominant at this pH, giving rise to the second, and 
crucial step in the reaction mechanism, the nucleophilic attack by the 
hydroxide oxygen on carbon dioxide (It is important to note that the 
reverse mode reaction will proceed at a pH lower than 7).
The mechanism of action for the formation of a hydrogencarbonate 
intermediate has been studied by Lipscomb28 and Lindskog22 and is 
believed to proceed by two discrete routes, (figure 4.8). The first of these, 
the Lipscomb mechanism, involves transfer of a hydrogen atom to one of 
the oxygen atoms not directly bonded to the zinc centre.
"" iK "  A




















Figure 4.8 Proposed mechanism for the formation of the hydrogencarbonate 
intermediate in the carbonic anhydrase reaction.
In the alternative Lindskog mechanism, the hydrogen atom remains with 
its original oxygen atom, with bonding to the zinc cation being transferred
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via a 5-co-ordinate transition state, to one of the formal carbon dioxide, 
oxygen atoms. The final step involves the displacement of the hydrogen 
carbonate ion by a molecule of water and the re-generation of the active 
hydrated zinc centre.
The validity of both the above mechanisms is still under much discussion 
and so in order to improve the understanding of the nature of the catalytic 
cycle and the relationship between the structure and reactivity, 
researchers have turned to model systems.
4.3 Models Systems For Carbonic Anhydrase
The first generation of model systems has centred around the synthesis 
of small molecules that mimic the active site fris-histidine zinc co­
ordination geometry or by introducing a metal-ion binding site into a 
protein, so that the active centre can be mimicked.29,30 A number of 
attempts have been undertaken to introduce a three histidine zinc (II) 
binding site into proteins. For example miniantibodies31 have been 
produced that contain similar binding sites and further research into 
metalloantibodies has had some success. In one such example32 small 
antigens were used to produce a possible binding cavity, although only a 
structural, not catalytic zinc binding site was introduced.
The use of small molecule models has proven invaluable in the study of 
the mechanism of action of carbonic anhydrases, with their ease of 
synthesis making them synthetically versatile. It has also allowed a closer 
examination of the Lewis acid properties as well as giving information 
regarding specific ligand binding to a zinc (II) species. There have 
however, been a number of fundamental problems associated with the 
generation of stable and discrete complexes of zinc (II) at neutral pH in 
that most do not exhibit a free co-ordination site on zinc. Such complexes 
have been known to dimerize, for example Karlin33 has generated a
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tetradentate nitrogen ligand (10) and attempted to generate a model 
system, (scheme 4.1). Unfortunately the dimeric product (11) resulted, 
although a reaction with carbon dioxide in air, to produce the trimer (12) 
indicates an affinity for carbon dioxide similar to the enzyme.
Scheme 4.1
These problems have been so pronounced that only a few four-co- 
ordinate zinc (II) complexes co-ordinated to three nitrogen donors have 
been structurally characterised to date.
More recently the groups of Kimura34,35 and Sakurai36 have developed 
zinc aqua complexes with 1,5,9-triazocyclododecane (13), (scheme 4.2) 
and used these in the calculations of the pKgOf water molecules bound at 
their zinc centres. They were found to exhibit pKa’s of around ~ 7.3, 
similar to the corresponding enzyme. These complexes were also found 
to act as functional models for the carbonic anhydrase enzyme in that 
they able to catalyse the reversible hydration of carbon dioxide, although 
somewhat modestly. The change in sp2 to sp3 character of the trinitrogen 
binding being noted as one of the possible reasons for loss of activity 
compared to the enzyme.
Z n (O H )2
(11) (12) p*
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Zn(0H )2.5H20
Scheme 4.2 One of the first functional models for carbonic anhydrase 
was the monomeric zinc aqua complex (14).
In order to produce functionally more realistic models of carbonic 
anhydrase that bear more resemblance to the active site, and turning 
away from macrocyclic ligands, Parkin37 synthesised the tris- 
(pyrazolyl)hydroxyborato zinc hydroxide complex (15). This was found to 
be an adequate functional model for the carbonic anhydrase enzyme, 
catalysing the conversion of carbon dioxide and water into 









In order to improve on this further, Parkin38 has synthesised a more 
accurate structural model which utilises imidazolyl functionalities instead 
of pyrazolyls. The complex (16), { 'n3-P(3-tBu-5-'Pr.imidazolyl)3ZnOH(L5) }
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was the first characterised monomeric zinc hydroxide complex bearing 
the three imidazolyl functionalities, and was found to be the best 
structural model for the carbonic anhydride enzyme, although research 






Although many functional models for carbonic anhydrase have been 
synthesised, their catalytic efficiency has been found to be many orders 
of magnitude lower than the enzyme. This is believed to be a result of 
most models focusing on the zinc hydroxide active site, and neglecting 
the various other structural effects of the other amino acid residues 
present near the active centre. It has been shown neighbouring amino 
acid group participation is a key feature in the active enzyme, in particular 
His 64 is needed to accelerate the proton ‘shuffle’ between water bridges 
near the catalytic centre.22
In an attempt to include such features in to a functional model and to 
produce a stereochemically rigid structure around a fourth co-ordination 
site, Walton29 has prepared a number of tris-imines (17) and zinc (II) 
complexes (18), (scheme 4.3) by varying the condensed aldehyde to 
change the ‘super-structure’ around the fourth site at the zinc centre. It 
was hoped that the hydrophobic pocket generated would lower the pKa of 
the zinc bound water and thus make it more nucleophilic, although no
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results have as yet been published as to its functional compatibility as a 





(17) R = HC=CHPh, Ph (18)
Scheme 4.3
In the search for even more structural simplicity, Parker39 has recently 
synthesised a similar cyclohexane based ligand, 1,3,5-triamino 







h 2n ^  ^ n h 2 Zn(0H )2
HoN
This ligand was found to co-ordinate to zinc (II) ions in a tridentate 
manor, leaving the fourth site free for hydroxide binding. The advantage 
of such a ligand is that it will allow for a greater degree of substitution on 
the cyclohexane ring that, in the future, will lead to even more structurally 
and functionally accurate models for the carbonic anhydrase enzyme.
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Although Walton and Parkin have developed more structurally rigid 
molecules, and the cyclohexane ring may allow much modification of 
peripheral structure, the models still lack the essential fr/s-imidazolyl 
moiety which appears essential for the activity of the native enzyme. To 
this end the basis of this part of the project is to synthesise a tris- 
imidazolyl ligand based on 1,3,5-cyclohexane molecule (20), as well as 
the even more structurally rigid trimethyl derivative (21), and to examine 
its ability to function as a carbonic anhydrase model (i.e. as a receptor for 
zinc (II) ions).
4.4 Design Of Receptor Molecules That Bind Selectively To 
Sugars In Aqueous/ Non-Aqueous Media
complexation has become an important and current goal in bioorganic 
chemistry in the search to understanding complex carbohydrate binding 
processes in nature.43
To this end the aim of this part of the project is to synthesise a receptor 
that has the ability to bind various polyhydroxyl substrates using the 
Kemp’s triacid phosphonate derivative (22) as our initial model 
compound. The phosphonates are appropriate for the study of binding of 
carbohydrates because they remain anionic over a wider pH range than 
carboxylates (pKa - 1 . 8  compared to 4.5), as well as their tetrahedral 
geometry allowing for greater modification.44
The use of artificial receptors'40-42 for the study of carbohydrate
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r - o H
MeO
(22)
It is hoped that the binding of a carbohydrate to our model receptor 
should occur via hydrogen bonding interactions between the hydroxyl 
group of the carbohydrate and the receptor phosphonate groups as 
shown below. Indeed previous studies have indicated that two 
phosphonate groups linked by an appropriate spacer should bind all four 
hydroxyl groups of a typical alkylglycoside,44 (figure 4.9).
Figure 4.9 Possible binding interactions for a saccharide molecule to a 
diphosphonate receptor.
In nature however, sugar binding proteins have much greater substrate 
affinities than most formally synthesised artificial receptors, this being 
due to the presence of additional charged amino acid residues at the 
heart of their binding pockets. One such example is the substrate 
recognition site of the maltose binding protein shown, (figure 4.10).
ihiii*«'H O-
PhCHi
p - o - " O — P
c? IIII
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Trp 62 Lys 15
Figure 4.10 The substrate recognition site of the maltose binding 
protein.
The aim of this project is to investigate the effectiveness of our model 
compound (22) to bind a range of saccharide substrates, (figure 4.11) 
and to hopefully modify the cyclohexane structure such that 
discrimination between enantiomers may be possible. This we envisage 
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Figure 4.11 Possible binding interactions for our molecular receptor (22) 
with a typical saccharide.
Structural differentiation may be possible by producing molecules with 
different cavity sizes; for example Diederich9 has recently synthesised
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two s im ila r cyc lophanes  (23) and (24), (figu re  4 .12 ) tha t a re  capab le  o f 
d isc rim ina ting  betw een m ono- and d isaccha rides  respective ly . It w as 
found  tha t b ind ing  to the  recep to r p roduced s tab le  (1 :1) com p lexes even 
in com petitive  p ro tic  so lvents, w ith  the  fo rm ation  o f the  ion ic  hydrogen 





Figure 4.12 C yclophane  recepto rs  capab le  o f d is tin gu ish in g  m ono- and 
d isaccha ride  m olecules.
Results:
4.5 Synthetic Studies Towards Possible Zinc Sensors (20) And 
(21)
In o rde r to  m ore fu lly  understand  the m echan ism  o f action  o f the  ca rbon ic  
anhyd rase  enzym e, a num ber o f both s truc tu ra l and func tiona l m odels 
have been syn thes ised  (see earlie r). The  m ain aim  o f th is  p ro ject is to 
syn thes ise  m ore accura te  m odel recepto rs  fo r th is  enzym e. To  th is  end 
two new  va rian ts  o f the  1 ,3 ,5 -cyc lohexy l de riva tives  (20) and (21) dev ised
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by Walton29 and Parkin38 have been suggested. These molecules, when 
synthesised, should act as excellent model systems as they should allow 
tri-dentate co-ordination to zinc (II) ions, leaving a fourth co-ordination 
site ‘free’ for binding of a hydroxide ion or water molecule, (figure 4.13).
(20)
(20), (21) R = H, Me(21)
Figure 4.13 Possible zinc (II) binding interactions in our triimidazole 
receptors.
The advantage over earlier models for the carbonic anhydrase enzyme 
should be the ability to easily modify the peripheral structure around the 
cyclohexane ring and hence eventually lead to the synthesis of much 
improved structural models with greatly enhanced functional properties.
4.5.1 Synthetic studies towards the possible zinc sensor: cis,c/s-1,3,5-tris 
(imidazylmethyl)-cyclohexane (20).
The desired starting material of choice was cis,c/s-1,3,5-cyclohexane 
tricarboxylic acid (9) Initial attempts at the esterification of the triacid (9), 
using distilled methanol with acid catalysis, proceeded in less than 
successful yield (~ 40%), and produced the cis/ trans isomer of the
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trimethyl ester (25) as the major product. In order to reduce the degree of 
epimerization the required cis/ cis triester (25) was obtained by treatment 
of the triacid (9), in cold distilled methanol, with acetyl chloride in near 
quantitative yield (95%), (scheme 4.5). The trimethyl ester (25) was then 
treated with lithium aluminium hydride in distilled methanol and produced 
the triol (26) in 79 % yield (the yield given is based on the direct dry- 
loading of the reaction mixture on silica-gel and subsequent flash 
chromatography). The triol (23) was then converted smoothly to the 
trimesylate (27) by treatment with methylsulfonyl chloride and 
triethylamine in DCM, and afforded the product as a crystalline white solid 
in quantitative yield.
C 0 2Hx










MesCI / EfcN 






In our attempts to synthesise the triimidazole (20) by nucleophilic SN2 
displacement, by imidazole, on the trimesylate (27) we encountered a 
number of problems. A list of some of the conditions used in the 
attempted synthesis of the triimidazole is indicated, (scheme 4.6).
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A. K2C03 / Imidazole
/ THF / RT => reflux 
/12 h
B. Imidazole / DMF 
/Reflux/12 h
 x  -
C. Et3N / Imidazole
/ DMF / RT => reflux 
/12 h
D. Imidazole / THF /
/ EtsN / reflux
(20)
Scheme 4.6
The reactions proceeded at best to produce small quantities of impure 
mono imidazole dimesylate (5%), trace amounts of diimidazole 
monomesylate and the complete loss of starting material in most cases. 
1H NMR spectra indicated that some low Rf polymerised material was 
present from the direct decomposition of the trimesylate (27), and some 
high field signals ~ 5.5-4.5 ppm, indicating the presence of an alkene. 
This has also indicated that some of trimesylate or alkylimidazole had 
undergone elimination. Whether the trimesylate (27) or any alkylated 
imidazole product had undergone elimination was not established at this 
time. To investigate this further the trimesylate (27) was converted to the 
tribromide (28) by treatment with a large excess of lithium bromide (x 10 
equiv.) and heating under reflux conditions in THF, (scheme 4.7).
^ O M e s
MesO .OMes
LiBr/THF
/ Reflux /1 2  h
Scheme 4.7
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This was undertaken to reduce possibility of the elimination reaction with 
respect to the trimesylate; the latter having a greater propensity to 
eliminate. In an attempt to prepare the triimidazole (20) from the 
tribromide (28), the sequence of reactions was repeated as for the 
mesylate (27), (scheme 4.6). Unfortunately either no reaction occurred 
(path B) and starting material was recovered or complete loss of starting 
material was observed with subsequent production of intractable multi- 
component mixtures (path A). On a repeat of the reaction, however, with 
THF/ imidazole and triethylamine (path D) on the tribromide (28), two 
reaction products were identified by 1H NMR/ mass spectral analysis. The 
two compounds were found to be the mono-A/-alkylated imidazole 
dibromide (29) and a very crude trace amount of di-A/-alkylated imidazole 
monobromide (30), with unreacted starting material accounting for the 
rest.
In order to attempt a triimidazole synthesis, more forcing conditions were 
utilised. W e envisaged that, as no noticeable elimination had occurred 
when with reactions on the tribromide (28), the use of imidazide anion 
might prove fruitful. To this end a trial reaction was undertaken on the 
model compound, cyclohexyl-methylene bromide (31), (scheme 4.8). In 
this reaction a solution of imidazole in dry DMF was treated with sodium 
hydride, then a solution of the cyclohexyl-methylene bromide at 0 °C. 
T.I.c. analysis indicated the complete loss of starting material and the 
formation of one major product, which was latter identified as the mono- 
A/-alkylated cyclohexyl-methylene imidazole (32) and was isolated in 
almost quantitative yield (94%).
(29) (30)
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ii) D M F / (31) (32)
Scheme 4.8
Surprisingly no elimination was observed on 1H NMR spectra, even when 
the reaction was repeated with upwards of three equivalents of sodium 
hydride, thus indicating that earlier problems may have occurred due to 
thermal not chemical elimination. This result was pleasing and 
unexpected because we had observed a large degree of elimination from 
use of much less forcing conditions applied in reactions of the trimesylate
The same conditions were applied when a reaction was undertaken on 
the cyclohexyl tribromide (28) and although reaction times were slightly 
prolonged, a complex mixture of products resulted, (scheme 4.9). 
Purification by flash chromatography allowed isolation of four of the 
components present in the mixture. Starting material and imidazole were 
identified as the first two of these components, and disappointingly 1H 
NMR and C.l. mass spectral analysis of the other two indicated that 
elimination products (33) and (34) had been produced. Flushing of the 
silica column used in the purification step with methanol failed to identify 
any trimidazole products and freeze drying of the aqueous extracts of the 
reaction work-up also proved equally unproductive. The reasons why 
elimination occurred this instant is unclear, although it has been 
suggested that an excess of sodium hydride may have reacted with water 
at the work-up stage to produce sodium hydroxide, which then catalyses 
the bromide or imidazole elimination.
(27).
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i) NaH / DMF / OC
ii) DMF / (28)
X
(33) 40% (34) 10%
Scheme 4.9
To test this, the tribromide (28) was dissolved in DMF and cooled, then 
treated with an excess of sodium hydride and allowed to warm to room 
temperature over one hour after water had been added. From t.I.c. 
analysis there appeared to be extensive decomposition to give complex 
mixtures. Crude 1H NMR spectra of the reaction indicated a complex 
mixture of products, and although none could be isolated, a whole host of 
signals in the 5.5-4.5 ppm range indicated that extensive elimination had 
occurred. Reactions were also undertaken using less than stoichiometric 
amounts of sodium hydride but unfortunately still gave elimination 
products. In general a single imidazole can almost certainly be introduced 
around the cyclohexane skeleton but the results would seem to indicate 
that the increasing steric constraints on the molecule after a single 
bromine displacement by imidazole allows competing elimination to 
dominate thereafter. Another equally valid possibility could well be that 
the substituted imidazole may be acting as an internal base, thus aiding 
elimination reactions.
4.5.2 Synthetic studies towards the possible zinc sensor cis,c/s-1,3,5- 
trimethyl-1,3,5-tris (imidazylmethyl)-cyclohexane trimethylamidazole (21).
Synthetic towards another possible structurally similar zinc receptor (21), 
in which the synthesis was been based upon Kemp’s acid (1), has also 
been undertaken.
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N.
N
C 0 2H c o 2h
(1) (21)
Synthetic studies towards the possible zinc receptor (21) are given in 
scheme 4.10. It can be noted many of the transformations are similar to 
those seen earlier, although many of the reagents used are different. The 
starting materials chosen were either 1,3,5-cyclohexane tricarboxylic acid 
(9) or the Kemp’s acid (1).
Prior to obtaining the Kemp’s acid directly, the trimethyl ester (35) was 
successfully synthesised, albeit in low yield, by treatment with LDA in 
THF, followed by addition of methyl iodide. A complex mixture of products 
were produced by t.I.c. but two successive acid/ base washes allowed 
isolation of a crude mixture of c/s/  trans and the required cis/ cis isomers 
in 52% overall yield. This could be further enriched to 95% cis/ cis by 
careful recrystallization from THF and DCM. As the yields for repeat 
reactions proved equally poor, and the required Kemp’s acid (1) was 
commercially available, it was decided to utilise this instead.
The Kemp’s acid (1) was converted to triol (36) by treatment with lithium 
aluminium hydride in distilled THF, and afforded the required product as 
white crystalline solid in 85% yield, as well as some mono- and diol 
products.
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C02H
i
ho2c^ x^ n co 2h
(9)
AcCI / MeOH





MesCI / Et3N 
DCM /OoC/12 h
UAIH4/THF
/ 0 °C /1 h
i) LDA / THF / 
-78 °C / 3 h












K2C03 / Imidazole 
'' / THF / RT
Scheme 4.10 A suggested route for the synthesis of a possible zinc 
sensor (21).
The synthesis of the trimesylate (37) and tribromide (38) have not been 
achieved at this time, although we reason that the formation of the
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required triimazole (21) should be possible by a displacement reaction on 
the trimesylate (37) or tribromide (38) by imidazole.
4.6 Initial Investigations Into The Synthesis Of A Possible 
Polyhydroxy Substrate Receptor (22)
In order that the synthesis of the model polyhydroxy receptor (22) could 
be attempted, the chemistry undertaken earlier has been utilised, (see 
schemes 4.5 and 4.7). The aim of this synthesis was to produce the 
required receptor by reaction of the previously synthesised tribromide
(28) with trimethyl phosphite, under Arbuzov45 conditions, (scheme 4.11).
Scheme 4.11 An initial route suggested for the synthesis of the possible 
polyhydroxy receptor (22).
The tribromide (28) was used for our initial investigations into the 
generation of a triphosphonate receptor (22). W e have argued that we 
should obtain the required level of reactivity without the large degree of 
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been used instead. T.I.c. analysis indicated loss of starting material and 
the presence of two main products on most occasions when a variety of 
different reaction temperatures and times were used. Although no 
evidence for the formation of the triphosphonate (39) was seen in 1H 
NMR spectra, there was evidence to support the formation of the mono- 




MeO. II II .O M e
(41)
1H NMR spectra of the two isolated products were complex, indicating 
that perhaps some degree of cis/  trans isomerization had occurred, 
although proton integration was accurate. The fact that no triphosphonate 
(39) was isolated, and because of previous difficulties encountered with 
attempts at triimidazole formation, it could be argued that the problem 
was one of a steric nature.
4.7 Future Work And Conclusions
W e have successfully synthesised all of the required precursors that will 
hopefully allow completion of model receptors for both the enzyme 
carbonic anhydrase and for various polyhydroxy molecules in the near 
future. There does, however, appear to be some limitation to the degree 
of substitution that can be tolerated on the basic cyclohexane molecule 
before elimination reactions predominate. Regarding the synthesis of the 
triimidazole molecules, this may be overcome by utilising a one carbon
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spacer or by using amide/ ester variants at the 1,3,5 positions to reduce 
steric interactions that appear to allow elimination pathways to 
predominate. Regarding the synthesis of a polyhydroxy receptor 
molecule, it may be possible to affect triphosphonate formation, by 
adapting Arbuzov45 methodology and investigating the synthesis of alpha- 
keto phosphonates instead of repeating the initial studies with triiodo/ 
chloro derivatives.
4.8 Experimental
cis, c/s-Trimethyl-1,3,5-cyclohexane tricaboxylate (25).
To a cooled solution (0 °C), in distilled methanol (40 ml), of the triacid (9) 
(5.00 g, 23 mmol) was added dropwise acetyl chloride (x 5 eq., 1.1 ml, 
0.115 mol). The solution was left to stir under nitrogen for 12 h. The 
solution was then concentrated in vacuo and the resulting oil basified via 
addition of aqueous sat potassium carbonate (100 ml) and extracted into 
diethyl ether (3 x 50 ml). The combined organic extracts were 
concentrated in vacuo and afforded a pale yellow oil that crystallized on 
standing. The solid was recrystallized from petrol (60-80 °C)/ ether to 
afford the required product as a white solid (5.90 g, 95%), mp 46-48 °C 
(from petrol-diethyl ether) (lit.,46 48-49 °C); vmax (nujol mull)/ cm*1 1736 
(C=Ot estei), 1255, 1174; 5H (400 MHz; CDCI3) 3.64 (9H, s, 3x O CH3), 
2.35 (3H, m, 3x CH), 2.22 (3H, d, J 12.5 Hz, 3x CH^), 1.48 (3H, q, J 12.5, 
3x CHax)\ 5c (100 MHz; CDCI3) 174.34 (q), 51.73 (O CH3), 41.60 (CH,
1,3,5-C), 30.33 {CH2, 2,4,6-C)\ m/z (C.l, isobutane) 259 (100%, (M+1)+), 
227 (90), 139(10).
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cis, c/s- 1,3,5-Tris(hydroxymethyl)-cyclohexane (26).
.OH
OHHO.
To a cooled solution of the triester (25), (1.00 g, 3.86 mmol) in distilled 
THF (50 ml) was added, portionwise, lithium aluminumhydride (x 3 eq., 
440 mg, 12 mmol). The mixture was stirred under nitrogen for a period of 
1.5 h, and t.I.c. (silica// 10% methanol/ EtOAc) indicated complete 
conversion to the required triol (26). Excess lithium aluminumhydride was 
quenched via addition ethyl acetate, after which the suspension was 
treated with silica-gel and then concentrated in vacuo. The silica was 
then subject to flash chromatography, eluting initially with 3% methanol/ 
ethyl acetate and gradient eluting to 10% methanol/ ethyl acetate. The 
required triol (26) was isolated as a white crystalline solid (536 mg, 79%), 
mp 113-116 °C (form methanol-ethyl acetate) (lit.,47 115-118 °C); vmax/  
(nujul moll) cm'1 3281 (O H ), 2922 (CH ), 1064 (C O ); 5H (270 MHz; DMSO- 
d6) 4.87 (3H, s, 3x O H) 3.34 (6H, d, J 6, 3x C H 2OH), 1.78 (3H, br. d, J 12, 
3x C H eq), 1.47 (3H, m, 3x CH), 0.52 (3H, q, J 12, 3x C H ax); 5C (67 MHz; 
CD3OD) 66.8 (C H 2), 39.5 (C H 2, 2,4,6-C), 33.0 (CH , 1,3,5-C\ m/z (C .l. 
isobutane) 175 (100%, (M+1)+); 158 (45, (M-OH+1)+); (HRMS: found M+, 
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A cooled (0 °C) suspension of the triol (26), (750 mg, 4.28 mmol) in DCM  
(30 ml) was treated with triethylamine (x 3.5 eg., 1.93 ml, 14.9 mmol) and 
then dropwise with methylsulfonyl chloride (x 3 eq., 1.00 ml, 12.8 mmol). 
Dissolution followed as the mixture was stirred rapidly under nitrogen. 
The solution was stirred to room temperature over 10 h, then 
concentrated in vacuo. Water (30 ml) was added and the product 
partitioned into DCM (3 x 50 ml). The organic phases were combined, 
dried (anhyd. Na2S 0 4) then concentrated in vacuo affording an off white 
solid. This was crystallized from DCM/ petrol (60-80 °C) to afford the title 
compound as a white crystalline solid, (1.42 g, quant.), mp 125-127 °C 
(from DCM-petrol) (lit.,48124 °C); vmax(nujol mull)/ cm'1 2942 (CH), 1360 (- 
S 0 2-0 -, asm. str.), 1173 (-SO2-O-, sym. str.); 5h (400 MHz; CDCI3) 4.01 
(6H, d, J 5.6, 3x CH2OMs), 2.96 (9H, s, 3x O CH3), 1.85 (3H, m, 3x CHeq), 
1.33 (3H, m, 3x CH), 0.81 (3H, m, 3x CHax); 5C (67 MHz; CD3OD) 73.7 
(CH20 S 0 2CH3), 37.7 (S-CHs), 36.6 (CH* 2,4,6-C) 31.8 (CH, 1,3,5-C)\ m/z 
(C.l, isobutane) 409 (60%, (M+1)+) 314 (34, (M -0 S 0 2CH3+1)), 219 (100, 
(M-2x O S 0 2Me+1).
cis, c/s-1,3,5-Tris(bromomethyl)-cyclohexane (28).
To stirred solution of the trimesylate (27), (320 mg, 0.96 mmol) in THF  
(10 ml) was added lithium bromide (x 10 eq., 832 mg, 9.8 mmol), and the 
solution heated under reflux conditions for 12 h under nitrogen. T.I.c. 
(silica// 5% MeOH/ EtOAc) indicated reaction completion with the loss of 
all starting material. The solution was concentrated in vacuo, partitioned 
between water (50 ml) and ethyl acetate (3 x 50 ml) and then dried 
(anhyd. Na2S 0 4). The combined organic extracts were concentrated in 
vacuo and chromatographed on silica, eluting with 20% ethyl acetate/
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petrol (40-60 °C) and afforded the required tribromide (28) as an orange 
oil that crystallized on standing, (530 mg, 65%); mp 52-55 °C (from petrol- 
ethyl acetate); 6H(400 MHz; CDCI3) 3.33 (6H, d, J 6.0, 3x CH2Br)), 2.02 
(3H, br. d, J 10, 3x CH^), 1.82 (3H, m, 3x CH), 0.83 (3H, br. q, J 10, 3x 
CHax); m/z (C.l, isobutane) 362 (5%, (M+1)+), 283 (30, (M-Br+1)+), 203 
(100, (M-2Br+1)+), 121 (27, (M-3Br+1)+); (HRMS: found M \  359.8733. 
C9H15Br3 requires M, 359.8728).
c/s^1,3-Bis(bromomethyl)-c/s-5-(imidazylmethyl)-cyclohexane (29).
To a solution of tribromide (28), (250 mg, 0.69 mmol) in THF (7.5 ml) was 
added imidazole (x 3 eq., 138 mg, 2.06 mmol) and triethylamine (x 3 eq., 
285 pi, 2.06 mmol), and the solution heated under reflux conditions for 5 
h. The solution was concentrated in vacuo and then chromatographed on 
silica eluting initially with 2% methanol/ ethyl acetate and gradient eluting 
to 10% methanol/ ethyl acetate. Two products were; a very crude sample 
of the diimidazole bromide (30) and the dibromide mono-imidazole (29). 
The mono-imidazole (29) was isolated as an orange oil (8 mg, 5%), mp > 
175 °C (decomp.); 6h (400 MHz; CD3OD) 7.14 (1H, s, CH), 7.03 (1H, s, 
CH), 6.90 (1H, s, CH), 3.97 (2H, d, J 7.2, CH^Imid.), 3.29 (4H, d, J 5.8, 2x 
CHpBr), 2.12-1.86 (3H, m, 3x CH^), 1.85-1.70 (3H, m, 1,3,5-H), 0.93-0.72 
(3H, m, 3x CHax).; m/z (C.l, isobutane) 352 (100%, (M+2H)+), 341 (55) , 
281 (15%, (M-imidazole+1)+).
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A/-Amidazylmethyl-cyclohexane (29).
O ’
To a stirred cooled (0 °C) solution of imidazole (383 mg, 5.64 mmol) in 
distilled DMF (50 ml) was added portionwise sodium hydride (65 wt%, x 1 
eq., 208 mg, 5.64 mmol), under nitrogen. After 20 minutes hydrogen 
evolution had ceased and the reaction mixture was treated, rapidly, with a 
solution of cyclohexylmethyl bromide (31), (1.00 g, 5.64 mmol) in DMF (5 
ml) and the solution left to stir to room temperature for a further 1 h. T.I.c. 
(silica// 5% MeOH/ EtOAc) indicated complete loss of starting material 
and the formation of one main product. The solution was concentrated in 
vacuo and then partitioned between water (50 ml) and ethyl acetate (4 x 
30 ml). The organic extracts were combined and dried (anhyd. Na2S 0 4), 
then concentrated in vacuo to afford the imidazole (32) as an off white 
solid (920 mg, 96%), mp 40-42 °C (from ethyl acetate); 5H(400 MHz; 
CDCI3) 7.41 (1H, s, CH), 7.04 (1H, s, CH), 6.87 (1H, s, CH), 3.74 (2H, d, J 
6.8, CH2Imid.), 1.74-1.59 (3H, m, 3x CHeq), 1.27-1.15 (3H, m, 3x CH),
1.05- 0.82 (3H, m, 3x CHax); 5C(67 MHz; CDCI3) 137.5 (CH), 129.2 (CH),
119.3 (CH), 53.5 (CH2lmid.), 39.3 (CH), 30.6 (CH2Br), 26.1 (CH2), 25.6 
(CH2); (HRMS: found M+, 164.1320. C i 0H16N2 requires M, 164.1314).
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To a stirred cooled (0 °C) solution of imidazole (56 mg, 0.83 mmol) in 
distilled DMF (5 ml) was added portionwise sodium hydride (40 wt%, x 1 
eq., 50 mg, 0.83 mmol), under nitrogen. After 20 minutes hydrogen 
evolution had ceased and the reaction mixture was treated, rapidly, with a 
solution of 1,3,5-tris (bromomethyl)-cyclohexane trimethylbromide (28), 
(100 mg, 0.28 mmol) in DMF (5 ml) and the solution left to stir to room 
temperature for a further period of 1 h. T.I.c. (silica/ 5% MeOH/ EtOAc) 
indicated incomplete loss of starting material and the formation of many 
products. The solution was allowed to stir for a further 12 h, then 
concentrated in vacuo and partitioned between sat. brine (20  ml) and 
diethyl ether ( 5 x 1 0  ml). The organic extracts were combined and dried 
(anhyd. Na2S 0 4) then concentrated in vacuo to afford a beige solid. The 
reaction mixture was chromatographed on silica, eluting with 5%  
methanol/ ethyl acetate and afforded two main elimination products; the 
diimidazole monoalkene (34), (5 mg, 10%) and the monoimidazole 
dia/kene (33), (20 mg, 40%).
For the monoalkene (34), mp 213-215 °C (from diethyl ether); 5H(400 
MHz; C D C I3) 7.47 (2H, s, 2x CH), 7.10 (2H, s, 2x CH), 6.85 (2H, s, 2x 
CH), 4.70 (2H, s, alkene), 3.68 (4H, d, J 5.8, 2x C H 2N), 3.48 (1H, s, 
C H eq), 2.28 (2H, m, 2x CHeq), 1.83 (2H, m, 2x CH), 0.85 (2H, m, 2x CHax), 
0.67 (1H, m, CHax)\ m/z (C.l, isobutane) 257 (26%, (M+1)+) 191 (57, (M- 
imidazole+1)+), 124 (100, (M-2x Imidazole)+); (HRMS: found M+, 
256.1660. C15H20N4 requires M, 256.1684).
For the dialkene (30), mp 128-131 °C (from diethyl ether) 5H(400 MHz; 
C D C I3) 7.42 (1H, s, CH), 7.08 (1H, s, CH), 6.88  (1H, s, CH), 4.78 (2H, s, 
alkene), 4.64 (2H, s, alkene), 3.80 (2H, d, J 7.16, C H 2N), 2.84 (1H, d, J 
4.3, CHeq), 2.30 (2H, dd, J 9.5 and 1.2, 2x CHeq), 2.04-1.92 (3H, m, 2x 
CHax, CH), 1.76 (1H, s, CHax); 5C (67 MHz; MeOD) 146.9 (q), 129.3 (C H ), 
126.2 (C H ), 121.5 (C H ), 109.7 (C H 2), 52.6 (C H 2), 44.8 (C H 2), 40.4 (C H ),
38.3 (C H 2); m/z (E.l.) 188 (100%, M), 119 (4, (U-lm idazolef) 107 (37, (M-
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CH2-imidazole)+); (HRMS: found M+, 188.1310. C12H16N2 requires M, 
188.1320).
cis, c/s-Timethyl-1,3,5-trimethylcyclohexane-1,3,5-tricarboxylate (35).
To a stirred cooled solution (0 °C) of diisopropylamine (x 3.3 eq., 1.84 ml, 
6.39 mmol) in THF (50 ml) was added n-butyllithium (1.6 M in hexane, 
4.0 ml, 6.39 mmol) and the solution left to stir under nitrogen for 20  
minutes. A solution of cis, c/s-1,3,5-cyclohexane trimethyl ester (25), (1.0 
g, 3.88 mmol) in THF (20 ml) was added at such a rate as to maintain the 
reaction temperature below 5 °C. The reaction mixture was left to stir for a 
period of 2 h, then methyl iodide (x 3.3 eq., 6.39 mmol) was added 
dropwise and the solution was allowed to warm to room temperature. 
Water was added (~ 2 ml) to quench the reaction and after a further 10 
minutes the solution was concentrated in vacuo and partitioned between 
water (50 ml) and diethyl ether (4 x 50 ml). The organic extracts were 
combined, dried (anhyd. Na2S 0 4) and concentrated in vacuo to afford an 
orange oil. T.I.c. (silica/ Et20 )  indicated the reaction mixture was a multi­
compound one. The reaction mixture was chromatographed on silica 
eluting, initially, with 10% diethyl ether/ petrol (40-60 °C) and gradient 
eluting to 30% diethyl ether/ petrol (40-60 °C). A sample containing 75%  
cis/ cis (35) was obtained. This was further purified to 95% by 
recrystallization from Et20 /  hexane, and afforded the required product as 
clear oil that solidified to a white crystalline solid on standing, (230 mg, 
20%), mp 77-80 °C (from diethyl ether-hexane) (lit.,2 80-81 °C); vmax/ cm'1 
2951 (CH), 1726 (C =0, estei), 1250, 1171; 5h (250 MHz; CDCI3) 3.65 (9H, 
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d, J 13.5, 3x CHax); m/z (C.l, isobutane) 301 (100%, (M+1)+), 239 (34, (M- 
C 0 2Me+1)+).
cis, c/s-1,3,5-Trimethyl 1,3,5-tris(hydroxymethyl)-cyclohexane (36).
OH
HO, OH
To a cooled solution of the triester (35), (200 mg, 0.66 mmol) in distilled 
THF (50 ml) was added, portionwise, lithium aluminum hydride (x 3 eq., 
77 mg, 2 mmol). The mixture was stirred under nitrogen for a period of 2 
h, and t.I.c. (silica//10% MeOH/ EtOAc) indicated complete conversion to 
the required triol (36). Excess lithium aluminum hydride was quenched via 
addition ethyl acetate, after which the suspension was treated with silica- 
gel and then concentrated in vacuo.
The silica was then subject to flash chromatography, eluting initially with 
1% methanol/ ethyl acetate and gradient eluting to 5% methanol/ ethyl 
acetate. The required product triol (36) was isolated as a white crystalline 
solid (122 mg, 85%), mp 189-191 °C (from methanol-ethyl acetate) (lit.,48 
185-189 °C); v ^ n u jo l mull)/ cm'1 3420 (OH), 2925 (CH), 1087; 8h (250 
MHz; CD3OD) 4.34 (3H, br. s, 3x OH) 3.55 (6H, s, 3x CH£>H)), 2.62-2.56 
(3H, br. d, J 14.0, 3x CH«,), 1.17 (9H, s, 3x CH3), 1.05 (3H, q, J 14.0, 3x 
C H ^ ; m/z (C.l, isobutane) 217 (100%, (M+1)4), 158 (66, (M-CQ>/We+1)+).
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c/s-1,3-Dimethylbromo-c/s-5-methyl-(dimethylphosphonate) 
cyclohexane (40) and c/s-1-methylbromo c/s-3,5-methyl- 
(dimethylphosphonate) cyclohexane (41).
A solution of the 1,3,5-tris (bromomethyl)-cyclohexane (28), (200 mg, 
0.55 mmol) was treated with freshly distilled trimethyl phosphite (x 15 eg.,
0.98 ml, 8.27 mmol) and left to stir at room temperature under nitrogen for 
12 h. T.I.c. (silica/ EtOAc) indicated that no product formation had 
occurred and therefore the reaction mixture was heated to reflux for 5 h. 
T.I.c. (as before) indicated that along with the loss of starting material, 
two main products had been produced. The reaction mixture was cooled 
and concentrated in vacuo to afford an orange oil. This was 
chromatographed on silica eluting initially with 20 % ethyl acetate/ petrol 
(40-60 °C), and gradient eluting to 50 % ethyl acetate/ petrol (40-60 °C). 
The two products were found to be the monophosphonate dibromide (40), 
(80 mg, 34%) and the diphosphonate monobromide (41), (31 mg, 13%). 
For the monophosphonate (40), mp decomposed >114 °C (from petrol- 
ethyl acetate); 5h(400MHz; CDCI3) 3.37 (6H, d, J 11.1, 2x OCH3), 3.33 
(6H, m, 2x CH2Br, 1x CH2P (0 )(0C H 3)2), 1-98 (3H, m, 3x CHeq), 1.77 (3H, 
m, 3x CH), 0.83 (3H, m, 3x CHax)\ m/z (C.l, isobutane) 393 (2%, (M+1)+) 
200, (20, (M-HBr-HPO(OCH3J2+1)+), 121 (32, (M-2xHBr-
HPO(OCH3) 2+1)+). For the diphosphonate (41), mp decomposed >161 °C 
(from petrol-ethyl acetate); 8H (400MHz; CDCI3) 3.74 (12H, d, J 10.8, 4x 
OCH3), 3.33 (6H, m, 1xCH2Br, 2x CH2P (0 )(0C H 3)2), 2.03 (3H, m, 3x 
CHeq), 1.76 (3H, m, bridge H ’s), 0.82 (3H, m, 3x CHax); m/z (C.l, 
isobutane) 311 (5%, (M-HPO(OCH3J2+1)+), 201 (6, (M-




Molecular Receptors Chapter 4
that these compounds were not fully characterized at this time due to 
their partial decomposition during chromatographic separation, and due 
to time restrictions at the end of this Ph.D.
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